











I declare that the work contained in this thesis is composed by me. All studies
were performed during my time as a research fellow in the Department of
Medicine, Royal Infirmary of Edinburgh. I have not submitted the thesis for





Abstract of thesis 12
Abbreviations 14
Chapter 1: Introduction 15
1.1 Pathophysiology of portal hypertension 16
1.1.1 Historical aspects 16
1.1.2 Basic principles: 16
Increased intrahepatic resistance 17
Circulatory changes 18
1.2 Development of varices and variceal haemorrhage 21
1.2.1 Background 21
1.2.2 Anatomical considerations 21
1.3 The natural history of gastro-oesophageal varices 25
1.3.1 Variceal formation 25
1.3.2 Progression of varices 28
1.3.3 Risk factors for the first variceal haemorrhage 28
1.3.4 Risk factors for variceal rebleeding 31
1.3.5 The outcome of patients with varices and variceal haemorrhage.31
3
1.3.6 Gastric varices 32
1.4 Drug therapy for portal hypertension 34
1.4.1 Haemodynamic studies of agents used in portal hypertension .. 34
Beta-blockers 37
Nitrates 44
Drugs acting on alpha-adrenergic receptors 49
Drugs acting on the renin-angiotensin system 50
Drugs acting on serotonin S2 receptors 54
Drugs affecting plasma volume 55
Combination therapy 56
1.4.2 Clinical application of drugs in portal hypertension 60
Primary prophylaxis 60
Secondary prophylaxis 71
1.5 The transjugular intrahepatic portosystemic stent-shunt (TIPSS)
in the management of variceal bleeding 79
1.5.1 Historical aspects and basic principles 79
1.5.2 Haemodynamic effects ofTIPSS 81
1.5.3 Complications ofTIPSS 84
1.5.4 The role of TIPSS in the management of variceal haemorrhage 90
Management of acute variceal bleeding 92
Prevention of rebleeding 95
4
1.5.5 New developments 101
TIPSS in combination with other therapies 101
Covered stents 101
Chapter 2: Methods 105
2.1 Methods of haeniodynamic monitoring 106
2.1.1. Hepatic venous pressure gradient (HVPG) 106
2.1.2 Systemic and cardiac haemodynamics 106
2.1.3 Hepatic blood flow 107
2.1.4 Analysis of neurohumeral agents 107
2.1.5 Assessment of renal function 108
2.2 Transjugular intrahepatic portosystemic stent-shunt (TIPSS).. 110
2.2.1 Insertion ofTIPSS 110
2.2.2 Follow up and shunt surveillance 110
2.2.3 Definitions 111
Chapter 3: Haemodynamic effects of low dose carvedilol, a




3.2 Patients and methods 115
3.2.1 Haemodynamic study protocol 116
3.2.2 Statistical analysis 116
3.3 Results 117
3.3.1 Portal haemodynamics 117
3.3.2 Hepatic blood flow 117
3.3.3 Systemic haemodynamics 118
3.3.4 Effect on hepatic and renal function 118
3.3.5 Tolerability I 18
3.4 Conclusions 125
Chapter 4: Haemodynamic effects of losartan, an angiotensin
II receptor antagonist, in patients with cirrhosis and portal
hypertension 126
4.1 Introduction 127
4.2 Patients and methods 127
4.2.1 Haemodynamic study protocol 128
4.2.2 Blood sampling and analysis 128
4.2.3 Assessment of renal function 128
4.2.4 Statistical analysis 129
6
4.3 Results 131
4.3.1 Hepatic haemodynamics and function 131
4.3.2 Systemic haemodynamics 131
4.3.3 Renal function 132
4.3.4 Effect on the renin-angiotensin system 132
4.3.5 Tolerability 132
4.3 Conclusions 135
Chapter 5: Transjugular intrahepatic portosystemic stent-
shunt for the management of variceal bleeding: clinical and
haemodynamic correlations 136
5.1 Introduction 137
5.2 Patients and methods 139
5.2.1 TIPSS procedure 142
5.2.2 Follow up 142
5.2.3 Statistical analysis 143
5.3 Results 144





5.3.5 Shunt insufficiency 145
5.3.6 Orthotopic liver transplantation 145
5.3.7 Correlations between portal pressure and clinical outcome 146
5.4 Conclusions 151
Chapter 6: Randomised controlled trial of VBL versus
standard TIPSS surveillance following TIPSS insertion for the
prevention of oesophageal variceal rebleeding 152
6.1 Introduction 153
6.2 Methods 155
6.2.1 Patient selection 155
6.2.2 Randomisation and treatments 155
6.2.3 Follow up 158
6.2.4 Outcomes 158
6.2.5 Sample size calculation 158
6.2.6 Calculation of costs of treatment 159
6.2.7 Statistical analysis 159
6.3 Results 162
6.3.1 Patients recruited 162






6.3.7 Shunt function in the first year 174
6.3.8 Orthotopic liver transplantation 174
6.3.9 Duration of hospital stay 175
6.3.10 Costs of treatments 178
6.3.11 Severity of liver disease at the end of follow up 178
6.4 Conclusions 180
Chapter 7: Discussion 181
7.1 The role of low dose carvedilol in cirrhotic portal hypertension 183
7.1.1 Effects of carvedilol on portal and systemic haemodynamics. 183
7.1.2 Bioavailability of carvedilol 185
7.1.3 Effects of carvedilol on renal function 186
7.1.4 Carvedilol in clinical practice 187
7.2 Haemodynamic effects of chronic administration of losartan .... 188
7.2.1 Effect on systemic and portal haemodynamics: Comparison with
other studies 188
7.2.2 Effect on renal function 190
7.2.3 Clinical implications of losartan therapy 191
9
7.3 The efficacy of TIPSS in the management of gastric and
oesophageal varices: Clinical and haemodynamic correlations. 192
7.3.1 Portal pressure of gastric varices 192
7.3.2 TIPSS as savage therapy in bleeding gastric varices 193
7.3.3 Survival following TIPSS: Gastric versus oesophageal varicesl94
7.3.4 Role of portal pressure in determining clinical outcome 195
7.3.5 Clinical implications 196
7.4 VBL versus long-term surveillance following TIPSS insertion for
the prevention of oesophageal variceal rebleeding 197
7.4.1 Comparison of variceal rebleeding 197
7.4.2 Comparison of mortality 198
7.4.3 Comparison of hepatic encephalopathy 199
7.4.4 Change in Child-Pugh score during follow up 200
7.4.5 Shunt function and surveillance 200
7.4.6 Cost implications 201






i wish to thank Professor Peter C Hayes for his support, enthusiasm and
supervison of all the studies. 1 am also indebted to Dr Doris N Redhead for
her expertise and guidance on studies of T1PSS. I am also most grateful for
the assistance of other members of the research team including Dr George
Therapondos, Dr Hock F Lui, Dr Ahmed Helmy, Dr Adrian J Stanley, Dr
Rajiv Jalan, Dr Ewan Forrest, and Dr Kostas Dabos. I also thank Professor
David J Webb for his expert guidance with the losartan haemodynamics
study. A special thanks to consultant hepatologists, DrNial DC Finlayson, Dr
Kenneth J Simpson, and Dr Alastair J MacGilchrist whose patients were
recruited for all the studies. I would also like to thank Dr Richard W Crofton
for introducing me to Professor PC Hayes' research team.
1 would like to extend my gratitude to Sister Kim Macbeth for her help with
patient recruitment and data collection, and to Sister Mary Castle and nursing
staff in the Department of Medicine for help with the haemodynamic studies.
I also wish to thank Mrs Susan Leiper and Mr Neil Johnston for technical
assistance with sample analysis for the haemodynamic studies.
Most important of all, I wish to thank my parents and brother for all their
support, encouragement and patience.
11
Abstract of thesis
Over the last 20 years, there have been significant advances in the
management of portal hypertension, with the introduction of drug therapy and
the transjugular intrahepatic portosystemic stent-shunt (TIPSS). This
development continues at a strong pace as our understanding of the
pathogenesis of portal hypertension deepens. There are 2 aims of this thesis:
1. To study the haemodynamic effects of two novel vasoactive agents on the
portal and systemic circulations.
a. Carvedilol, a vasodilating non-cardioselective beta-blocker with op
antagonism. The acute and chronic haemodynamic effects of this
agent will be studied, with particular attention paid to patient
tolerability.
b. Losartan, an angiotensin II receptor antagonist. The chronic effects of
this agent will be studied in patients with well compensated cirrhosis.
These laboratory based studies will assist in determining the suitability
of these agents for use in controlled clinical trials on patients at risk of
variceal bleeding.
2. TIPSS has been used extensively in the management of portal
hypertension, particularly variceal bleeding. Two studies will be presented in
this thesis aimed at answering the following questions.
a. Is TIPSS effective for the management of gastric variceal bleeding?
Gastric variceal bleeding is less common than oesophageal variceal
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bleeding, hence there are relatively few studies investigating the effect
of TIPSS on bleeding gastric varices. This study will also compare
gastric variceal bleeding with oesophageal variceal bleeding, and aim
to correlate clinical outcomes with haemodynamic data.
b. Is it necessary to continue portographic TIPSS surveillance
indefinitely if variceal band ligation is combined with TIPSS for the
prevention of oesophageal variceal rebleeding? This is the hypothesis
for a randomised controlled trial comparing TIPSS alone with TIPSS
plus variceal band ligation. This study will address 2 drawbacks of
TIPSS, namely the need for long-term portographic to ensure TIPSS
patency and hepatic encephalopathy.
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ANG II Angiotensin II
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TIPSS Transjugular intrahepatic portosystemic stent-shunt
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1.1 Pathophysiology of portal hypertension.
Portal hypertension results in elevated portal pressure accompanied by
significant changes in the systemic circulation. Normal portal pressure is
between 1 - 4 mm Hg, with progressive increases in the portal pressure with
time until complications develop such as gastro-oesophageal varices.
Despite reports of a "threshold" value of portal pressure above which
varices develop, varices particularly of gastric origin can develop and bleed
at relative low portal pressures (Stanley and others 1997a). The exact
pathogenesis of portal hypertension is the topic of much debate and
research.
1.1.1 Historical aspects.
The phenomenon of portal hypertension has been known for hundreds of
years, and was identified as a potential cause of gastrointestinal bleeding by
Vesalius and Morgagni (Sandblom 1993). The term 'portal hypertension'
was first used in 1906 (Gilbert and Villaret 1906), and until 1937, the
increase in portal pressure could only be measured directly at laparotomy
(Sandblom 1993).
1.1.2 Basic principles.
Portal hypertension is a clinical syndrome that results from an increase in
intrahepatic resistance and increased portal blood flow. Ohms law dictates
that the change in portal pressure (AP) is the product of portal blood flow
(Q) and the resistance to flow (R):
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Equation 1: AP = Q x R.
Resistance cannot be quantitatively measured unlike blood flow and
pressure. Pouseuille's Law for deriving resistance brings together
coefficient of viscosity (q), length of vessel (L), and radius of vessel (r).
8 q L
Equation 2: R = 7t r4
Incorporating equation 2 into equation 1 results in:
Q x 8 n L
Equation 3: AP = 71 r4
Under normal physiological conditions, the length of the vessel is constant,
while the viscosity is also unchanged if there are no large changes in the
haematocrit. Therefore, the portal pressure under normal conditions is
principally affected by the portal blood flow and the radius of the blood
vessel.
Increased intrahepatic resistance
The initial event in the pathogenesis of portal hypertension is increased
intrahepatic resistance (the "backward theory") (Vorobioff and others 1983;
Grose and Hayes 1992). The non-diseased liver is very compliant and can
respond to increased portal inflow by distension of the vascular tree, thus
maintaining the normal equilibrium and maintaining normal portal pressure
(Greenwark and Stark, 1971). However, in portal hypertension there is
increased resistance to portal inflow, principally due to fibrosis and
regenerative nodules compressing the vasculature. In addition, it has been
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shown that swelling of hepatocytes and capillarisation of hepatic sinusoids
(loss of endothelial fenestrations and collagen deposition in the space of
Disse) are part of the increased vascular resistance.
There are fixed anatomical factors responsible for this increased resistance,
and reversible factors. The latter is more complex and had been the focus of
much research, and it has been demonstrated that intrahepatic resistance can
be reduced by as much as 20-30% by pharmacological therapy (Bhathal and
Grossman 1985).
The activated hepatic stellate cell (HSC), similar to pericytes in other
organs, has been shown to contract or relax in response to vascular
mediators such as endothelin-1 (ET-1) (Kojima and others 2001), and
angiotensin II (ANG II) (Bataller and others 2000). Furthermore, the
activated HSC also plays an important role in hepatic fibrosis (Poo and
others 1999). The role of vascular mediators will be explored later.
Circulatory changes
Increased intrahepatic resistance leads to the formation of the collateral
circulation to decompress the portal circulation. The increased collateral
blood flow through the formation of porto-caval shunts may contribute to a
reduction in the portal blood flow and hepatic perfusion (Lebrec and
Moreau 2001). However, portal hypertension is sustained as a result of
increased splanchnic blood flow in an attempt to rectify the reduced hepatic
perfusion, or the "forward theory" (Vorobioff and others 1983; Grose and
Hayes 1992). The presence ofmarked splanchnic vasodilatation in patients
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with cirrhosis was reported by Kotelanski (Kotelanski and others 1972),
although the exact pathogenesis remains uncertain.
Cirrhosis and portal hypertension results in the hyperdynamic circulation
first described by Kowalski & Abelmann (Kowalaski and Abelmann 1953),
and later validated by others (Murray and others 1958). The characteristic
features are increased cardiac output and decreased systemic vascular
resistance, the latter mainly due to splanchinc vasodilatation. It has been
proposed that peripheral vasodilatation may also contribute to reduced
systemic vascular resistance (Schrier and others 1988), although some
investigators suggest the peripheral circulation is vasoconstricted due to
increased vasoconstrictor mediators such as angiotensin II and endothelin
(Newby and Hayes 2002). Heart rate and stroke volume are also increased
and directly proportional to cardiac output. These findings occur in patients
with both intrahepatic (Bayley and others 1964) and extrahepatic portal
hypertension (Lebrec and others 1983). The arterial pressure in patients with
portal hypertension is normal or lower than in controls (Lowke 1962;
Mashford and others 1962). In addition, the severity of liver disease is
inversely proportional to the arterial pressure (Plevris and others 1990).
Furthermore, cardiac output is higher in patients with cirrhosis and liver
failure with ascites than in patients with good liver function (Fernandez-
Seara and others 1989) without ascites (Braillon and others 1986). Systemic
haemodynamic alterations are associated with a significantly increased total
plasma volume (Perera 1946), which is correlated with the severity of the
liver disease and the presence of ascites. Effective blood volume or central
blood volume, i.e. the volume in the heart cavities, lungs and central arterial
19
tree, appears to be reduced in patients with cirrhosis (Hendrickson and
others 1989).
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1.2 Development of varices and variceal haemorrhage.
1.2.1 Background.
The development of gastro-oesophageal varices and subsequent variceal
haemorrhage is the most serious complication of portal hypertension. At the
time of diagnosis, 30% of compensated cirrhotic patients and 60% of
decompensated patients have varices (D'Amico, Balliers, 1997), and at least
two thirds of cirrhotics will develop varices during long term follow up
(Anonymous 1988). The in-hospital mortality following the first variceal
bleed varies from 30% to 50% (D'Amico and others 1995; Stanley and
Hayes 1997). Although this exceeds that ofmyocardial infarction, not every
hospital in the UK has specialised units to manage variceal haemorrhage.
These dismal statistics have been the stimulus for much research in the
prevention of the first variceal bleed and the prevention of variceal
rebleeding.
1.2.2 Anatomical considerations.
An understanding of the fundamentals of the anatomy of the portal system,
and the formation of varices is essential to appreciate the phenomenon of
variceal bleeding, and the therapies available to manage portal hypertension.
The portal vein is 6-8 cm long, 1.2 cm in diameter and is formed by the
union of the superior mesenteric and splenic vein posterior to the neck of the
pancreas. It then runs posterior to the duodenum to divide into the right and
left branch. The system then drains into the liver.
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Of interest to investigators in portal hypertension is the detailed venous
drainage of the oesophagus. This comprises of the following components
(Butler 1951):
a. Intrinsic veins that are within the wall of the oesophagus comprising
subepithelial and submucous veins, the latter of which have
perforating veins that penetrate the muscle layers of the oesophagus.
b. Extrinsic veins which form from the perforating veins. They drain to
larger venous trunks in the neck (inferior thyroid veins), the thorax
(azygous veins), and abdomen (left gastric vein).
The intrinsic circulation of the lower oesophagus and upper stomach is of
particular relevance to clinicians, since it is at these sites that bleeding
secondary to portal hypertension occurs most frequently. There are 4 clearly
defined areas, which have been studies extensively (Vianna and others
1987):
Gastric zone
This is 2-3 cm in length, extending downwards from the gastro-oesophageal
junction. The veins are within the lamina propria and submucosa, which
drain into the left gastric vein and splenic vein via the short gastric veins
and polar gastric vein.
Palisade zone
This is 2-3 cm starting from the gastro-oesophageal junction, in continuity
with the gastric zone. The veins are located predominantly in the lamina
propria, with there being no anastamosis between the extrinsic and intrinsic
circulations. The gastro-oesophageal junction is the only part of the
alimentary canal that separates two luminal structures with opposite cavitary
pressures (Cohen and Harris 1972).
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Perforating zone
This commences 2-3 cm above the gastro-oesophageal junction, extending
for 2 cm proximally. The veins continue from the lamina propria of the
palisade zone. The characteristic features of this zone are the perforating
veins. These veins occur at the confluence of the veins from the palisade
zone, form loops draining caudally, and then pass at right angles through the
layers of the oesophagus to its outer surface. The similarity with the musical
sign has led to them being referred to as "treble clef' veins. Thus, the
perforating zone acts as the principal means of communication between the
intrinsic and extrinsic systems.
Truncal zone
This zone extends for 8-10 cm above the perforating zone. The veins run in
the submucosa, and drain distally into the perforating zone. There are also
perforating veins scattered throughout this zone.
Anatomical changes duringportal hypertension
In the presence of portal hypertension the collateral circulation develops in
an attempt to decompress veins at the cardia, anal canal, falciform ligament,
the abdominal wall and retroperitoneal tissues, the diaphragm, stomach,
pancreas, spleen, adrenal, and testis via the left renal vein. Gastro-
oesophageal varices occur within the framework of the intrinsic veins.
However, in portal hypertension the vessels are more dilated and tortuous,




Fundal varices were noted to be present in 40% of patients in one series
(Vianna 1988), with the main source of supply being the short gastric veins
(Smookler 1956).
Varices in the gastric and palisade zones
These varices are located predominantly within the submucosa, just below
the gastro-oesophageal junction, being principally supplied by the left
gastric vein. Also seen in the palisade zone are varices in the cardia that are
in continuity with those at the lower oesophagus arranged in a longitudinal
pattern.
Varices in the perforating and truncal zones
The perforating zone is the main site of oesophageal varices of clinical
relevance. In the presence of portal hypertension the perforating veins
become incompetent allowing the retrograde flow of blood from the
extrinsic circulation to the intrinsic circulation (McCormack and others
1983). This turbulent blood flow can be exacerbated by pressure changes
resulting from respiratory movements, coughing and stretching. The
presence of much perforating veins at regular intervals in this zone explains
why varices form in large nodular patterns here, and also tend to bleed in the
distal rather than proximal oesophagus.
Para-oesophageal varices
The extrinsic circulation is dilated in two-thirds of patients with cirrhosis
(Vianna 1988). The para-oesophageal varices are grossly dilated, with
tortuous extrinsic vessels extending from the lower third of the oesophagus
and proximal stomach, draining into the azygous system in the thorax, and
left gastric vein in the abdomen. Interestingly, para-oesphageal varices may
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occur without there being gastro-oesphageal varices in 13% of patients with
portal hypertension in one series (Vianna 1988). These patients may have
effective shunts diverting venous blood to the extrinsic circulation. The
observation that the azygous blood flow is not related to the presence of
oesophageal varices supports this (Cales and others 1985). There is also
recent evidence to suggest that patients with large para-oesohageal varices
have a greater risk of developing recurrent varices and rebleeding following
endoscopic variceal eradication (Leung and others 1997).
1.3 The natural history of gastro-oesophageal varices.
1.3.1 Variceal formation.
Recent studies based on endoscopic appearances studies suggest that at least
two thirds of cirrhotic patients will develop oesophageal varices during their
lifetime (Lay and others 1997) (Anonymous 1988). Larger or high risk
oesophageal varices as defined endoscopically are seen in 15 -25 % of
patients in these studies. Work by Schepis and colleagues demonstrated that
the risk of developing varices is greater in those with prothrombin activity
less than 70%, platelet count less than 100 000/mL, and ultrasonographic
portal vein diameter greater than 13 mm (Schepis and others 2001).
There are relatively few studies reporting on the incidence of gastric varices.
Sarin reported an incidence of just 4% in cirrhotic patients who had not bled
(Sarin and others 1992), although this increased to 27% in patients who had
a history of gastrointestinal bleeding. He defined four subtype of varices
(Figures la-Id): 1) GOV 1 (gastro-oesophageal varices type 1), which are
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oesophageal varices extending distally for 2-5 cm below the gastro-
oesophageal junction; 2) GOV 2 (gastro-oesophageal varices type 2), which
are oesophageal varices extending into the gastric fundus; 3) IGV 1 (isolated
gastric varices type 1), which are gastric varices in the fundus not in
communication with oesophageal varices; and 4) IGV 2 (isolated gastric
varices type 2), which are gastric varices in other parts of the stomach.
GOV1, the commonest at 70% of gastric varices, are also known
descriptively as cardial varices. GOV2 and IGV I, at 21% and 6.7% of
gastric varices respectively, together are referred to as fundal varices. Others
have shown that 25.1% of cirrhotics had gastric varices at screening
endoscopy, with 18.2 % of patients having both oesophageal and gastric
varices (Kim and others 1997).
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Figure la: Figure lb:
Gastro-oesophageal varices type 1 Gastro-oesophageal varices type 2
Figures la-Id: Sarin's classification of gastric varices (Sarin and others 1992).
1GV2
Figure 1c:
Isolated gastric varices type 1
Figure Id:
Isolated gastric varices type 2
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1.3.2 Progression ofvarices.
Once oesophageal varices have developed, their rate of progression is very
variable. They may even regress as has been demonstrated in one study of
patients with alcoholic liver disease during periods of abstinence (Dagradi
1972). Others have reported an annual incidence of oesophageal varices of
up to 12% per year in patients with severe primary biliary cirrhosis over a
5.6 year follow up period (Gores GJ, Gastroenterology 1989). A recent
study published in abstract form reported on 484 cirrhotic patients who did
not have oesophageal varices, followed up over 131 months (D'Amico and
others 2001). 41% of patients developed oesophageal varices at 10 years,
and the progression from small to large varices was 5% per year.
1.3.3 Riskfactors for thefirst variceal haemorrhage.
The factors related to the development of the first variceal haemorrhage and
variceal rebleeding has been extensively studied over the last two decades.
The risk of the first variceal haemorrhage varies from 5% per year in an
unselected population, up to 30% in patients with large oesophageal varices
(D'Amico and others 1995; D'Amico and others 1999). The risk of bleeding
in patients with small varices is 7%.
Clearly the size of varices is important in order to identify those most at
risk. Where good views can be obtained, most endoscopists are in
agreement about the size and colour of oesophageal varices (Anonymous
1987). A recent study of 251 patients screened for entry into a randomised
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controlled trial revealed that 35% of patients had large or very large varices,
20.8% had medium sized varices, and 25.3% had small varices (Jensen
2002). A simplified way of grading oesophageal varices had been adopted
by our unit (Jalan and Hayes 2000) as follows: 1) Grade 1 - varices that
collapse after air insufflation; 2) Grade 2 - varices between grade 1 and 2;
3) Grade 3 - varices large enough to occlude the lumen.
It has also been reported that the presence of endoscopic appearances
consistent with reduced variceal wall thickness, such as red signs and red
whale markings signify a high risk of variceal bleeding (Dagradi 1972;
Beppu and others 1981). Beppu and colleagues reported that 80% of
patients with blue varices and cherry red spots bled, although subsequent
studies suggest that this is probably an overestimate (Anonymous 1988).
The influence of portal pressure on the risk of variceal bleeding has been
extensively studied. Variceal bleeding is uncommon below a threshold
hepatic venous pressure gradient (HVPG) of 12 mm Hg (D'Amico and
others 1995). Groszmann and associates looked at a larger number of
patients in a randomised double-blind placebo controlled trial to investigate
whether lowering the HVPG with propranolol protects against a variceal
bleed over a 2-year follow-up period (Groszmann and others 1990). They
found that a HVPG of < 12 mmHg protected patients from variceal
haemorrhage and improved survival. However, it is not clear whether a
higher value of HVPG increases the risk of varices.
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Variceal wall tension also plays an important role in determining the risk of
variceal bleeding (Polio and Groszmann 1986). Once variceal wall tension
exceeds the elastic limit of the vessel the first variceal bleed will occur. The
following equation defines the various factors responsible for variceal wall
tension (WT):
WT = (Pi - Pe) X r/w
Pi is intravariceal pressure, Pe the oesophageal luminal pressure, r the radius
of the varix, and w the thickness of the variceal wall. It can be seen that the
WT varies directly with the radius of the varix, and the difference between
the intravariceal pressure and the intraluminal pressure. Another important
concept is that varices can bleed even at low pressures if they are large as in
the case of significant fundal gastric varices, a phenomenon previously
reported in our unit (Stanley and others 1997a). The presence of a negative
intrathoracic pressure also explains why oesophageal varices are more likely
to bleed than varices at other sites.
The severity of liver disease on the risk of the first variceal bleed was
originally confirmed by the North Italian Endsocopy Club (NIEC) in a
prospective study of 321 patients over a median follow up of 23 months
(Anonymous 1988). Multiple regression analysis revealed that the Child
class, presence of red whale signs, and size of oesophageal varices were
independent predictors of the first variceal haemorrhage. These variables
were used to derive a prognostic NIEC index on the risk of variceal
bleeding. There was a striking 40 times increased 1 year cumulative risk of
bleeding between the lowest and highest risk patients.
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1.3.4 Riskfactors for variceal rebleeding.
The risk of variceal rebleeding is highest in the first 5 days, being as high as
40.5% (de Franchis and Primignani 2001), and is much reduced after 6
weeks (Graham and Smith 1981). A third of patients experience rebleeding
within the first 6 weeks, and only a third of survivors rebleed thereafter. A
significant number of early rebleeding episodes are associated with death,
emphasising the need to develop therapies that prevent early rebleeding. The
studies also highlight the need to scrutinise the timing of randomisation
when comparing clinical trials of therapies to prevent early rebleeding.
The reported risk factors for early rebleeding include low albumin, the
presence of gastric varices, high blood urea and infection. HVPG has also
been studied and values of>16-20 mmHg have been associated with
rebleeding (Ready and others 1991; Moitinho and others 1999b). A recent
study with a 8 year follow up of patients on pharmacological therapy
identified an increase in HVPG > 20% of baseline or a HVPG > 12 mmHg
as independent risk factors associated with rebleeding and increased
mortality (Abraldes and others 2003).
1.3.5 The outcome ofpatients with varices and variceal haemorrhage.
Despite all the advances in therapy, the mortality after variceal haemorrhage
remains high. The development of varices in cirrhotic patients puts them in
a worse prognostic group, even before they have bled. Studies indicate that
once varices have developed the progression from compensated to
decompensated cirrhosis doubles compared with patients who have not
developed varices (D'Amico and others 1986; Pagliaro and others 1994).
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The mortality of compensated cirrhotic patients is 1% per year, but in the
presence of varices increases to 3.4% per year. After variceal bleeding and
in the presence of ascites the mortality increases several fold to 57%, with
most deaths occurring within the first 6 weeks after the index bleed. The
long-term mortality after variceal rebleeding varies between 4 and 78%,
with a mean of 46% (de Franchis and Primignani 2001).
The most important variable influencing the mortality after variceal
bleeding the severity of liver as defined by the Child Pugh score (Jalan and
Hayes 2000). The 1-year mortality for patients in Pugh Class A, B, and C
are 5%, 25%, and 50% respectively. Markers of the severity of portal
hypertension such as the HVPG are also important indicators of the
mortality (Vinel and others 1986). A recent study by Moitinho and
colleagues demonstrated that a HVPG of> 20 mm Hg measured shortly
following a variceal bleed was associated with a 64% 1 year mortality
compared with 20% where the HVPG was < 20 mm Hg (Moitinho and
others 1999b). A recent study over a 8 year follow up period of patients on
pharmacological therapy identified HVPG > 20% of baseline or a HVPG >
12 mmHg as independently associated with mortality (Abraldes and others
2003).
1.3.6 Gastric varices.
Gastric variceal bleeding has not been so extensively studied. It is known
that the natural history of bleeding gastric varices differs from that of
oesophageal varices. Although the risk of bleeding from gastric varices is
less than that of oesophageal varices, the outcome once bleeding has
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occurred is worse, particularly for isolated gastric varices (1GV) (Sarin and
others 1992). It has been reported that patients with large gastric varices
have a lower portal pressure than those with oesophageal varices (Chao and
others 1993; Stanley and others 1997a) which may be as a result of the
development of gastro-renal porto-systemic shunts (Watanabe and others
1988) or large size of the varices resulting in increased variceal wall tension
as noted above. Wantabe and colleagues also demonstrated increased
collateral flow at the expense of reduced portal venous flow in patients with
gastric varices. The authors proposed that reduced portocollateral resistance
might account for the latter finding. However, it is unclear as to why
patients bleed at portal pressures of < 12 mmHg. Other factors such as the
presence of red spots, variceal size and that of gastritis may be important.
Therefore, particularly in patients with gastric varices it would not be safe to
regard reducing the portal pressure gradient of < 12 mmHg as a therapeutic
goal.
33
1.4 Drug therapy for portal hypertension
There have been major advances in the primary and secondary prevention of
variceal haemorrhage over the last 20 years involving endoscopic,
radiological and pharmacological approaches. Many of these drugs have not
been studied in clinical trials, but provide data about the underlying
pathogenesis of portal hypertension (Table 1). Despite the recent increase in
the use of alternative endoscopic therapies, an effective and we II-tolerated
drug remains a clinically important goal.
1.4.1 Haemodynamic studies ofagents used in portal hypertension
Propranolol was the first drug used to reduce portal pressure in 1982 by
Didier Lebrec (Lebrec and others 1982). Since then an improved
understanding of the mechanisms behind portal hypertension has led to the
use of a variety of pharmacological agents that act by altering portal
haemodynamics favourably.
Many studies have looked at the HVPG as a prognostic marker and as a
guide to the efficacy of pharmacological agents. The HVPG is the
difference between the wedged hepatic venous pressure (WHVP) and free
hepatic venous pressure (FHVP). The HVPG correlates with the true portal
pressure in patients with alcoholic cirrhosis (Boyer and others 1977),
hepatitis B (Lin and others 1989)and hepatitis C (Perello and others 1999),
but underestimates the true portal pressure in conditions such as primary
biliary cirrhosis and chronic active hepatitis (Boyer and others 1977).
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The aim of pharmacological therapy is to prevent or reduce the risk of
variceal bleeding, and because this is unusual if the HVPG is less than 12
mmHg, this has been adopted as a haemodynamic target (Groszmann and
others 1990). A reduction in the portal pressure of greater than 20% has also
been proposed as a therapeutic goal (Feu and others 1995). In clinical
practice it is also important to combine drug efficacy with tolerability.
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In 1982 Lebrec and colleagues investigated the portal hypotensive effect of
propranolol in a placebo-controlled haemodynamic study in alcoholic
cirrhotic patients (Lebrec and others 1982).Other studies have corroborated
these findings reporting reductions in the HVPG of between 10 and 31%
(Table 2). The fall in portal pressure is produced by a combination of
reduced cardiac output (beta i antagonism) and reduced splanchnic blood
flow (beta i antagonism). Changes in portal blood flow are probably mainly
a result of beta i blockade (Bosch and others 1984). It was also observed by
others that propranolol consistently reduced collateral blood flow as derived
from the azygous blood flow, which is elevated in patients with portal
hypertension (Mastai and others 1987).
Vorobioff and colleagues (Vorobioff and others 1987) studied the acute and
chronic effects of propranolol on alcoholic cirrhotics with oesophageal
varices over an average of 106 days. A portal hypotensive effect of 25%
was maintained chronically. However, 30% of patients failed to respond
after chronic dosing. This paper highlighted the considerable non-response
rate to propranolol confirmed by later studies of up to 38% following long
term follow up (Abraldes and others 2003). This may be explained by a
portal hypertensive model demonstrating that a rise in the portocollateral
resistance accompanies the reduction in portal blood flow thus reducing the
overall portal hypotensive response to propranolol (Kroeger and Groszmann
1985).
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Table 2: The effect of propranolol on portal and systemic
haemodynamics.




















(% decrease from the baseline)
Lebrec, 1982 40mg All A Acute Not stated 31 23 12 Not
stated
Bosch, 1984 83mg Not Stated Acute 2 22.6 11.5 13.4 34.2
Mastai et, 1987 lOmg IV A/B/C:
9/3/0
Acute NS 17 10 NS 31









Westaby, 1984 > or = 2mg IV A/B: 2/7 Acute 13 31 21 Not
stated
Brail Ion, 1987 lOmg IV Mean score:
5.3
Acute NS 26 15 NS 36






Acute NS 24 13 12.8 38
Groszmann, 1990 132mg* Mean score: 8 Chronic NS 22 29 Not
stated
NS




Chronic NS 10 10 25 29
Bendtsen, 1991 160mg" A/B/C.
7/5/2
Chronic NS 20 24 39 47
Aramaki, 1992 90mg A/B/C:
7/4/0
Chronic NS 14 12 NS Not
stated
Vorobioff, 1993 140mg" Mean score:
7





- Dose required to reduce the mean pulse to 25% of baseline
NS - Not significant
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Another chronic study with a longer foliow-up period of I year failed to
demonstrate a sustained fall in portal pressure gradient when propranolol
was compared with placebo, despite significant reductions in hepatic blood
flow, azygous blood flow and cardiac index (Aramaki and others 1992).The
investigators suggested that the splanchnic hyperdynamic circulation
observed in cirrhotics might be partly reversible in some patients without
drug therapy. This may be explained by the fact that patients in the second
study were clinically better and had reduced sympathetic tone, but probably
more importantly all had stopped drinking alcohol. Patients who were not
studied after 1 year due to bleeding episodes or death could introduce
selection bias despite the initial haemodynamic parameters being
comparable to that of the group who were studied. The findings add weight
to the hypothesis that reduction in collateral blood flow and therefore
variceal blood flow is the mechanism behind the beneficial effect of
propranolol in preventing bleeding. Feu and colleagues investigated the
concept of reduced variceal flow using a non-invasive pressure sensitive
endoscopic technique (Feu and others 1993). Their findings suggested that
even in patients in whom the HVPG did not fall significantly there appeared
to be a fall in variceal pressure, of similar magnitude to those patients that
responded to propranolol.
Groszmann and associates looked at a larger number of patients in a
randomised double-blind placebo-controlled trial to investigate whether
lowering the HVPG with propranolol protects against a variceal bleed over a
2-year follow-up period (Groszmann and others 1990). They found that a
HVPG of less than 12 mmHg protected patients from variceal haemorrhage
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and improved survival. It is of note that in this study almost all patients bled
within the first year and that treatment with propranolol did not result in a
greater portal pressure reduction than placebo after 3 months of treatment,
suggesting propranolol had a protective effect earlier on. The authors did
point out that this might have been due to a greater dropout rate of patients
with the highest pressures in the placebo group from terminating events
such as variceal bleed and death. Fifty-one patients were studied in both
groups and after 24 months the final number was 9 and 12 in the placebo
and propranolol groups respectively. It is questionable whether these small
numbers allow meaningful analysis. Values for HVPG were higher in the
patients who dropped out of the placebo group at 3-12 months. However,
other papers (McCormack and others 1983; Stanley and Hayes 1997;
Abraldes and others 2003) have supported this observation, lire latter study
concluded that an increase in HVPG > 12 mmHg or a 20% increase in
HVPG independently predicted death or bleeding (Abraldes and others
2003). Interestingly it has been demonstrated that bleeding may occur at
pressures below the threshold level of 12 mmHg (Jalan and others 1995c),
although the numbers quoted in this study are quite small.
Nadolol.
Nadolol is also a non-selective beta-blocker, which was first studied by
Gatta and colleagues (Gatta and others 1984; Gatta and others 1985; Merkel
and others 1986; Gatta and others 1987a). These studies suggested a similar
mechanism of action and efficacy to propranolol. Nadolol, unlike
propranolol, has low hepatic metabolism and lipid solubility resulting in a
longer half life. The main chronic effects at a dose that reduced the heart
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rate by 25% were of significant reductions in HVPG (19-22%), cardiac
output and effective hepatic blood flow. Mean arterial pressure, liver and
renal functions were all unaffected. Recent studies also suggest that nadolol
therapy results in a significant reduction in portal blood flow and renal blod
flow (Bolognesi and others 1994).
Timolol.
This is a non-selective beta-blocker that has only been studied in one
haemodynamic study (Escorsell and others 1997). The mean reduction in
the portal pressure gradient was 20%, which is comparable to that of
propranolol and nadolol. The drug has not been studied in any clinical trials.
Atenolol.
Hillon and colleagues, in a comparative haemodynamic study with
propranolol, first investigated atenolol, a selective beta i receptor antagonist
in portal hypertensive patients with cirrhosis (Hillon and others 1982). They
found a 16% reduction in HVPG, which significantly correlated with
cardiac output. Propranolol produced a greater reduction of portal pressure,
although the reduction in cardiac output was similar to that of atenolol. It
was postulated that the extra-cardiac effects of propranolol were responsible
for the difference.
Another comparative study looked at the effect of atenolol, propranolol and
prazosin (an alpha blocker) on portal haemodynamics in a chronic study
with an 8-week follow-up period (Mills and others 1984). Atenolol resulted
in a non-significant 15% reduction in HVPG compared with a significant
25% reduction in HVPG with propranolol therapy. The findings again
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suggested a significant correlation between cardiac output and portal
pressure with atenolol but not with propranolol. Both beta-blockers were
well tolerated.
Atenolol therefore appears less effective at reducing portal pressure than
propranolol, which suggests that the beta 2 receptor blockade has a major
role to play in the mechanism of action propranolol.
Metoprolol.
Metoprolol is another beta 1 selective beta-blocker. Initial haemodynamic
studies suggested that it was of equal efficacy to propranolol in reducing
portal pressure (Westaby and others 1984). The study also demonstrated
significant falls in cardiac output in both groups, but a reduced hepatic
blood flow only in the propranolol group. The latter finding led the authors
to conclude that metoprolol may even be preferable to propranolol in
patients with advance liver disease. It has, however, been little studied.
Beta 2 receptor antagonists
ICI 11855 is a selective beta 1 antagonist, which was studied by Bihari et al.
in 17 patients (Bihari and others 1984). There was a significant reduction in
the portal pressure 60 min following administration of the drug, which was
accompanied by significant reductions in the heart rate and cardiac index,
both of which were not related to the fall in the portal pressure.
Another selective beta 2 antagonist mepindolol was compared with
intravenous propranolol in patients with cirrhosis and portal hypertension by
Brallion and colleagues (Braillon and others 1985). The effect on the HVPG
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and systemic circulation was similar to that of propranolol, but at the
expense of significantly reduced hepatic blood flow, which was not the case
with propranolol. Clearly both these drugs have a significant effect on the
systemic circulation, and mepindolol offers no benefit over propranolol in
reducing portal pressure. This may explain why they have not been studied
further.
Carvedilol
Carvedilol is a novel vasodilating non-selective beta-blocker with weak
alpha i receptor antagonism and calcium channel antagonism. It has a rapid
onset of action with 2-4 times greater beta-blocking action than propranolol.
Forrest and colleagues performed the first acute haemodynamic study on
cirrhotic patients using 25 mg oral carvedilol (Forrest and others 1996a). A
20% fall in HVPG from 17 to 14 mmHg was achieved mainly due to a fall
in wedge hepatic venous pressure. A significant fall in MAP of 10% was
noted particularly in ascitic patients. Hepatic blood flow, azygous blood
flow and renal blood flow were unaffected. This effect of carvedilol on
HVPG was similar to that of propranolol as demonstrated in previous
studies (Table 2). The chronic effect of carvedilol was investigated by
Stanley et al (Stanley and others 1999). A 21% drop in HVPG was
maintained chronically. The fall in HVPG was mainly as a result of a
significant drop in the wedge hepatic venous pressure. There was no change
in renal function or hepatic blood flow. Poor tolerability was noted in three
out of the 17 patients who experienced dizziness, breathlessness or
hypotension.
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Further studies have demonstrated a reduction in HVPG of between 13%
and 27% follwing acute administration of carvedilol, and greater efficacy
than propranolol (Banares and others 1999) (Banares and others 2002) (De
and others 2002). All studies demonstrated a significant reduction in the
mean arterial pressure, an effect which may limit clinical efficacy. Lower
dose regimes may address this issue, but such studies are relatively few (De
and others 2002) .To date there are no clinical studies looking at the effect
of carvedilol in preventing variceal bleeding.
Nitrates
Isosorbide-5-mononitrate (ISMN) is a long acting organic nitrate, and is the
only nitrate to be used in large randomised controlled trials for preventing
variceal bleeding. The molecular mechanism of action of nitrates is
uncertain. It is thought the vasodilatory actions may be a result of enhanced
production of intrahepatic nitric oxide or cyclic-GMP (Abshagen 1992).
There have been a number of haemodynamic studies using ISMN in patients
with portal hypertension (Table 3). All the studies with the exception of one
(Tsai and others 1989), which included predominantly Childs A patients,
demonstrated significant reductions in the HVPG. This appears to have been
achieved by a fall in the WHVP. Three studies looking at the chronic effects
show that the effect of reduced portal pressure is sustained (Garcia-Pagan
and others 1990; Grose and others 1994; Jones and others 1995). Indeed the
portal hypotensive effect seemed to be amplified after rechallenge following
chronic dosing, confirming lack of tolerance.
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Pronounced effects on other parameters may help to explain the mechanism
underlying the fall in HVPG, which is comparable to that of propranolol.
Early studies (Hayes and others 1988) noted that the hepatic blood flow fell
acutely, and this along with an increase in systemic vascular resistance
index (SVRI) suggested that a baroreceptor-mediated splanchnic
vasoconstriction may be responsible for the fall in portal pressure rather
than portal venous dilation. However, recent work demonstrated a
significant fall in the portal pressure gradient without affecting the portal
blood flow in patients with a transjugular intrahepatic portosystemic stent
shunt (TIPSS) (Forrest and others 1996b). It was clear, therefore, that in the
study group of patients reflex baroreceptor-mediated vasoconstriction of the
splanchnic bed could not be the case and that any vasoconstrictive effect to
account for the rise in SVRI was limited to the periphery. The observed
findings were attributed to reduced intrahepatic vascular resistance rather
than a reduction in the liver blood flow (which would be undesirable).
Chronic administration resulted in no change or even an increase in the
hepatic blood flow (Navasa and others 1989; Garcia-Pagan and others 1990)
and may reflect the buffer response of hepatic artery blood flow to a
decrease in portal llow (Lautt 1985).
Isosorbide-5-mononitrate also reduces the cardiac preload and hence the
cardiac output, at least acutely. Significant correlation between the reduction
in portal pressure gradient and cardiac output suggests that this may partly
be responsible for the reduced portal blood flow observed in this study
(Hayes and others 1988). In all cases the mean arterial pressure fell acutely.
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It is interesting to note that chronic administration does not appear to have a
significant effect on cardiac output or mean arterial pressure.
Azygous blood flow has already been demonstrated as a useful indicator of
variceal blood flow in patients with cirrhosis (Bosch and Groszmann 1984).
Azygous blood flow responds in a variable fashion to ISMN. Jones and
colleagues demonstrated no significant change in the azygous blood flow in
response to varying doses of nitrates, both acutely and following chronic
dosing (Jones and others 1995). However, a relationship was noted between
baseline azygous blood flow and the response to nitrates, with those patients
with a high azygous blood flow responding by reducing their flow and vice
versa. The dose did not seem to influence the azygous blood flow.
Nitrate tolerance is clearly documented in cardiovascular medicine
(Elkayam and others 1987; Jugdutt and Warnica 1989) However, of the
studies looking at the chronic effects of ISMN therapy only one has reported
partial tolerance in five out of 11 patients (Garcia-Pagan and others
1990),with others reporting no tolerance (Grose and others 1994; Jones and
others 1995).The exact mechanism behind why patients with cirrhosis do
not develop nitrate tolerance is unknown. It has been suggested that patients
with cirrhosis may not be able to develop compensatory mechanisms that
are necessary to bring about nitrate tolerance (Jones and others 1995).
An important observation with nitrate monotherapy has been the deleterious
effect on renal function (Salmeron and others 1993). Activation of the renin-
angiotensin system was felt to be a major factor. In particular, patients with
ascites suffered from a reduced glomerular filtration rate, sodium excretion
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and renal plasma flow. It is interesting that combination therapy with other
portal hypotensive agents abolished these undesirable renal effects. The
combination therapies will be covered later.
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Drugs acting on alpha-adrenergic receptors
Prazosin.
Prazosin is an alpha i receptor blocker, which was initially studied by Mills
and colleagues in a comparative haemodynamic study with propranolol and
atenolol over an 8-week follow-up period (Mills and others 1984). An 18%
reduction of the HVPG was obtained with prazosin compared with 25%
with propranolol. Prazosin did not affect the cardiac index or hepatic blood
flow, and had no effects on renal function or sodium handling. It acts by
reducing intra-hepatic resistance. In a recent study impressive results were
obtained with acute and chronic reductions in the HVPG of 25.7% and
19.1% respectively, which are comparable to propranolol (Albillos and
others 1994). However, this was accompanied by a significant fall in the
MAP and systemic vascular resistance. An important finding in this study
was the tendency to increased ascites and oedema as a result of a reduction
in sodium excretion and expansion of the plasma volume. Tolerance was
also felt likely to have occurred following chronic administration. Hepatic
blood flow and liver function, as quantified by indocyanine green clearance
and galactose elimination, were noted to have improved. These findings
were mirrored in a subsequent study and thus the use of prazosin in clinical
practice was not an attractive proposition (Albillos and others 1995). There
are at present no clinical trials using prazosin in primary or secondary
prophylaxis of variceal haemorrhage.
Clonidine.
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Clonidine is a centrally acting alpha 2 agonist that acts by reducing
peripheral noradrenaline outflow and thus the sympathetic tone in patients
with cirrhosis (Willett and others 1986; Moreau and others 1987; Esler and
others 1992). A fall in the HVPG was believed to occur secondary to
reduced post sinusoidal hepatic vascular resistance. Azygous blood flow
was reduced, but hepatic blood flow remained unaffected. The change in
hepatic haemodynamic parameters was unrelated to changes in the systemic
haemodynamics, where there was a reduction in the cardiac output and
mean arterial pressure. The hepatomesenteric circulation was more sensitive
to the actions of clonidine in cirrhotic patients compared with healthy
controls. Clonidine resulted in a greater fall in the portal pressure compared
with propranolol (Albillos and others 1992), and a recent study looking at
the effects of clonidine and propranolol in cirrhotic patients found that only
propranolol or a combination of propranolol and clonidine resulted in a fall
in the portal blood flow (Tincani and others 1995). Despite these results,
there are no randomised clinical trials using clonidine for primary or
secondary prophylaxis in patients with varices. The effect on systemic
haemodynamics may limit its use.
Drugs acting on the renin-angiotensin system
The interest in ANG II receptor antagonism stems from the observation that
there is activation of the renin-angiotensin system in cirrhosis, the degree of
which is proportional to the severity of cirrhosis, and portal hypertension
(Bosch and others 1980). Studies have shown that ANG II has a direct effect
on portal pressure, via ATI type receptors (Campbell and others 1991).
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Animal models demonstrate that ANGII mediates vasoconstriction of the
portosystemic collaterals leading to increased portocollateral resistance
(Campbell and others 1991), and to have diminished vasoconstrictive effects
on the splanchnic circulation leading to increased portal blood flow
(Sitzmann and others 1990). Recent interest has concentrated on the role of
the activated hepatocyte stellate cells (HSC), particularly in light of the
finding that ATI type receptors on human activated HSC mediate the
vasoconstrictive and mitogenic actions of ANG II (Bataller and others 2000;
Rockey 2000). Blockade of the ATI receptor may therefore result in
relaxation of the activated HSC and reduced intra-hepatic resistance and
portal pressure. This selective blockade may also result in the unopposed
action of ANG II on AT2 type receptors, leading to endothelium mediated
vasodilatation, further enhancing the pharmacological effects of such agents
(Burnier 2001).
Saralasin
Initial attempts at ANG II receptor blockade were hindered by pronounced
systemic hypotension (Arroyo and others 1981), although the latter was not
seen at higher doses possibly due to the partial agonist effect of saralasin at
such doses, leading to vasoconstriction and potentially hypertension
(Burnier 2001). Newer agents such as losartan and irbesartan, which have
no intrinsic agonist activity, have resulted in greater success (Debernardi-
Vernon and others 1999; Schneider and others 1999).
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Losartan
Losartan is a pro drug that is converted to the active metabolite E-3174,
whose maximum plasma levels are obtained after 3-4 hours. It was used at a
dose of 25 mg/day in 45 patients with cirrhosis and either moderate or
severe portal hypertension, in a study by Schneider and colleagues
(Schneider and others 1999). Both acutely after 4 hours and following
chronic administration there was a significant reduction in the portal
pressure approaching 45%, the largest reported to date for any
pharmacological agent. This is particularly impressive considering the
minimal effect on blood pressure, with only one patient experiencing
symptomatic hypotension.
Two publications have compared losartan with propranolol, with different
results (Gonzalez-Abraldes and others 2001; De and others 2003). The first
paper does not support the observation by Schneider (Gonzalez-Abraldes
and others 2001). This study randomised 25 patients to losartan at a mean
dose of 47 ± 9 mg/day following a variceal haemorrhage, and compared the
portal hypotensive effect of six weeks therapy with that of propranolol (n =
15). Propranolol produced a significantly greater reduction in the HVPG
(10% versus 2%), despite the fact that losartan had a significant effect on
MAP (-8%), which was not seen with propranolol. There was a significant
reduction in the glomerular filtration rate in Childs B patients taking
losartan, with propranolol having no detrimental effect on renal function.
Adverse effects related to therapy were reported in 28% of patients. The
second randomised study using 25 mg losartan (n = 19) reported a portal
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hypotensive effect (> 20% reduction in HVPG from baseline) in 80% of
patients compared with a 45% response rate for propranolol (n = 20),
particularly in non-ascitic patients and in alcoholic liver disease (De and
others 2003). There was no significant difference in the HVPG reduction
between losartan and propranolol of 27% and 14% respectively. The
findings are particularly striking considering the lack of adverse effects such
as systemic hypotenson or impairment of renal function.
Irbesartan.
Irbesartan, which has a longer half-life than losartan may have a more
sustained effect on portal pressure. It also has the pharmacological benefit
of not requiring hepatic conversion to the active metabolite, with no dosage
adjustment necessary in hepatic impairment (Marino and others 1998). Two
studies in cirrhotic patients have been published (Schepke and others 2001;
Venon and others 2003). In the first study (Schepke and others 2001),
cirrhotic patients randomised to irbesartan 150 mg/day experienced a mean
HVPG reduction of 12 % (p < 0.05 compared with placebo). However, there
was a significant reduction in creatinine clearance and a 22 % drop out rate
due to systemic hypotension. Natriuresis remained unchanged. In the second
study (Venon and others 2003), 300mg irbesartan for 2 months resulted in a
5% reduction in the HVPG compared with 20% for propranolol (p < 0.001).
In addition, irbesartan was poorly tolerated compared with propranolol on
account of systemic hypotension and a reduction in creatinine clearance.
Irbesartan appears to have no additional benefit over propranolol in efficacy
and tolerability.
53
Angiotensin receptor antagonists appear on the basis of the above studies
not to have significant benefits over propranolol, with the exception of the
study by Schneider and colleagues. Most of the studies have looked at
patients with more advanced liver disease with ascites, resulting in the
unfavourable side effect profile. Caution is also necessary because of the
deleterious effect on renal function demonstrated in the past with captopril
(Gentilini and others 1993).
Drugs acting on the seretonin S2 receptors
It has been shown in an experimental model that portal hypertensive animals
are more sensitive to the vasoconstrictor effects of seretonin on mesenteric
veins, and that administration of ketanserin, a 5HT2 receptor blocker with
alpha adrenergic antagonist activity, resulted in significant reductions in the
portal venous inflow and portal pressure (Cummings and others 1986).The
reduction in portal pressure caused by ketanserin was due mainly to a
decrease in portal venous inflow secondary to a decreased cardiac output, an
effect only seen in portal hypertensive rats. This would be consistent with
venous dilatation and pooling of blood in the portal venous system
secondary to 5HT2 receptor blockade. These findings led to human studies
investigating the effect of 5HT2 receptor blockade on portal pressure.
Early trials in cirrhotic patients demonstrated a significant reduction of 23%
in the HVPG following ketanserin administration, which was accompanied
by reductions in the azygous blood flow and mean arterial pressure with the
hepatic blood flow remaining unaffected (Hadengue and others 1987).
Subsequent studies corroborated these findings (Deflandre and others 1988;
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Vorobioff and others 1989). The chronic administration of ketanserin was
associated with a sustained drop in the portal pressure of 14.6%, a reduction
in the cardiac index, and a drop in the mean arterial pressure (Vorobioff and
others 1989). This study also demonstrated that 50% of patients developed
reversible portosystemic encepahlopathy. Hypotension probably results
from alpha receptor blockade.
Combination treatments have also been studied. Ketanserin in combination
with propranolol, both administrated intravenously, has been shown to
reduce the HVPG in patients who did not initially respond to propranolol
(Hadengue and others 1987). Ritanserin, a more selective serotonin S2
blocker, was combined with propranolol in a study investigating the
haemodynamic effects of the chronic dosing of these agents (Ladero
Quesada and others 1994). An initial reduction in the portal pressure was
noted, but this effect was not sustained during follow up.
These agents have not been studied in randomised controlled trials for the
prevention of variceal bleeding or for the treatment of variceal bleeding.
The high incidence of encepahlopathy observed with monotherapy, and the
potential for systemic hypotension may limit their clinical use. Combination
therapy with non-selective beta-blockers seems more promising.
Drugs affecting plasma volume
The expansion of plasma volume leading to increased cardiac index is
believed to play a major role in sustaining portal hypertension (Zimmon and
Kessler 1974). Thus diuretics or a low sodium diet may in theory help to
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reduce portal pressure. Early studies suggested that spironolactone had the
potential to be as potent a portal hypotensive agent as propranolol (Klein
1985). A significant reduction in the portal pressure of between 10 and 15%
was shown to be accompanied by reductions in plasma volume, cardiac
output, mean arterial pressure and azygous blood flow (Katsuta and others
1993; Garciapagan and others 1994; Sugano and others 1998). Hepatic
blood flow was unaffected. Although there was no significant correlation
between the plasma volume and HVPG, a significant inverse relationship
between post treatment serum aldosterone levels and the HVPG was noted,
thus confirming the mode of action of aldosterone (Katsuta and others
1993). The reductions in the HVPG following spironolactone administration
were not affected by dietary sodium content suggesting that a low sodium
diet alone is not sufficient to reduce the portal pressure (Garciapagan and
others 1994; Sugano and others 1998). A recent small study reported a good
portal hypotensive response in patients who failed to respond to propranolol,
particularly when the two drugs were combined (Sen and others 2002). In
clinical practice the use of spironolactone, like propranolol, may be limited
by its side effects, particularly painful gynaecomastia, present in 55% of
male patients in one series (Nevens and others 1996).
Combination therapy
Combination therapy was first used for the treatment of portal hypertension
using nitrates and vasopression (Groszmann and others 1982; Hallenmans
and others 1983). Enhancement of the portal hypotensive effect was
observed. Studies using propranolol, as already discussed, have revealed
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that 30% of patients failed to reduce portal pressure (Vorobioff and others
1987). This observation and the fact that nitrate monotherapy consistently
reduced portal pressure led to studies to investigate the effect of combined
nitrate and beta-blocker therapy (Table 4), a combination that was first
investigated in vitro by Kroeger and Groszmann (Kroeger and Groszmann
1985). In general there is an enhanced portal hypotensive effect of the
combination therapy using ISMN leading to a further 13-16% fall in the
HVPG. This effect is particularly striking in those patients who did not
respond to a beta-blocker alone (GarciaPagan and others 1990). The
mechanism proposed has been that of a decrease in the outflow resistance
(Merkel and others 1997). It is of note that 1 year after combination therapy
with nadolol there did not seem to be any additional effect of the nitrate
either in the hepatic or systemic haemodynamics, despite there being a
sustained effect after 3 months of therapy (Merkel and others 1999). This
may be partly explained by a study by Bendsten and associates who
demonstrated that placebo treatment had an equal effect to propranolol after
1 year suggesting that portal hypertension improves spontaneously in some
patients (Bendtsen and others 1991). Although studies looking at the short
term effect of nitrates failed to demonstrate tolerance (Grose and others
1994; Jones and others 1995), nitrate tolerance could still be an explanation
for the lack of effect due to a longer follow-up period in this study (Grose
and others 1994; Merkel and others 1999).
The hepatic blood flow and liver metabolic activity are unaffected, but the
azygous blood flow decreased in most cases with the effect being less
pronounced with longer duration of treatment. Mean arterial blood pressure
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and cardiac output both fell, again with the effect most pronounced
following acute administration.
Renal function and ascites formation have been the focus of some of the
studies (Morillas and others 1994; Merkel and others 1995; Albillos and
others 1998), particularly as ISMN has been associated with a deterioration
in renal function (Albillos and others 1994). The findings suggest that the
combination of ISMN with either propranolol or nadolol had no detrimental
effect on renal function in patients with or without ascites, despite
significant effects on hepatic haemodynamics. These encouraging findings
have led to a number of clinical trials using such combinations.
Other combination therapies have also been studied. A small randomised
study showed a greater portal hypotensive effect of prazosin and
propranolol than ISMN and prazosin, with no effect on hepatic or renal
function (Albillos and others 1998). Undesirable systemic effects
unfortunately offset the impressive hepatic haemodynamic results with more
patients experiencing symptomatic hypotension in the prazosin arm of the
study, thus limiting its use in clinical practice.
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1.4.2 Clinical application ofdrugs in portal hypertension.
Primary prophylaxis
Beta-blockers versus placebo.
Propranolol and nadolol have been compared with placebo in 11
randomised controlled trials in patients with varices (Table 5), although 4 of
these were published in abstract form (Cerbelaud and others 1986; Pascal
and Cales 1987; Strauss and others 1988; Colman and others 1990). Another
large trial involving 319 patients treated with either placebo or propranolol
is not comparable with the other trials (Plevris and others 1994). Here
patients were unselected with regard to the presence of cirrhosis and varices.
This accounts for the low event rate with just 11 patients bleeding and
probably explains why no difference was found in the two groups.
The results ofmeta-analyses of these trials are very favourable for the
treatment group, with reductions in the number of bleeding episodes
approaching 50% (Hayes and others 1990; Poynard and others 1991;
D'Amico and others 1995; Cheng and others 2003). Overall deaths due to
bleeding were significantly reduced by 45% in one of these studies and
overall deaths by 22% (p = 0.052)(Hayes and others 1990). These results
were mirrored in a recent meta-analysis (Cheng and others 2003). The other
two analyses did not show any benefit on overall survival, although in one
study mortality from bleeding episodes was reduced by 50% (Poynard and
others 1991). This analysis also demonstrated that the presence of ascites
was associated with greater mortality and bleeding risk. One of the main
problems with many of the trials is the low number of patients, resulting in
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insufficient power to detect a reduction in bleeding risk and especially
mortality. The study by Colman et al (Colman and others 1990) is unique in
showing an increase in bleeding rate in the treatment group. However, the
sample size of this study is low and the very low event rate in the control
group suggests that patient selection may have been responsible.
A recent randomised placebo controlled trial by Cales and colleagues
involving 206 patients with no or only small (< 5 mm) varices was
performed to investigate whether propranolol prevents the development of
varices (Cales and others 1999). After a 2-year follow-up period 31% of
patients in the propranolol arm and 14% of patients taking placebo
developed large varices (p < 0.05). There was no difference in the rate of
bleeding or mortality in the two groups. The low bleeding rate in the
placebo group may reflect the small numbers of patients in Child's C class
(13%). However, the high incidence of the development of varices in the
propranolol group is striking. The authors postulated that above a certain
portal pressure the development of varices is not directly related to portal
pressure and other 'non-haemodynamics' play a part. Another mechanism
proposed was that of increased vascular resistance in the collateral
circulation following propranolol administration, although it is not clear
what the relationship between collateral resistance and the development of
varices is. Until further studies are performed it is not recommended that
propranolol be prescribed for the prevention or the development of varices
and bleeding in cirrhotic patients with small or no varices.
Studies have shown propranolol to be safe in long-term use in patients with
cirrhosis, but up to a third of patients are intolerant of the side effects
61
resulting in discontinuation of the drug (Walle and others 1988). The dosage
in most of the studies is that required to reduce the resting heart rate by
25%. This usually means starting therapy with a dose 40 mg twice daily and
working up to an average maintenance dose of 160 mg/day. Nadolol is
typically administered at a dose of 80 mg/day. Fatigue is the most important
side effect. Compliance can be a major problem, especially in patients with
alcoholic liver disease.
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Tabic 5: Beta-blocker therapy in the primary prophylaxis of variceal
haemorrhage.
Number of patients Bleeding rate (%) Death rate (%)
Trial Drug Control Treatment Control Treatment Control Treatment
Pascal 1984 Propranolol 35 34 26 3 37 3
Mills, 1987 Propranolol 43 38 77 50 44 39*
Pascal, 1987 Propranolol 112 118 61 26 49 28
Anonymous 1989 Propranolol 89 85 41 26* 49 41*
Strauss, 1988 Propranolol 16 20 25 20* 44 35*
Colman, 1990 Propranolol 25 23 8 35 28 26*
Anreani, 1990 Propranolol 41 42 39 6* 46 34*
Conn, 1991 Propranolol 51 51 22 4 22 16*
PROVA, 1991 Propranolol 72 68 18 18* 19 10*
Ideo, 1988 Nadolol 49 30 30 6 18 10*
Lebrec, 1988 Nadolol 53 53 20 17* 19 19*
*
- Not significant compared with control.
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Isosorbide-5-mononitrate
There are 2 published randomised controlled trials comparing 1SMN with
placebo. In the first, there was a tendency towards reduced bleeding and
death in the ISMN group, although the results did not reach statistical
significance (Fassio and others 1993). It is also of note ISMN was well
tolerated. The second study comparing ISMN (in patients intolerant of beta-
blockers) with placebo in 133 consecutive cirrhotic patients with gastro-
oesophageal varices, reported no difference in the rate of variceal bleeding
following a 2-year follow-up period (Garcia-Pagan and others 2001). There
was no significant difference in survival. There was no difference in the
incidence of ascites or deterioration in renal function. The authors
concluded that ISMN has no place in the primary prophylaxis against the
first variceal haemorrhage.
Others have compared ISMN with propranolol (Angelico and others 1997).
This was a large randomised trial over a 7-year follow-up period involving
1 18 patients. The probability of bleeding was identical in both the groups.
Mortality was significantly greater in the nitrate group, but this was only in
patients above 50 years of age.
A smaller study demonstrated that ISMN was less effective than nadalol in
preventing bleeding in 27 patients with ascites (Borroni and others 2002).
Mortality was unaffected, but sodium excretion was reduced by almost 50%
in the nitrate group.
The use of nitrates in the primary prophylaxis is controversial, and the most
up to date evidence is against its use. Also, the reduced mortality seen with
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propranolol is not present in patients treated with nitrates. Caution is needed
in prescribing nitrate monotherapy on account of the potential for
deterioration in renal function and the increased mortality seen in the older
age group (Angelico and others 1997). This may explain why there are not
so many trials using nitrate monotherapy and many more looking at
combination therapy.
Combination therapy.
As discussed earlier, combination therapy has been shown to be effective in
producing a sustained portal hypotensive response. Nadolol monotherapy
has been compared with nadalol and ISMN dual therapy by Merkel and
colleagues with the results of long-term follow-up published recently
(Merkel and others 1996; Merkel and others 2000). Initial results following
a 30-month follow-up period in 146 patients demonstrated a significant
reduction of greater than 50% in the cumulative risk of variceal bleeding in
the combination treatment group compared with nadolol alone, with no
effect on mortality. However, there was a high incidence of side effects in
the combination group (51%), which were severe enough to cause
withdrawal from the study in 1 1 % of patients. This compares with 4% in the
nadalol only group.
Long-term follow-up of these patients over 7 years has revealed a sustained
effect of combination therapy in preventing variceal haemorrhage (Merkel
and others 2000). Survival was unaffected. A larger sample size would be
required to show up any survival differences. Two significant findings are
of note. First, long-term administration did not result in further side effects
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leading to withdrawal from the study. Thus, side effects usually occur early
after the initial doses for nitrates, and in the first few months as in the case
of beta-blockers. Secondly, there was no significant effect on the occurrence
of de novo ascites in the two groups. Previous studies have shown a
deleterious effect on renal function and sodium handling when using nitrate
monotherapy (Salmeron and others 1993).
Three double-blind placebo-controlled randomised studies have been
published (Pietrosi and others 1999; Abecasis and others 2003; Garcia-
Pagan and others 2003) The first of these compared propranolol and placebo
with propranolol and ISMN in 349 patients of whom 57% had > 5 mm size
varices (Garcia-Pagan and others 2003). Bleeding rates at 2 years in both the
groups were 10.6% and 12.5% respectively (p = NS). Mortality was also
similar in both groups, but there were significantly more side effects in the
combination group. Development of ascites and renal function were
unaffected.
The second study published in abstract form involved fewer patients
(Pietrosi and others 1999). Patients with large oesophageal varices and red
colour signs were randomised to either nadolol plus placebo (n =27), or
nadolol plus ISMN (n =30). There was no significant difference in the
bleeding rate or mortality following a 2-year follow-up. Side effects were
significantly more common in the combination group (53% vs. 26%, p =
0.03). However, the study was terminated early on account of excess
mortality in patients treated with nadolol and ISMN in a parallel trial for the
prevention of rebleeding (Patti and others 2001). Thus, it is not appropriate
to make valid conclusions based on this trial.
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The large randomised study compared nadolol plus spironolactone versus
nadolol plus placebo, and found no differences in the incidence of the first
variceal bleed but the combination therapy had a benefitial effect on the
combined end-point of bleeding and ascites (Abecasis and others 2003).
Beta-blocker and ISMN combination therapy, in particular nadolol and
ISMN, appears to be more effective than nadolol monotherapy in preventing
the first variceal bleed. Until further studies are performed there does not
appear to be any advantage in adding ISMN to propranolol. The side-effect
profile of combination therapy is considerably worse, and this is likely to
limit its clinical application. Outside of clinical trials patients and clinicians
may not be so vigilant in continuing therapy that leads to so many side
effects when alternatives such as endoscopic treatments are available.
Pharmacological agents compared with endoscopic treatments.
Sclerotherapy has been compared with placebo and propranolol in two
studies (Andreani and others 1990; Anonymous 1991), and the efficacy of
sclerotherapy and propranolol combination therapy assessed in one of these
and a further study (Anonymous 1991; Avgerinos and others 2000). One
study revealed that bleeding from a portal hypertensive source was
significantly less in the propranolol group than the sclerotherapy group
(4.7% vs. 21.4%, p < 0.003) (Andreani and others 1990). None of the
studies showed differences in variceal bleeding, or mortality when
propranolol was compared with sclerotherapy.
A recent trial, which selected patients with high intra-oesophageal variceal
pressures, randomised patients to propranolol (42 patients) or to propranolol
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plus sclerotherapy (44 patients) (Avgerinos and others 2000). After a 2-year
follow-up period, 23% of the patients in the combination group bled due to
varices or congestive gastropathy as compared with 14% in the propranolol
group (not significant). Fifty-two per cent in the combination group
developed complications as compared with 19% in the propranolol group (p
=0.002). The mortality rate was similar in both groups. The findings are
similar to those in an earlier study where patients were unselected with
regard to the characteristics of varices (Anonymous 1991).
Endoscopic band ligation is a recent technique that has been compared with
sclerotherapy in a meta-analysis (Laine and Cook 1995), and was found to
be superior to sclerotherapy in the secondary prophylaxis against variceal
rebleeding with fewer complications and quicker eradication of varices.
Band ligation has been compared with propranolol for the primary
prophylaxis of variceal bleeding in three published trials (De and others
1999) (Lui and others 2002) (Sarin and others 1999) (Table 6). In the first
study (De and others 1999), 30 patients with grade III or higher varices were
studied over a 17-month follow-up period. There was no difference in the
bleeding rate in the two groups. Sarin and colleagues (Sarin and others
1999) studied 89 patients with greater than 5 mm varices and observed that
over a 17-month period the probability of bleeding was 43% in the
propranolol group and 15% in the ligation group (p = 0.04). There was no
difference in mortality. The very high bleeding rate in the propranolol group
contrasts with that observed in other trials. The dose of propranolol was also
lower than in other trials. A recent multicentre trial involving 172 patients
compared propranolol, 1SMN and band ligation over a mean follow up of 20
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months (Lui and others 2002). Banding was superior to ISMN but similar to
propranolol in preventing the first bleed. There was no difference in the
overall mortality in the three groups. A very significant proportion of
patients had to withdraw from drug therapy as result of side effects. A meta¬
analysis of these studies and additional studies published in abstract form
(Gameel and others 1996; Chen and others 1997; Chen and others 1998)
was recently published (Imperiale and Chalasani 2001). This revealed that
banding reduced the risk of the first variceal bleed by 64% and mortality by
45% compared with controls. This compares with 52% risk reduction of the
first bleed when banding was compared with propranolol, with no effect on
mortality.
Clearly, of the two modes of endoscopic treatments, banding is preferable to
scelotherapy because there are fewer iatrogenic complications and it has
been shown to be at least as good as if not better than propranolol. Banding
is particularly useful where patients are intolerant of drug therapy.
Sclerotherapy combined with propranolol does not offer any further benefit
over propranolol monotherapy. It remains to be seen whether this is also the
case with banding. It appears that banding is at least as good as propranolol
in the primary prevention of variceal bleeding and will probably be widely
employed, because of its lack of dependence on compliance and the
attraction of eradicating oesophageal varices.
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Table 6: Studies" of primary prophylaxis of variceal haemorrhage
involving variceal band ligation





Sarin, 1996 VBL/Control 35/33 9 39b
Lay, 1997 VBL/Control 62/64 19 60b
Lo, 1999 VBL/Control 64/63 22 35
Sarin, 1999 VBL/PPL 45/44 15 43b
De BK, 1999 VBL/PPL 15/15 13 7
Gotoh, 1999 VBL/EVS 25/25 20 0b
Svoboda, 1999 EVS/VBL/Control 52/55/50 29 54c
Lui, 2002 VBL/PPL/ISMN 44/66/62 7 14/23
VBL: variceal band ligation




b: p < 0.05
c:
p < 0.05 (VBL vs Control)
70
Secondary prophylaxis
It is clear that secondary prevention following a variceal bleed is essential in
view of the high rate of rebleeding without intervention (Williams and
Westaby 1994). There is a greater choice of endoscopic, pharmacological,
radiological and surgical therapies for secondary prophylaxis than for
primary prophylaxis.
Beta-blockers versus placebo.
There were several trials in the 1980s, and a meta-analysis of these
performed in our centre revealed significant benefits of propranolol therapy
(Hayes and others 1990). In a population of 1080 patients there was a 39%
reduction in rebleeding episodes, a 40% reduction in deaths from bleeding
and a 25% reduction in total mortality in the propranolol groups.
Heterogeneity was significant for rebleeding episodes, but not when deaths
from bleeding or overall mortality were assessed. Although not all of these
trials were randomised or placebo controlled, further analysis of selected
trials that met more strict criteria and those where there was no significant
heterogeneity, demonstrated significant benefits from propranolol therapy in
the reduction of rebleeding and improved mortality rates.
There are 12 published randomised controlled trials comparing beta-
blockers with placebo against variceal rebleeding (Burroughs and others
1983; Lebrec and others 1984; Villeneuve and others 1986; Cerbelaud and
others 1986; Queuniet and others 1987; Kobe and Schentke 1987; Gatta and
others 1987b; Colombo and others 1989; Sheen and others 1989; Garden
71
and others 1990; Colman and others 1990; Rossi and others 1991) (Table 7).
Propranolol was assessed in 11, nadalol in one and atenolol in another study
which also included propranolol (Colombo and others 1989). The latter
study found atenolol to be less effective than propranolol at reducing
rebleeding and improving patient survival. A meta-analysis of these trials
(D'Amico and others 1995) demonstrated a significant reduction in the
rebleeding rate from 66% in the placebo group to 44% in the treatment
group (pooled odds ratio of 0.4). There was no significant effect of drug
therapy on survival, which may reflect the heterogeneity of the study
populations, particularly with respect to aetiology, severity of the liver
disease and the time to treatment from the index bleed. Only two of these
studies included a significant proportion of Child's C patients (Villeneuve
and others 1986; Garden and others 1990), and benefit for the Child's C
patients was seen in one (Garden and others 1990).
A recent meta-analysis also revealed that there was a significantly greater
reduction in the variceal rebleeding rate in the beta-blocker treated patients
than in the placebo group (20% mean improvement rate, p < 0.001)
(Bernard and others 1997a). In addition, this study also demonstrated that
there was a significant improvement in the survival rate in the treatment
group with a mean improvement of 5.5% (p = 0.05), with this being more
marked in patients with more advanced liver disease. These finding were
reinforced by a further meta-analysis (Cheng and others 2003). The
methods of analysis did not reveal any significant heterogeneity amongst the
trials. It would therefore seem appropriate that beta-blocker therapy for
secondary prophylaxis can be recommended for patients regardless of the
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degree of liver disease. Although the prevalence of adverse events was
significantly higher in the treatment group, because adverse events were
only mentioned in some of the studies it remains somewhat unclear of the
impact of this on practice.
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Table 7: Beta-blocker therapy in the secondary prophylaxis against
variceal rebleeding.
Number of patients Rebleeding rate (%) Death rate (%)
Trial Drug Control Treatment Control Treatment Control Treatment
Burroughs, 1983 Propranolol 22 26 59 54 23 15
Lebrec, 1984 Propranolol 36 38 64 21 22 8
Villeneuve, 1986 Propranolol 37 42 81 76 38 45
Carbelaud. 1986 Propranolol 50 50 78 40 33 26
Queuniet. 1987 Propranolol 48 51 64 57 21 23
Gatta. 1987 Nadalol 12 12 67 25 25 8
Kobe. 1987 Propranolol 28 26 46 38 32 23
Colombo. 1989 Propranolol 30 32 47 25 23 12
Colombo. 1989 Atenolol 30 32 47 31 23 9
Sheen. 1989 Proparanoiol 18 18 55 28 11 0
Garden, 1989 Propranolol 43 38 77 47 44 37
Colman. 1990 Propranolol 26 26 50 35 4 4
Rossi. 1991 Propranolol 27 27 63 48 33 26
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Combination therapy.
There is only one published trial assessing the effect of combination drug
therapy in preventing variceal rebleeding (Gournay and others 2000). In this
randomised study involving 95 patients, after a 2-year follow-up period,
overall rebleeding and survival was not improved by the addition of ISMN
to propranolol compared with propranolol alone. However, there was a
significant reduction in the risk of rebleeding when patients were stratified
according to age, i.e. less than 50 years old versus over 50 year olds or by
adding an extra year of follow up. It is also of note that more patients
experienced side effects leading to discontinuation of medication with the
combination therapy. However, no adverse events concerning renal function
or effect on ascites was observed with the combination therapy.
Another two studies published in abstract form reinforce the findings of the
above study that combining beta-blockers with ISMN offers no additional
benefit in reducing the overall rebleeding rate and mortality (Pasta and
others 1999) (Masliah and others 1997). In fact, one of these studies
reported greater mortality in patients treated with nadolol and ISMN than
nadolol alone (32% vs. 14%, p = 0.02) (Pasta and others 1999). Clearly the
full paper would need to be published and analysed before firm conclusions
can be made.
It appears that combination therapy may have a role in secondary
prophylaxis, but adverse side effects may limit its clinical use. Further
studies are necessary before confident recommendations can be made.
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Pharmacological agents compared with endoscopic treatments.
There have been several trials comparing sclerotherapy with beta-blockers
alone or beta-blockers combined with sclerotherapy. Meta-analysis of these
studies demonstrated a small benefit of sclerotherapy over propranolol on
the rebleeding rate but no effect on survival (Hayes and others 1990).
Sclerotherapy was associated with a greater number and severity of
complications. Propranolol combined with sclerotherapy was found to be
better than sclerotherapy in reducing the rebleeding rate, but there was no
difference in survival. The rationale being that the addition of propranolol
reduces the risk of rebleeding in the first few months before the varices are
completely eradicated. However, the meta-analysis revealed significant
heterogeneity in all these trials. A recent abstract found that propranolol and
sclerotherapy were significantly more effective at reducing the rebleeding
rate than sclerotherapy alone (11/35 vs. 16/30 patients, p < 0.001)
(Benedeto-Stojanov and others 2000). It is interesting that most of the
difference was accounted for by a greater incidence of bleeding from gastric
varices and congestive gastropathy in the sclerotherapy only group.
Propranolol in combination with sclerotherapy was found to be superior, in
terms of rebleeding rate and survival, to propranolol alone based on the
results of two studies. In the meta-analysis the odds ratios for rebleeding in
the above trial comparisons were not as low as that when comparing
propranolol with placebo. The trials comparing the latter were also of a
higher quality with a longer follow-up period. Another meta-analysis
comparing propranolol with sclerotherapy mirrors these findings in that
sclerotherapy was more effective at reducing variceal rebleeding, but was
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associated with more iatrogenic adverse events (Bernard and others 1997b).
Survival was similar in the two groups.
The combination of nadolol and 1SMN was found to be superior to
sclerotherapy in a recent trial (Villeneuve and others 1986). Rebleeding rate
and treatment related complications were significantly lower than in
sclerotherapy. Overall survival was, however, identical in the two groups. It
is interesting that patients in whom the hepatic venous wedge pressure fell
by 20% or more had far fewer episodes of rebleeding.
Banding has been compared with beta-blocker and 1SMN combination
therapy in preventing recurrent variceal bleeding in 5 studies (Goulis and
others 1998; Minyana and others 1999; Villanueva and others 2001; Patch
and others 2002; Lo and others 2002), with 2 published in abstract form
only (Goulis and others 1998; Minyana and others 1999). Of the studies
published as full papers one concluded that nadolol and nitrate combination
was superior to VBL, and those patients with a haemodynamic response
defined as a reduction in the HVPG of> 20% or to <12 mm Hg, had a lower
rebleeding rate and mortality than those who did not respond (Villanueva
and others 2001). Lo and colleagues demonstrated greater efficacy ofVBL
over nadolol and ISMN therapy (Lo and others 2002), although the doses of
the drugs was half that used by Villanueva and colleagues. The study by
Patch and colleagues demonstrated similar efficacy of VBL versus
propranolol plus ISMN in the prevention of variceal rebleeding, with no
difference in the haemodynamic parameters during follow up (Patch and
others 2002). The latter finding may have been due to the HVPG
measurements being performed at a later stage than Villanueva et al, thus
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missing those patients at most risk since the risk of rebleeding is highest in
the first month. It should be noted that Patch and colleagues failed to recruit
the target number of patients due to a large number requiring salvage
T1PSS, thus the results are subject to a type II error. Furthermore, only 41%
of patients actually received combination drug therapy and there were more
patiens with Child C disease than in the other two papers.
The combination of beta-blockers and ISMN appears to be promising,
particularly if patients exhibit a haemodynamic response (Villanueva and
others 2001). Future large multicentre studies would assist in fully
evaluating combination therapy for the prevention of variceal rebleeding,
and should incorporate F1VPG measurements in response to therapy shortly
after randomisation.
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1.5 The transjugular intrahepatic portosystemic stent-shunt
(TIPSS) in the management of variceal bleeding.
TIPSS has made a significant impact on the management of portal
hypertension since its introduction in the 1980's. Randomised controlled
trials and meta-analyses demonstrate its superiority over endoscopic
methods in the prevention of variceal rebleeding, although most studies do
not demonstrate any survival benefit (Papatheodoridis and others 1999). The
severity of the underlying liver disease as defined by the Pugh score at the
time of TIPSS has the greatest impact on survival. Most centres advocate
the use of TIPSS as a salvage procedure where endoscopic methods fail to
control variceal bleeding. There is also evidence to support the use of TIPSS
for the prevention of variceal rebleeding in refractory ascites, hepatorenal
syndrome, hepatic hydrothorax, and Budd Chiari Syndrome. Hepatic
encephalopathy and shunt dysfunction are the principal disadvantages of
TIPSS, although careful patient selection, TIPSS surveillance and probably
the use of the newer covered stents can minimise these.
1.5.1 Historical aspects and basic principles.
The concept of TIPSS has been around since the late 196(Ts and 70's
(Rosch and others 1969; Rosch and others 1971). The original investigators
looked at imaging the portal circulation via the transjugular route. They
succeeded in entering the portal vein through the hepatic parenchyma, and
this led to the idea of creating a fistula between the hepatic vein and portal
veins giving rise to a portosystemic shunt. Initial attempts at creating a
TIPSS in animal models using non-expandable tubing (Rosch and others
1971), drilling (Koch and others 1973), and cryoprobe freezing (Reich and
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others 1977) were hampered by shunt dysfunction, with primary patency
limited to a maximum of 2 weeks.
The introduction of balloon angioplasty catheters in the latter half of the
1970's was key to the successful creation of TIPSS. Animal models
demonstrated the potential for TIPSS to be kept patent for up to a year by
regular dilatations, despite the high early occlusion rate (Burgener and
Gutierrez 1988). The first clinical application ofTIPSS was by Colapinto
and colleagues in 1982, who used a 9mm catheter to significantly reduce
portal pressure (Colapinto and others 1982). Further studies were performed
in patients with cirrhosis and variceal bleeding, where despite a significant
reduction in the portal pressure, most patients rebled and died or required
surgery. The fact that most of the fistulae were patent at autopsy suggested
that further measures were necessary to maintain portal decompression.
The use of expandable metal stents in the mid 1980s led to the development
of 10mm Palmaz stents which were initially used in animal models (Palmaz
and others 1985; Palmaz and others 1986). The patency of these shunts was
much better in patients with chronic rather than acute portal hypertension,
lasting for up to 48 weeks. These experiments led to the first clinical
application of expandable metal stents involving the use of 2 Palmaz stents,
resulting in both hemodymamic and clinical improvement in portal
hypertension (Rockey 2000). The patient unfortunately died at day 12 from
adult respiratory distress syndrome, although the shunt was noted to be
patent at autopsy. These early experiences stimulated enormous interest
among interventional radiologists and gastroenterologists, resulting in many
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centres using TIPSS and further refining the technique and expanding its use
for other indications.
1.5.2 Haemodynamic effects ofTIPSS.
The effects of TIPSS on the hyperdynamic circulation in cirrhosis have been
well studied.
Portal circulation
Successful TIPSS results in immediate reduction of portal pressure.
Traditionally the portal pressure gradient (PPG) is utilised and is:
Portal pressure - Inferior vena cava pressure
It was widely believed that variceal bleeding was very unlikely below a
threshold HVPG of 12 mm Hg (D'Amico and others 1995), leading to this
being adopted as therapeutic goal following TIPSS insertion, and is
achieved for most patients in our and others' series (Tripathi and others
2004). The azygous blood flow, which is a measure of the collateral blood
flow, decreases acutely following TIPSS insertion, both acutely with a
maximum decrease of 30% of baseline values 1 year following TIPSS
insertion (Lotterer and others 1999). This study also identified a correlation
between the change in PPG following TIPSS insertion and the azygous
blood flow.
Systemic circulation
The potential for a TIPSS to aggravate an already hyperdynamic circulation
was demonstrated in earlier studies in our unit (Stanley and others 1998a).
The acute effect at 30 minutes post TIPSS insertion is an increase in cardiac
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output (CO), right atrial pressure (RAP), pulmonary artery, and pulmonary
wedge pressure, with a fall in systemic vascular resistance (SVR). No
change was observed in heart rate (HR) or mean arterial pressure (MAP).
The fall in the portoatrial pressure gradient correlated with the rise in CO
and drop in SVR. These changes were confirmed in a recent large cohort
study over a 1 year period following TIPSS insertion (Lotterer and others
1999). In addition to the acute effects reported by Stanley and colleagues,
there was an increase in MAP and HR. The acute increase in CO persisted
for up to 3 months, although the SVR started to increase after a week
(Figure 2). Other parameters of the systemic circulation returned to normal
after a year.
Therefore, the acute detrimental effect on the hyperdynamic circulation
following TIPSS insertion is not maintained in the long term. The acute
increase in the cardiac output and increase in venous return may result in
acute pulmonary edema or unmask pre-existing cardiomyopathy
(Braverman and others 1995; Huonker and others 1999). Caution is needed
in patients with pulmonary hypertension or known cardiac dysfunction.
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Figure 2: Change in systemic and portal haemodynamics pre and post
TIPSS (Lotterer and others 1999)
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1.5.3 Complications ofTIPSS.
The complications relate to the procedure itself, the underlying liver disease
and the function of the shunt.
Procedural
The overall rate of procedure related mortality in our unit of almost 500
consecutive TIPSS over a 10-year period is 1.2% (Tripathi and others 2004).
Direct complications of the TIPSS included gallbladder perforation and
intraperitoneal haemorrhage. There are also other rare non-fatal procedure
related complications such as portal vein to bile duct fistula, localized
collection between gallbladder and liver, shunt migration, pneumothorax,
and neck haematoma. An unusual complication was the presence of a right
atrial clot noted at routine portography resulting in shunt insufficiency. This
was successfully removed under ultrasound guidance.
Patients with liver disease are immunocompromised, and the insertion of a
TIPSS does not appear to increase the risk of infection, although an unusual
type of infection can occur in the presence of a thrombus or vegetation in
the TIPSS known as "endotipsitis" (Sanyal and Reddy 1998). The patient
presents with fever, hepatomegaly and positive blood cultures. Prolonged
antibiotic therapy is required. As in the case of infective endocarditis there
is usually one organism isolated. We have a policy of administering
intravenous 3rd generation cephalosporins pre and for 48 hours post TIPSS
insertion. Nevertheless, TIPSS infection has to be considered when no other
source of sepsis can be identified.
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In around 13% of patients there may be clinically significant haemolysis,
which may manifest as jaundice or anaemia (Jalan and others 1996b). This
usually resolves within 3-4 weeks as the TIPSS becomes covered with a
neointimal layer.
Hepatic encephalopathy
One of the principal concerns of TIPSS has been the increased risk of
hepatic encephalopathy, and this is confirmed with the current studies. The
overall risk of hepatic encephalopathy following TIPSS of 34% compares
with 19% following endoscopic therapy, resulting in 1 episode of de novo or
worsening hepatic encephalopathy for 1 in 8 patients treated with a TIPSS
(Burroughs and Vangeli 2002). This obviously has major implications on
the quality of life of patients, and the resources needed to manage
encephalopathy including shunt occlusion in up to 5% (Tripathi and others
2004). Selecting patients free from hepatic encephalopathy prior to TIPSS
insertion may reduce the incidence of post TIPSS encephalopathy (Jalan and
others 1995a). However, in clinical practice this is difficult to accomplish
particularly where TIPSS is used to rescue those who have failed
endoscopic therapy, since these individuals are likely to be encephalopathy
from recurrent bleeding and/or have limited alternative treatment options.
Shunt insufficiency
Shunt insufficiency is a significant limitation of TIPSS. Fifty percent of
shunts will become insufficient i.e significantly stenosed or blocked within a
year ofTIPSS insertion (Table 8, Figure 3), (Jalan and others 1997b; Jalan
and others 1998) with most episodes resulting from acute thrombosis and
leading to variceal rebleeding, probably as a result of thrombogenic biliary
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material entering the shunt (Jalan and others 1996a; Sze and others 1999).
Early controlled studies revealed a lower incidence of complete occlusion
after heparin with no reduction in the re-intervention rate (Sauer and others
1996). A recent study suggested that heparin combined with antiplatelet
drugs reduces the risk of stenosis of the hepatic vein and variceal
rebleeding, although no effect was seen for stenosis within the stent
(Siegerstetter and others 1999).
Later episodes of shunt dysfunction result from pseudointimal hyperplasia.
Regular invasive portographic surveillance, which is essential for
maintaining shunt patency is not available in all centres, and places an
additional burden on resources. Non-invasive methods of assessing TIPSS
patency such as Doppler ultrasound are not as sensitive as regular
portography (Ferguson and others 1995), and studies which used this
method had a higher rebleeding rate (Papatheodoridis and others 1999). In
any case, Doppler ultrasound does not allow for interventions, such as
balloon angioplasty and re-stenting nor the measurement of portal pressure.
Variables identified as predicting shunt insufficiency include PPG pre-
TIPSS of > 18 mmHg (Jalan and others 1995a), and the presence of diabetes
has been shown to be associated with delayed shunt occlusion (Shah and
others 2001). A recent study published in abstract form identified stent
diameter, distance of shunt through IVC, duration of the procedure, and
PPG post-TIPSS as independent predictors of early shunt insufficiency
(Balata and others 2002).
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The observations that variceal bleeding occurs rarely at PPG < 12 mmHg
(Groszmann and others 1990) or if there is a > 25% reduction in the PPG ,
has led to shunt insufficiency being defined as an increase in the PPG to >
12 mm Hg or an increase in the PPG ofmore than 20% of the immediate
post-TIPSS value if the pre-TIPSS PPG was < 12 mmHg (Jalan and others
1998). Primary patency is defined as patency without intervention.
Secondary or assisted patency, defined as patency with intervention, is over
70% during a follow up period of 20 months in our series (Tripathi and
others 2004).
An interesting observation in our experience is that the risk of variceal
rebleeding 2 years post TIPSS is very low, even in the presence of shunt
insufficiency (Tripathi and others 2004). This may reflect the fact that
patients who survive this long post-TIPSS are usually in the better
prognostic group, and therefore have a lower risk of variceal bleeding. This
finding brings into question the need for continued portographic
surveillance 2 years post TIPSS insertion, and merits further study.
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Table 8: Shunt insufficiency: Portographic appearances. (Tripathi and
others 2004)
Abnormality on portography Frequency (%)
Intimal hyperplasia 60
Hepatic vein stenosis 21
Thrombosis within shunt 6
Occluded shunt 12
Portal vein thrombosis <1%
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Figure 3: Kaplan Meier graph of primary patency of standard stents
used for TIPSS (Tripathi and others 2004)
Time (months)
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1.5.4 The role ofTJPSS in the management ofvariceal haemorrhage.
Variceal haemorrhage is a life threatening complication of portal
hypertension with an in-hospital mortality between 30-60% depending on
severity of liver disease (Jalan and Hayes 2000). There has been much
research in recent years aimed at finding the best possible therapy to prevent
and treat variceal haemorrhage. In most centres endoscopic therapy is
instituted as first line therapy, with pharmacological therapy such as
terlipressin having an important role (Ferguson and others 2003). Broad
spectrum antibiotics should be administered to all patients with cirrhosis
following gastrointestinal haemorrhage, as this has been shown to improve
survival (Ferguson and others 2003). In refractory cases or where the risk
of variceal rebleeding is high, TIPSS is utilised (Figure 4). It terminates
variceal haemorrhage in over 90% of patients, and prevents rebleeding 80-
90% of patients (Stanley and others 1996). The availability ofTIPSS still
remains restricted to large teaching hospitals, but its use appears to be
growing. Despite the increasing use ofTIPSS, the number of controlled
studies involving the use ofTIPSS in the management of variceal
haemorrhage is rather limited. At the present time there is no evidence to
support the use of TIPSS in the prevention of the first variceal bleed, so
TIPSS cannot be recommended for primary prophylaxis.
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1 Surgery
Management ofacute variceal bleeding
The role of TIPSS in the management of acute variceal haemorrhage as
"salvage" therapy is well established. In such cases patients have been
treated with endoscopic therapy and/or pharmacological therapies without
success. Many clinicians would attempt a second endoscopic procedure
prior to referring the patient to specialized centres for a TIPSS, but this will
depend on the severity of the acute bleed. In severe cases where balloon
tamponade is needed to control bleeding, a TIPSS may be indicated at an
earlier stage. Prior to the introduction of TIPSS patients would have been
referred for a surgical procedure such as oesophageal transection, which is
associated with a high mortality in this setting (Jalan and others 1995b).
Studies indicate that TIPSS results in control of acute variceal bleeding in
over 90% of cases (Haag and others 1993; Helton and others 1993; Laberge
and others 1993; Le Moine and others 1994; Rubin and others 1995; Jalan
and others 1995b; Jabbour and others 1996; Sanyal and others 1996;
Perarnau 1997; Gerbes and others 1998; Chau and others 1998; Banares and
others 1998; Barange and others 1999; Azoulay and others 2001; Bizollon
and others 2001) (Table 9 ). However, the mortality is high and reflects the
severity of liver disease at the time ofTIPSS insertion. Overall rebleeding
rate is 18% and mortality is 38%, with most deaths occurring early
(Burroughs and Patch 1999).
The rather dismal statistics prompted investigators to identify clinical and
haemodynamic variables that could predict poor outcome. Early studies
from our unit identified Child-Pugh score, hyponatraemia, pre-TIPSS
encephalopathy, and pre TIPSS PPG > 16 (in alcoholic cirrhotics) to predict
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mortality post TIPSS (Jalan and others 1995a; Stanley and others 1998b).
The role of portal pressure as a predictor of mortality was reinforced by
recent studies (Patch and others 1999; Moitinho and others 1999a). Others
have suggested a greater role of the model of end stage liver disease
(MELD) as a predictor of early mortality (Salerno and others 2002). There
still remains some controversy regarding the best prognostic model
following a recent study which failed to identify any single variable to
predict mortality following salvage TIPSS (Azoulay and others 2001). The
utility of such models is limited as many clinicians even knowing the likely
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Prevention ofvariceal rebleeding
Endoscopic therapies versus TIPSS
There are 13 trials comparing endoscopic therapies (usually injection
sclerotherapy) with TIPSS for the management of variceal bleeding and
especially rebleeding (Table 10) ([Anon] 1995; Cabrera and others 1996;
Cello and others 1997; Rossle and others 1997; Jalan and others 1997a;
Sauer and others 1997a; Sanyal and others 1997d; Merli and others 1998;
Garcia-Villarreal and others 1999; Sauer and others 2000; Narahara and
others 2001; Pomier-Layrargues and others 2001; Gulberg and others 2002).
One of these studies has been published in abstract form([Anon] 1995). In
most trials TIPSS was also used to rescue refractory bleeders in the
endoscopic therapy arm (Cabrera and others 1996; Cello and others 1997;
Rossle and others 1997; Sanyal and others 1997a; Jalan and others 1997a;
Merli and others 1998; Garcia-Villarreal and others 1999; Sauer and others
2000; Narahara and others 2001; Pomier-Layrargues and others 2001;
Gulberg and others 2002).
The variceal rebleeding rate of 19% in the TIPSS arm compares favourably
with 47% in the endoscopic therapy arm (Papatheodoridis and others 1999).
Taking all the 13 trials together the number needed to prevent one variceal
rebleeding episode is 4 (Burroughs and Vangeli 2002). A reduced rate of
rebleeding is demonstrated by all but 2 studies which showed similar
efficacy of TIPSS and endoscopic therapy (Sanyal and others 1997b;
Gulberg and others 2002). The rate of rebleeding appears to be related to the
Pugh score, although the results with surgical shunts are better (Rosemurgy
and others 1996). The majority of rebleeding episodes are related to shunt
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insufficiency, which is reflected in the high early rebleeding rates in most
trials.
However, there appears to be no benefit of TIPSS over endoscopic therapy
in overall rates ofmortality (27.3% versus 26.5% respectively)
(Papatheodoridis and others 1999). The risk of rebleeding and death was
highest in the trials with > 40% patients in Pugh class C. A recent
retrospective study over an 11-year period in our unit identified this group
to have a lower mortality than those treated with endoscopic therapy for
variceal haemorrhage (Jalan and others 2002). We currently do not use
TIPSS to prevent rebleeding in Child Pugh A patients. The cost of
endoscopic therapy and TIPSS is similar because TIPSS is so much more
effective in reducing rebleeding and the potential need for very expensive
intensive care unit bed.
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Pharmacological agents compared with TIPSS.
The only publication is a study recently published, which randomised
patients to either TIPSS only (n = 47) or propranolol plus ISMN
combination therapy (n =44) (Escorsell and others 2002). The TIPSS arm
had significantly fewer episodes of rebleeding (13% vs. 39%, p = 0.007),
but encephalopathy was significantly higher in the shunted group (38% vs.
14%, p = 0.007). Mortality was similar for both groups. The cost of TIPSS
was more than twice that of drug therapy. Interestingly, the drug treated arm
has more frequent improvement in the Pugh score during follow up. This
finding is not fully explained by the authors, and it would have been useful
to know how many of the patients with alcoholic liver disease remained
abstinent in each arm.
It should be emphasised that the addition of propranolol to endoscopic
therapy does to confer any benefit over endoscopic therapy alone, although
the incidence of encephalopathy is less (Rossle and others 1997; Sauer and
others 1997a; Sauer and others 2002). However, outside of clinical trials it
is unlikely that most patients will comply fully with follow up banding
sessions and drug therapy particularly those patients with alcoholic
cirrhosis.
TJPSS versus surgery
The use of surgical shunts is limited by the very high mortality rates in
patients with advanced liver disease. Early experience strongly favored the
use of TIPSS over oesophageal transection, with the latter associated with a
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higher mortality and rate of infection (Jalan and others 1995b), despite
similar efficacy as TIPSS in the prevention of variceal rebleeding. This
probably reflects the fact that most patients referred for a TIPSS had
advanced liver disease, thus making such major surgery particularly
hazardous. The only randomised controlled study comparing shunt surgery
using a portacaval H-graft with TIPSS revealed more episodes of variceal
rebleeding in the TIPSS arm (11% versus 0%), although the technical
success of the TIPSS procedure was poorer than with most other series
(Rosemurgy and others 1996). It is also noteworthy that the average portal
pressure following TIPSS insertion was high at 25 ± 7.5 mm Hg. Others
have looked at distal splenorenal shunt (DSRS) surgery versus TIPSS in a
non-randomised study of cirrhotic patients in Pugh class A & B (Khaitiyar
and others 2000). The results were in favor of surgery with lower rates of
rebleeding (6.3% vs. 25.7%), encephalopathy ((18.8% vs. 42.9%), and shunt
dysfunction (6.3% vs. 68.6%). There was no difference in survival (6.2%
versus 5.7%). From the limited data it appears that surgery may be better
suited to patients in Pugh class A to B, with TIPSS being used in patients
with more severe liver disease who would not normally be candidates for
shunt surgery.
TIPSSfor the management ofgastric variceal bleeding
The management of bleeding gastric varices has been a particular challenge
to clinicians. The risk of bleeding from gastric varices is less than that of
oesophageal varices, the outcome once bleeding has occurred is worse,
particularly for isolated gastric varices (IGV) (Sarin and others 1992).
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Historically the management of gastric variceal bleeding has been sub
optimal. Endoscopic measures have met with varying degrees of success
(Ramond and others 1986; Gimson andjothers 1991), although current UK
guidelines recommend endoscopic treatment as the first line in the
management of the acute gastric variceal bleed (Jalan and Hayes 2000).
Iatrogenic complications such as embolic phenomena and the potential for
equipment damage may limit the use of tissue adhesives (See and others
1986; Lee and others 2000). Thrombin seems to be promising (Przemioslo
and others 1999), but large multi centre controlled trials have yet to emerge
(Williams and others 1994; Yang and others 2002). Two of the previous
studies have used bovine thrombin which has the potential risk of prion
transmission (Williams and others 1994; Przemioslo and others 1999).
Surgical shunts may be of value in patients with early liver disease (Thomas
and D'Cruz 1994), but have the disadvantage of high mortality in patients
with advanced liver disease particularly in the emergency setting.
Due to gastric variceal haemorrhage being relatively uncommon, there are
relatively few studies looking at the efficacy ofTIPSS in bleeding gastric
varices, and no controlled studies. Previous work has demonstrated that
TIPSS was equally effective in the management of bleeding from either
gastric or oesophageal varices (Stanley and others 1997a). The
complications of TIPSS such as encephalopathy and shunt dysfunction were
also similar. TIPSS has recently been studied in the management of
refractory variceal bleeding either from gastric alone (Barange and others
1999) or gastric compared with oesophageal varices (Chau and others
1998). The results suggest that TIPSS is effective in the arresting
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haemorrhage from and prevention of rebleeding from gastric varices. Chau
and colleagues also found that portal pressure in patients who had early
rebleeding before 7 days was lower in patients with GVB (Chau and others
1998).
1.5.5 New developments.
TIPSS in combination with other therapies
One of the limitations ofTIPSS is the high incidence of shunt insufficiency
and the need for lifelong invasive portography and intervention. There have
been two recent studies investigating the effect of adjuvant drug therapy in
patients with an insufficient TIPSS (Brensing and others 2002; Bellis and
others 2003). The administration of intravenous propranolol in the presence
of an insufficient TIPSS resulted in a significant reduction in the PPG of
30%, although the effect was not so pronounced in those patients with
severe shunt insufficiency. A second study confirmed these findings with
propranolol, although no effect was seen with nitrates. Both these studies
were uncontrolled, and no data was available on the incidence of variceal
bleeding. If controlled studies are favourable, the addition of drug therapy to
reduce the need for shunt surveillance sounds attractive. However, it is
likely only to be of temporary benefit. In addition, the side effect profile of
propranolol is not favorable in our experience, and compliance could be a
major problem (Luo and others 1998).
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Covered stents
The idea of covering the stent to reduce clotting and intimal hyperplasia,
comes from cardiovascular medicine where it has been successful. Early
results with covered TIPSS using Dacron were rather disappointing,
possible due to its non-biocompatible nature (Otal and others 1999).
Subsequent studies using polytetrafluoroethylene (PTFE) have been more
successful. The Viatorr endoprosthesis is made of titanium, which supports
a reduced permeability expanded PTFE graft with a bile resistant
membrane. It comprises a 2cm unlined distal section, and a lined section
available in 4-8 cm lengths, separated by a radio opaque marker (Figure 5a).
It is available in 8, 10, and 12mm diameters. Unlike uncovered stents
(Figure 5b), the length of the tract is determined prior to stent deployment.
This is measured using a catheter with markings at 1 cm intervals. The aim
is to cover the entire tract from the portal vein entry point to the inferior
vena cava. This is likely to favor the patency of the Viatorr stents by
reducing the risk of hepatic vein stenosis. Encouraging results in
animals(Nishimine and others 1995; Haskal and others 1997) have been
reproduced in humans in small uncontrolled studies (Saxon and others 1997;
Haskal 1999; Cejna and others 1999; Andrews and others 1999; Rose and
others 2001; Cejna and others 2002; Otal and others 2002). Overall the
results are impressive, with primary patency rates between 80-100%. Our
results on a 100 patients with the Viatorr endoprosthesis showed a primary
patency of 92%, and variceal rebleeding rate of 9.5% over an average follow
up period of 10 months (Barkell et al, Abstract in press). The rates of
encephalopathy were comparable to standard uncovered TIPSS. The main
reasons for shunt insufficiency seem to be inadequate covering of the tract
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in the hepatic vein, resulting in hepatic vein stenosis. In some cases we had
to use an uncovered stent to extend the tract to the hepatic vein, and this was
another source of shunt insufficiency. However, the absence of shunt
thrombosis in our series is remarkable. Interim results of a randomised
controlled trial also show excellent shunt patency (Bureau and others
2002b). Clearly if in the final analysis the results are favorable, there may be
much reduced need for long-term portographic surveillance.
A potential complication of PTFE covered stents is the development of
segmental hepatic ischaemia, which has been reported in a small number of
patients (Bureau and others 2002a; Laberge and Kerlan 2003). This arises
from extending the tract to the hepatic vein almost as far the IVC, resulting
in a partial Budd Chiari like syndrome. Some patients reported abdominal
pain, and were found to have abnormalities on the CT scan. In all cases
patients were managed conservatively, and did not have long-term
complications. We have had experience of one asymptomatic patient who
was noted to have an abnormal area of low attenuation in a CT scan. These
changes resolved on further scanning 3 months later, probably as a result of
collaterals. It is therefore important to bear in mind this complication,







2.1 Methods of haemodynamic monitoring.
All haemodynamic measurements are performed under controlled
conditions with the patient in the supine position using fluoroscopic
guidance. The following measurements are performed:
2.1.1 Hepatic venous pressure gradient (HVPG).
After infiltration with 10ml 2% lignocaine a 7 FG venous introducer
(Cordis, USA) is inserted into the right femoral vein using the Seldinger
technique. Under fluoroscopic guidance either a Swann Ganz catheter
(Baxter Healthcare Corporation, USA) or the Sidewinder II torque balloon
catheter (Cordis Corporation, USA) is inserted though the main right hepatic
vein for the measurement of the free and wedged hepatic venous pressures
(FHVP and WHVP). The HVPG is derived from these values as the WHVP
minus FHVP. All haemodynamic measurements are taken in triplicate, with
the mean of these values being used for analysis.
2.1.2 Systemic and cardiac haemodynamics.
The same standard Swann Ganz catheter is used to measure the right atrial
pressure, the cardiac output, and pulmonary artery pressures. The cardiac
output is measured using the standard thermodilution technique. The mean
arterial pressure (MAP) was measured using an automatic
sphygmomanometer (Hewlett Packard series 54 model 78339A) and was
calculated as (Pulse Pressure/3) + Diastolic blood Pressure. The systemic
vascular resistance (SVR) is calculated as (79.96 ((MAP - RAP (right atrial
pressure) / CO (cardiac output)).
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2.1.3 Hepatic bloodflow.
Hepatic blood flow (HBF) was derived from measurements of the
indocyanine green (ICG, Akorn) clearance and extraction. ICG was infused
at the beginning of the study as a lOmg intravenous bolus via a peripheral
cannula followed by an infusion of 0.2mg/min ICG (Caesar and others
1961). After an equilibration time of 40 minutes three samples were taken
simultaneously from the right hepatic vein and femoral vein. The peripheral
and hepatic samples were centrifuged at 1500g for 20 minutes, and the
optical density of the supernatant determined. The value for optical density
was then plotted on a standard graph and the % concentration extrapolated
(Figure 6). The following formula was next used to calculate HBF:
HBF = (ICG Clearance / ICG Extraction) / (1-Haematocrit)
= (Q/(Cp - Ch)) / (1 -Haematocrit)
0 is the infusion rate of ICG at 0.2 mg/min. Cp and Ch are peripheral and
hepatic % concentrations of ICG derived as above. The final value for HBF
has to be multiplied by a factor of 100 to derive HBF in ml/min. This
method cannot be used if Cp - Ch is less than 10% i.e. hepatic excretion less
than 10%.
2.1.4 Analyses ofneurohumeral agents.
Venous blood was sampled after the patient was in the supine position for
30 mins for baseline biochemical and haematological measurements. Ten ml
was admixed with 0.5 ml of 0.45% O-phenanthroline/4.65% disodium
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EDTA for measuring ANG II concentration, and 1 ml of 1% disodium
EDTA and 1000 KIU aprotinin (Bayer AG, Leverkusen, Germany) for
measuring plasma renin activity (PRA). The samples were placed on ice and
immediately centrifuged at 1500g for 20 minutes. Plasma was frozen and
stored at -80°C until assayed. Plasma ANG II concentrations were measured
by radioimmunoassay following extraction using Bond Elut columns
(Varian, Harber City, CA) as previously described (Morton and Webb
1985). PRA was measured under standard conditions through the generation
of ANG I using radioimmunoassay as previously described (Haber and
others 1969). Aldosterone levels were obtained from samples of plasma
analysed from frozen with a commercial radioimmunoassay (Peninsula
Laboratories, California, USA) using a technique previously
described(Demers and others 1976).
2.1.5 Assessment ofrenal function.
Urine was collected over a 24-hour period to measure creatinine clearance
and urinary sodium excretion. 24 hour creatinine clearance in mL/min was
calculated as:
(Urine creatinine x urine volume in 24 hours ) / (serum creatinine x 1440)
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Figure 6: Graph used to extrapolate % concentration of indocyanine
green (ICG, Akorn) from optical density of the supernatant from
samples of peripheral and hepatic blood after infusion of ICG.
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2.2 Transjugular intrahepatic portosystemic stent-shunt
(TIPSS).
2.2.1 Insertion of TIPSS.
TIPSS is a non-surgical means of diverting blood from the portal circulation
through the hepatic parenchyma to the systemic circulation, thereby creating
a portosystemic shunt (Chalmers and others 1992). The internal jugular vein
is first entered percutaneously, and a catheter is passed through the superior
vena cava, right atrium, inferior vena cava, and in most cases the right
hepatic vein under fluoroscopic guidance. A needle is inserted through the
catheter to puncture the hepatic parenchyma, creating a tract to link the
hepatic vein and usually right portal vein. This tract is kept patent by using
an expandable metal stent. These stents included Palmaz stents (Johnson &
Johnson, Norderstedt, Germany), the newer covered stents (Wallgrafit,
Boston Scientific, Boston, Mass or Jostent, Jomed, Zurich, Switzerland or
the latest Viatorr Gore PTFE stents), and Wallstents (Boston Scientific,
Boston, Mass, USA). All patients had intravenous Cefotaxime 1 hour pre-
and for 48 hours post-procedure.
2.2.2 Follow up and shunt surveillance.
Doppler ultrasound was performed at 1 week. Urgent portography was
carried out if there was Doppler evidence of shunt dysfunction, or if there
was clinical evidence of shunt dysfunction, such as variceal rebleeding or
increased ascites. Intervention at portography includes balloon angioplasty,
shunt extension, or insertion of a parallel shunt. All subjects are followed up
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at 4-6 month intervals with full clinical, haematological and biochemical
assessment, until death, liver transplantation, or loss to follow up. Routine
portography was performed six monthly where possible, or at other times if
there was clinically indicated.
2.2.3 Definitions.
Variceal rebleeding
Any subsequent haematemesis or melaena with a 20 g/L reduction in
haemoglobin requiring an unscheduled endoscopy. Non-variceal causes of
rebleeding were also documented.
Early mortality
Death within 6 weeks of the index variceal bleed.
Shunt insufficiency
An increase in the portal pressure gradient (PPG) to > 12 mm Hg or an
increase in the PPG > 20% from the post-TIPSS value where the pre-TIPSS
value is < 12 mm Hg. (Jalan and others 1997b). The Doppler criteria for
shunt insufficiency is a peak velocity of< 90 cm/s (Ferguson and others
1995; Jalan and others 1998).
Primary patency




The absence of shunt insufficiency with intervention.
Successful portal pressure reduction
PPG immediately post-TIPSS of< 12 mm Hg (where PPG pre-TIPSS > 12
mm Hg) or a > 20% reduction in the PPG pre-TIPSS (where PPG pre-TIPSS
< 12 mm Hg).
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CHAPTER 3
Haemodynamic effects of low dose carvedilol, a vasodilating




Carvedilol is a non-selective beta-blocker with vasodilating properties as a
result of weak ai antagonism and calcium channel antagonism. Its effect on
portal hypertension has been studied in several clinical studies as previously
mentioned, with the main findings being of a reduction of the HVPG of
between 20 - 28%, at the expense of systemic side effects on account of the
significant reduction in the MAP (Forrest and others 1996a; Stanley and
others 1999; Banares and others 1999). Lower doses have also produced a
significant portal hypotensive effect, although a short follow up limited the
assessment of the tolerability ofCarvedilol (De and others 2002).
The aim of this study was to investigate the acute and chronic effects at a
low dose of 12.5 mg per day of carvedilol on portal and systemic
haemodynamics. Patient tolerability was also assessed at this dose over a 4
week period.
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3.2 Patients and methods.
10 patients, 7 male and 3 female with a mean age of 53 ± 4.0 years, were
recruited, all of whom had biopsy proven or clinical, biochemical and
ultrasonographic evidence of cirrhosis. Eight patients had alcoholic liver
disease, one patient had primary biliary cirrhosis, and one hepatitis C virus
related cirrhosis. Seven patients had Child-Pugh grade B disease, 1 grade A,
and 2 grade C. Six patients had ascites at the time of the study or in the past.
All patients had gastroesophageal varices, with none having bled. All
patients gave informed consent and the study was approved by the Lothian
Medicine and Oncology Ethics Committee. The study protocol was in
accordance with the ethical guidelines of the 1975 Declaration of Helsinki.
All patients had baseline haemodynamic measurements performed
following an overnight fast. They were then administered 12.5mg of oral
carvedilol (Roche Pharmaceuticals) and haemodynamic measurements were
repeated after one hour. After completion of the acute study, patients were
instructed to take 12.5mg of carvedilol daily at 09:00 for four weeks, after
which time the haemodynamic measurements were repeated before and one
hour following the administration of 12.5mg of carvedilol as per initial
protocol. There was no change in the observed alcohol consumption for the
duration of the study. There were no detectable serum ethanol levels prior to
each study or during follow up.
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3.2.1 Haemodynamic study protocol.
Haemodynamic measurements were performed with the patient in the
supine position. The HVPG, MAP. RAP and HBF were measured using the
techniques mentioned earlier. The CO was measured using the standard
thermodilution technique. SVR was derived from these measurements.
3.2.2 Statistical analysis.
All results are expressed as mean ± SEM. Parametric data were analysed
using the paired Student /-test and the Pearson's correlation. Wilcoxon
signed rank test and Spearman correlation were used for non-parametric
data. Significance was taken at the 5% level. Microsoft Excel 2000 and




Nine patients completed both the acute and chronic studies. One male
patient with Child's C disease who had a hypotensive reaction to acute
dosing with carvedilol, and developed an alcoholic hepatitis, completed only
the acute phase of the study.
J.J. 1 Portal haemodynamics.
Following acute administration of carvedilol, there was a 23.9% reduction
in the HVPG (from 16.37 ± 2.14 to 12.56 ± 3.91 mmHg; p < 0.05), due
principally to a reduction in WHVP (from 22.03 ± 1.28 to 16.86 ± 1.15
mmHg; p < 0.01) with no significant change in the FHVP (Table 11).
Chronic administration resulted in a sustained and even greater fall in the
HVPG from the baseline average value of 16.37 ± 0.71 to a predosing value
following chronic dosing of 9.27 ± 1.40 mmHg (p < 0.001, -43.4%). In all
cases except one there was a > 20% reduction in the HVPG after chronic
dosing. There was no additional effect on the HVPG following rechallenge
with carvedilol (Figures 7, 8, 9, 10).
J. J. 2 Hepatic bloodflow.
ICG clearance and extraction was measured in five patients (Table 11). In
the acute phase of the study, there was a significant reduction in HBF from
1725 ± 435 to 718 ± 179 mL/min (p < 0.05, n=5) following acute
administration. Following chronic dosing one patient had an initial ICG
extraction < 10%, therefore HBF could not be calculated. There was no
further significant reduction in the HBF following chronic administration or
rechallenge with carvedilol (n = 4).
117
3.3.3 Systemic haemodynamics.
The MAP fell acutely from 90.33 ± 4.95 to 81.56 ± 5.84 mmHg (p < 0.01),
but with chronic administration and rechallenge there was no additional
change. The CO also fell acutely with no additional effect after chronic
dosing or rechallenge. The heart rate (HR) fell acutely and with chronic
dosing, but was unaffected following rechallenge with carvedilol. The RAP
fell acutely and following rechallenge. SVR was unaffected. The changes in
HVPG did not correlate with changes in the MAP, CO, HR or RAP.
3.3.4 Effect on hepatic and renal function.
The serum ALT, bilirubun, creatinine and clotting parameters were
unaffected by chronic administration.
3.3.5 Tolerability.
No side effects were reported except in 1 patient who experienced
palpitations, and no patients were withdrawn because of side effects. The
patient who became hypotensive after acute dosing experienced a fall in the
MAP from 64mm/Hg to 57 mm/Hg. He successfully completed the acute
study and remained asymptomatic. His blood pressure normalised after 3
hours and following colloid administration.
There were 6 patients with a history of ascites although only 4 had ascites at
the time of the study, which limited valid statistical analysis. These patients
exhibited a similar reduction in HVPG following acute and chronic dosing
of 26.41% and 38.38% respectively. There was no significant reduction in
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the MAP (-1.23%). No patients experienced deterioration in ascites or renal
function during follow up.
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Table 11: Haemodynamic data following acute and chronic dosing of
carvedilol. The first baseline refers to measurements performed before
drug administration. The second baseline refers to measurements
performed after 4 weeks administration of 12.5 mg/day carvedilol. +60
mins refers to the measurements performed 60 minutes following
administration of 12.5 mg carvedilol at the index visit, and following
rechallenge after chronic drug administration.
ACUTE DOSING AFTER CHRONIC DOSING
Baseline +60mins Baseline +60mins
HVPG (mmHg) 16.37 + 0.71" 12.56+ 1.30* 9.27+ 1.40p 10.27+ 1.16
WHVP(mmHg) 22.03 + 1.28 16.86+ 1.15* 16.92+1.65 16.98+ 1.47
FHVP (mmHg) 5.67+1.03 4.3 + 0.56 7.59 + 0.93 6.64+ 1.00*
HR (bpm) 88.33 + 5.81 79.11 ± 4.93* 71.78 + 4.62 71.89 + 4.93
MAP (mmHg) 90.33 + 4.95 81.56 + 5.84* 85.67 + 4.29 83.22 + 3.76
CO (1/min) 7.11 ±0.93 6.29 + 0.75* 6.72 + 0.77 6.74 + 0.84
RAP (mm/Hg) 3.22+ 1.02 1.22 + 0.57* 6.00+ 1.22 3.33+1.18:
SVR (dyn.Cm) 1111 + 138 1118 + 131 1151 ± 112 1156+ 164
HBF (mL/min) 1725 + 435 718+ 179*f 539 + 99 720 ± 203v
Mean ± SE.
MAP: mean arterial pressure. HR: heart rate. WHVP: Wedged hepatic
venous pressure. FHVG: Free hepatic venous pressure HVPG: hepatic
venous pressure gradient. CO: cardiac output. SVR: systemic vascular
resistance. RAP: right atrial pressure. FIBF: hepatic blood flow.
N = 9 unless otherwise stated
a-(3 - p < 0.001
} - p < 0.01 compared to baseline
*
- p < 0.05 compared to baseline
f - n=5 V - n=4
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Figure 7: Effect on hepatic venous pressure gradient following chronic
dosing of carvedilol. Baseline refers to measurements at the index visit
prior to drug administration. Chronic 1 refers to measurements after 4
weeks administration of 12.5 mg/day of carvedilol before rechallenge
with the drug.
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Figure 8: Overall effect of carvedilol on hepatic venous pressure
gradient. Baseline refers to the index value prior to drug
administration. Acute refers to + 60 minutes after first dose. Chronic 1
and chronic 2 refer to measurements after 4 weeks administration of
12.5 mg/day of carvedilol before and after rechallenge with the drug.
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Figure 9: Acute haemodynamic effects of carvedilol. The values
represent % change 60 minutes following administration of 12.5 mg of
carvedilol at the index visit. MAP: mean arterial pressure. HR: heart
rate. HVPG: hepatic venous pressure gradient. CO: cardiac output.































Figure 10: Haemodynamic effects of carvedilol following chronic
dosing. The values represent % change of measurements at the index
visit prior to drug administration and at the second visit following 4
weeks of 12.5 mg/day of carvedilol prior to rechallenge i.e. % difference
between baseline and chronic 1 as in Figure 8. MAP: mean arterial
pressure. HR: heart rate. HVPG: hepatic venous pressure gradient. CO:



















This study demonstrates the significant portal hypotensive effect of low
dose carvedilol, which compares favourably with propranolol. This effect is
achieved with minimal detrimental effects on the systemic circulation.
Carvedilol should be considered for use in large randomised controlled trials
for the prevention of the first variceal bleed.
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CHAPTER 4
Haemodynamic effects of losartan, an angiotensin II receptor
antagonist, in patients with cirrhosis and portal hypertension.
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4.1 Introduction.
Plasma ANG II concentrations are elevated in cirrhosis and have been
implicated as a cause of portal hypertension. There is conflicting evidence
regarding the efficacy and tolerability of losartan, a specific ATI receptor
antagonist with no agonist activity, in patients with cirrhosis and portal
hypertension (Schneider and others 1999; Gonzalez-Abraldes and others
2001). We aimed to study both the systemic and portal haemodynamics and
tolerability after chronic administration of losartan in patients with pre-
ascitic cirrhosis.
4.2 Patients and methods.
Twelve patients with biopsy, radiological, biochemical or clinical evidence
of cirrhosis were recruited. The baseline characteristics are summarised in
Table 12. All the patients were pre-ascitic, and were on no diuretics or other
vasoactive medication prior to and throughout the study period. Seven
patients had oesophageal varices, 6 had Grade 11 and 1 had Grade III
varices, with none having variceal bleeding in the past. All patients gave
written informed consent, and the study was approved by the local research
ethics committee. The study protocol was in accordance with the ethical
guidelines of the Declaration of Helsinki.
Baseline haemodynamic measurements were performed at 09:00 following
an overnight fast. The patients were then instructed to take 25mg of losartan
(Cozaar, Merck Sharp & Dohme Limited, NJ, USA) at 21:00 hours for four
weeks. Schneider and colleagues (Schneider and others 1999) demonstrated
a significant effect on portal hypertension with the 25 rng dose, hence the
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use of this dose. Patients were followed up at 2 weeks in the clinic for
assessment of side effects, blood pressure, serum creatinine and liver
function. After 4 weeks of treatment, the haemodynamic measurements
were repeated as in the initial protocol. There was no change in the
observed alcohol consumption for the duration of the study. There were no
detectable serum ethanol levels prior to each study or during follow up.
4.2.1 Haemodynamic study protocol.
All blood sampling and haemodynamic measurements were performed in
the hepatic haemodynamics suite in the supine position. The MAP, HVPG,
RAP and HBF were measured according to methods mentioned earlier. The
CO was measured using the standard thermodilution method. SVR was
derived from these measurements as mentioned earlier.
4.2.2 Blood sampling and analysis.
Venous blood was sampled after the patient was in the supine position for
30 mins for baseline biochemical and hematological measurements. In
addition, ANG II concentration, plasma renin activity (PRA), and
aldosterone levels were measured by techniques described previously.
4.2.3 Assessment ofrenalfunction.
Prior to the first dose of losartan, urine was collected over a 24-hour period
to measure creatinine clearance and urinary sodium excretion. After four




All results are expressed as mean ± SEM. Parametric data were analysed
using the paired Student t-test and the Pearson's correlation. Wilcoxon
signed rank test and Spearman correlation were used for non-parametric
data. Significance was taken at the 5% level. The SPSS package (version 9,
Chicago, Illinois, USA) was used for statistical analysis.
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Table 12: Baseline characteristics.
Characteristic (n = 12)
Sex (M/F) 7/5
Age (years) 53 ± 3
Child's class (A/B) 9/3




Primary biliary cirrhosis 3
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4.3 Results
All patients completed the study.
4.3.1 Hepatic haemodynamics andfunction.
After administration of losartan for 4 weeks there was no significant
reduction in the HVPG (15.4 ± 1.5 to 13.6 ± 1.6 mm Hg, -11.7 %, p = 0.1),
despite a significant reduction in the WHVP (20.3 ± 1.8 to 17.3 ± 1.8 mm
Hg, -14.8 %, p<0.05) (Table 11). In 5 cases there was a > 20 % reduction in
the HVPG, while in 3 cases there was a reduction in the HVPG to < 12 mm
Hg in patients with a HVPG of > 12 mm Hg at baseline (n = 10). (Figure
11) In the first 3 patients repeat haemodynamic measurements performed at
60 minutes post dosage did not demonstrate any acute effect on the HVPG.
It was not possible to calculate the hepatic blood flow in 3 patients where
the hepatic extraction of ICG was < 10%. In the remainder there was no
change in the hepatic blood flow (552.5 ± 72.9 to 559.7 ± 106.6 mL/min, n
= 9, p = NS).
The liver function tests in all patients were unaffected.
4.3.2 Systemic haemodynamics.
There was a significant reduction in the MAP (97 ± 3 to 89 ± 4.0 mm Hg, -




The creatinine clearance was unaffected (90 ± 14 to 93 ± 19 mL/min, P =
NS, n = 7), as was the 24-hour urinary sodium excretion (154 ± 61 to 122 ±
36 mmol/day, P = NS, n = 5).
4.3.4 Effect on the renin-angiotensin system.
There was a significant increase in the serum plasma renin activity from 2.7
± 0.4 to 5.2 ± 1.1 ng/mL/hr after chronic dosing (p < 0.05) confirming
activation of the renin-angiotensin system. There was a strong trend towards
increased serum ANG II levels (8.0 ± 1.8 to 24.2 ± 8.5 pg/mL, p = 0.08).
Serum aldosterone levels were unaffected (Table 13).
4.3.5 Tolerability.
One patient experienced symptomatic hypotension after the first dose of
losartan, but elected to continue with the study and experienced no further
symptoms. During follow up he was noted to have a 35% reduction in the
MAP from 122 to 79 mm Hg. This patient was found subsequently to have
systemic hypertension and commenced on drug therapy. There were no
other side effects reported during follow up.
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Table 13: Effects on haemodynamic and humoral mediators following
chronic dosing
Baseline After 4 weeks
HVPG (mm Hg) 15.4 ±1.5 13.6 ±1.6
WHVP(mmHg) 20.3 ±1.8 17.3 ±1.8*
FHVP (mm Hg) 4.9 ±0.6 3.7 ± 0.7
HR(bpm) 88.3 ± 5.8 79.1 ±4.9
MAP (mm Hg) 97 ± 3 89 ±4*
CO (1/min) 5.8 ± 0.3 5.7 ±0.3
SVR (dyn.Cm) 1324 ±48 1240 ±97
PRA (ng/mL/hr) 2.7 ±0.4 5.2 ±1.1*
ANG II (pg/mL) 8.0 ±1.8 24.2 ±8.5**
Aldosterone (pg/mL) 52.5 ± 12.8 77.5 ± 27.4
* : P < 0.05 compared with baseline.
** : P = 0.08 compared with baseline
HVPG: Hepatic venous pressure gradient. WHVP: Wedged hepatic venous pressure
gradient. FHVP: Free hepatic venous pressure gradient, HR: Heart rate, MAP: Mean
arterial pressure. CO: Cardiac output. SVR: Systemic vascular resistance. PRA: Plasma
renin activity
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Figure 11: Effect on hepatic venous pressure gradient following chronic
dosing.
A: mean HVPG ± SEM pre dosing
B: mean HVPG ± SEM post chronic dosing
Values in the centre of the chart refer to individual patient data.
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4.4 Conclusions.
Losartan. at the 25mg dose, appears to be well tolerated in patients with pre-
ascitic cirrhosis. However, chronic administration did not result in a
significant reduction in the HVPG. Therefore, losartan is unlikely to be
effective for the prevention of variceal bleeding.
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CHAPTER 5
Transjugular intrahepatic portosystemic stent-shunt




The management of gastric variceal bleeding remains a clinical challenge.
Endoscopic treatments with sclerotherapy (Gimson and others 1991) have
resulted in good initial haemostasis, but were marred by a high rebleeding
rate. Recent evidence on the use of tissue adhesives (Zimmer and others
1998; Akahoshi and others 2002; Sarin and others 2002) and thrombin
(Yang and others 2002; Heneghan and others 2002) for bleeding gastric
varices are more promising.
TIPSS has been used extensively for the treatment for bleeding varices, with
recent meta-analyses confirming its superior efficacy over endoscopic
methods in preventing oesophageal variceal rebleeding, although mortality
was unaffected and the rates of hepatic encephalopathy are higher with
TIPSS (Papatheodoridis and others 1999; Burroughs and Vangeli 2002).
There are relatively few studies on the use of TIPSS for bleeding gastric
varices, although the available evidence is encouraging with the efficacy of
TIPSS in preventing gastric variceal rebleeding as good as for oesophageal
variceal bleeding (Stanley and others 1997a; Barange and others 1999;
Albillos and Ruiz 1999).
Despite reports that varices bleed almost exclusively at portal pressures > 12
mmHg (Groszmann and others 1990), it has been shown that patients with
directly measured PPG < 12mm Hg remain at risk of variceal bleeding
(Jalan and others 1995c). Furthermore, it is recognised that gastric varices
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occur at lower portal pressures than oesophageal varices (Watanabe and
others 1988).
The aim of this study is to compare retrospectively the clinical outcome of
patients who have bled from gastric and oesphageal varices requiring a
TIPSS procedure. Haemodynamic and clinical correlations were made, and
the patients who bled at PPG of < 12 mmHg were studied to identify
whether they differed from the group who bled at higher portal pressures
with regard to site of variceal bleed, rebleeding and survival.
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5.2 Patients and methods.
Over a 9-year period, 436 patients underwent a TIPSS procedure in our
centre. In 377 patients the primary indication was variceal haemorrhage
with the remainder having ascites (n = 44) or portal hypertensive
gastropathy (n = 9) or other indication (n = 6). Patients were excluded if the
TIPSS procedure had failed (n = 24), if they had participated in a trial
comparing TIPSS versus TIPSS and banding and were randomised to the
TIPSS and banding arm (where TIPSS angiographic surveillance was
performed for the first year after TIPSS only, n = 40), or if there was
insufficient data (n = 21). After exclusions there were a total of 292 patients
from which the study populations were selected.
In the eligible patients 40 had a TIPSS performed for gastric variceal
bleeding (GVB), 232 for oesophageal variceal bleeding (OVB) alone, 12 for
both gastric and oesophageal variceal bleeding and 8 for ectopic variceal
bleeding. All varices were thought to have arisen because of portal
hypertension secondary to parenchymal liver disease. In 38 cases ofGVB
bleeding was believed to have been from varices in the fundus or cardia, and
2 cases from varices along the lesser curve. Table 14 illustrates the baseline
characteristics of these patients. There were more patients with cryptogenic
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Table 15: Patient characteristics depending on the portal pressure






Age (years) 54.9 ± 1.9 52.5 ±0.8 N.S.
Sex
Male 25 (65.8%) 157(61.8%) N.S.
Female 13 (34.2%) 97 (38.2%) N.S.
Aetiology
Alcoholic liver disease 27 (71.1%) 151 (59.4%) N.S.
Primary biliary cirrhosis 3 (7.9) 27(10.6%) N.S.
Hepatitis C 0 20 (7.9%) N.S.
Cryptogenic cirrhosis 5 (13.2%) 23 (9.1 %) N.S.
Autoimmune 1 (2.6%) 8(3.1%) N.S.
Cystic fibrosis 0 6 (2.4%) N.S.
Primary sclerosing cholangitis 1 (2.6%) 7 (2.8%) N.S.
Hepatitis B 1 (2.6%) 3 (1.2%) N.S.
Others 0 9 (3.5%) N.S.
Portal Pressure Gradient
(mm Hg)
Pre TIPSS 9.8 ±0.4 22.1 ±0.4 <0.001
Post TIPSS 4.2 ±0.5 7.6 ±0.3 <0.05
Reduction post TIPSS 5.6 ±0.5 14.6 ±0.5 <0.001
Child Pugh Score 9.1 ±0.5 9.9 ±0.2 N.S.
Indication
Oesophageal variceal bleeding 20 (52.6%) 212(83.5%) <0.001
Gastric variceal bleeding 14(36.8%) 26(10.2%) <0.001
Gastric and oesophageal variceal 2 (5.3%) 10(3.9%) N.S.
bleeding
Ectopic variceal bleeding 2 (5.3%) 6 (2.4%) N.S.
Group 1: all patients with PPG <12 mmHg.
Group 2: all patients with PPG >12 mmHg.
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In order to make haemodynamic and clinical correlations the patients were
further divided into 2 groups according to the direct PPG at the time of
index TIPSS. In addition to the patients in Table 14, these groups also
incorporated those patients who bled from both oesophageal and gastric
varices (n=12) and from ectopic varices (n=8). Group 1 included those
patients with PPG < 12 mm Hg (n = 38), and group 2 those patients with
PPG >12 mm Hg (n = 254). The baseline characteristics of these patients
are detailed in Table 15. There was no difference in the age, sex, aetiology
of liver disease or Child Pugh score of the two groups.
5.2.1 TIPSS procedure.
All patients were referred for a TIPSS from within the Royal Infirmary of
Edinburgh, or from other hospitals within Scotland. Our unit operates a 24-
hour facility for emergency TIPSS insertion. TIPSS insertion was performed
by an experienced radiologist using an established technique (Chalmers and
others 1992). Where the original pressure was > 12 mm Hg the aim was to
reduce the portal pressure gradient to below 12 mmHg. The patency of the
TIPSS shunt was assessed by Doppler ultrasound within a week of insertion,
and by portograms at 3 months then 6 monthly thereafter or whenever there
were clinical features suggestive of shunt insufficiency.
5.2.2 Follow up.
The patients were followed up clinically at 3 monthly intervals to assess
their clinical condition with emphasis being placed on any episodes of
encephalopathy and variceal rebleeding. Early mortality, variceal
rebleeding, and shunt insufficiency were defined as stated in chapter 2.
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Follow up time was defined as the time interval in months between the
initial TIPSS insertion to the most recent clinic review, liver transplantation,
or death.
5.2.3 Statistical analysis.
All results are expressed as mean ± standard error ofmean (S.E.M) or
percentage where indicated. Statistical significance for parametric data was
determined using Students /-tests, and for non-parametric data using Chi
Squared and Mann Whitney (/-test. The Kaplan-Meier method was used to
analyse patient survival, and cumulative rebleeding risk, with comparison
between the two groups determined by the log rank test. Univariate and
multivariate relations between survival and variables of interest in those
patients who bled from gastric varices and oesophageal varices at PPG > 12
mm Hg was performed using Cox Regression analysis. These variables
were: aetiology of cirrhosis (alcoholic or non-alcoholic), site of bleeding
(from gastric or oesophageal varices), sex and age of patients,
encephalopathy, ascites, bilirubin, prothrombin time, albumin, and the time
interval between the index bleed and TIPSS insertion. Significance was
taken at p < 0.05 for all tests. All statistical analysis was performed using
the SPSS package (Version 10, SPSS Inc., Chicago, 1L).
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5.3 Results.
5.3.1 PPG pre and post TIPSS.
The PPG pre-TiPSS was significantly higher in patients with OVB
compared with GVB (21.4 ± 0.5 versus 15.8 ± 0.8 mm Hg, p < 0.001).
Following TIPSS insertion all patients who had bled from gastric varices
had the PPG reduced to < 12 mmHg, while in 22 (9.5%) patients who bled
from oesophageal varices the post-TIPSS PPG was >12 mmHg. However,
the mean PPG post-TIPSS was similar in the GVB and OVB groups. (Table
14)
5.3.2 Rebleeding.
The mean follow up period was 19.8 ± 1.3 and 36.7 ± 5.1 months in the
OVB and GVB groups respectively (p < 0.01). The longer follow up time in
the GVB group may reflect the greater proportion of patients recruited in or
prior to 1995 compared with the OVB group (62.5% versus 29.7%, p <
0.001). In this time, 34 (14.7%) of the patients in the OVB group rebled,
and 8 (20%) of the patients in the GVB group rebled. The cumulative risk of
rebleeding was similar in both groups. (Figure 12) In 31 (73.5%) cases of
variceal rebleeding there was evidence of TIPSS dysfunction.
5.3.3 Mortality.
During the follow up period there was a significant difference in the
cumulative risk of death in favour of the GVB group (p < 0.05 by Kaplan-
Meier method). This was true for 30 day mortality (15% versus 23.8%), 1
year mortality (30.7% versus 38.6%) and 5 year mortality (49.5% versus
74.9%). (Figure 13) There was no significant difference in the time interval
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to TIPSS from the variceal bleed (5.4 ± 0.9 days versus 4.9 ± 0.4 days for
GVB and OVB groups respectively, p = N.S.). The principal cause of death
was similar in both groups, with liver failure or sepsis accounting for 82
(64.1 %) deaths in the OVB group and 12 (75%) deaths in the GVB group.
5.3.4 Encephalopathy.
The rate of encephalopathy prior to TIPSS insertion was similar in the OVB
and GVB groups (27.6% versus 30.0%, p = NS). There was no significant
difference in the episodes of new or worsening encephalopathy in the
oesophageal and gastric varices groups (16.35% versus 17.5% respectively,
p = NS) All episodes of encephalopathy were managed initially with
lactulose and protein reduction. In 3 cases the shunt was reduced in size, and
in 8 cases it was necessary to block the shunt with a filter ± coils.
5.3.5 Shunt insufficiency.
There was no difference in the overall incidence of shunt insufficiency in
the study period between the two groups (42.67% versus 55% in the OVB
and GVB groups respectively). In 1 patient in the GVB group problems
with maintaining TIPSS patency resulted in elective surgery with the
creation of a distal spleno-renal shunt.
5.3.6 Orthotopic liver transplantation.
Twenty-one patients required an orthotopic liver transplantation, 19 (8.2%)
in the oesophageal varices group and 2 (5%) in the gastric varices group (p
= NS).
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5.3.7 Correlations between portalpressure and clinical outcome.
When patients with a pre-TIPSS PPG <12 mmHg were analysed it was clear
that gastric variceal bleeding accounted for significantly more cases than for
those patients who bled at PPG > 12 mmHg (36.8% vs 10.2%, p<0.001,
Table 15). However, there was no overall difference in the rebleeding rate
and mortality in the 2 groups. Rates of shunt insufficiency and
encephalopathy were also similar in the two groups. In group 1 the final
PPG post-TIPSS is similar in those patients that rebled (n = 9) compared
with those that do not rebleed (n = 29) of 5.1 ± 0.1 mmHg and 3.9 ± 0.5
mmHg respectively (p = 0.2). In group 2 the PPG post-TIPSS is
significantly higher in patients who rebled post-TIPSS (n = 35) compared
with those that do not rebleed (n = 219) of 9.4 ± 0.8 mmHg and 7.3 ± 0.3
mmHg respectively (p < 0.005). In addition 75% of the patients in group 2
who rebled had a PPG post-TIPSS of> 7 mmHg.
When patients who bled from either oesophageal varices or gastric varices
with PPG pre-TIPSS of > 12 mmHg were analysed, there was a significant
difference in mortality in favour of gastric varices (p = 0.02 by Kaplan-
Meier method). 30 day mortality (12% versus 24.2%), 1 year mortality
(33.8% versus 40.4%), and 5 year mortality (39.4% versus 79.1%) were all
significantly better in the gastric varices group (Figure 14). Univariate
analysis showed that the following variables were associated with higher
mortality in the patients who bled from gastric or oesophageal varices at
PPG > 12 mm Hg : increasing age (p < 0.01); bleeding from oesophageal
varices (p=0.04); high prothrombin time (p < 0.05); high bilirubin (p <
0.001), low albumin (p = 0.001); presence of ascites (p < 0.001); and
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encephalopathy (p < 0.05). Multivariate analysis of these variables revealed
that greater age of patients (p < 0.05), high bilirubin (p < 0.05) and a low
albumin (p < 0.001) were independent variables predicting mortality. There
was no difference in the rebleeding rate. The mortality and rebleeding rates
were similar in the GVB and OVB groups who bled at PPG < 12 mmHg.
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Figure 12: Kaplan Meier graph of rebleeding for all patients who bled from gastric
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Figure 13: Kaplan Meier graph of survival for all patients who bled from gastric
and oesophageal varices treated with a TIPSS
Time (months)
p=0.046
Time 0 10 20 30 40 50 60
(months) months months months months months months
Gastric 40 25 22 20 18 16 11
varices
Oesophageal 232 128 101 60 40 25 8
varices
149
Figure 14: Kaplan Meier graph of survival for all patients who bled from gastric and
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This study demonstrates that TIPSS is equally effective in the prevention of
gastric or oesophageal variceal rebleeding. In addition, mortality is
significantly better in the GVB group who bled at PPG > 12 mmHg, and
warrants further study. The findings also highlight the significant number of
patients with gastric varices who bled at PPG <12mmHg, and challenge the
use of this cut off value as a treatment goal particularly in such patients. Our
results also suggest that clinicians should aim for a PPG post TIPSS of < 7
mmHg for patients who have variceal bleeding at PPG > 12 mmHg. TIPSS
therefore has a major role in the management ofGVB, which can be very
difficult to control by other measures. Further long-term prospective studies




Randomised controlled trial of VBL versus standard
TIPSS surveillance following TIPSS insertion for the
prevention of oesophageal variceal rebleeding
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6.1 Introduction.
Long term patency ofTIPSS is a major clinical problem. Studies indicate
that without regular TIPSS surveillance and intervention, approximately
50% of stents will occlude after a year (Lind and others 1994; Haskal and
others 1994; Stanley and others 1997b; Jalan and others 1997b; Latimer and
others 1998; Jalan and others 1998). Regular invasive portographic
surveillance, which is essential for maintaining shunt patency is not
available in all centres, and places an additional burden on resources.
Moreover, non-invasive methods of assessing TIPSS patency such as
Doppler ultrasound are not as sensitive as regular portography (Ferguson
and others 1995), and lead to a higher rebleeding rate (Papatheodoridis and
others 1999). In any case, Doppler ultrasound does not allow for
interventions, such as balloon angioplasty and re-stenting or the
measurement of portal pressures.
VBL has replaced injection sclerotherapy in most centres as the favoured
endoscopic treatment for the prevention of variceal rebleeding. VBL is
associated with a high rate of rebleeding particularly in the month following
the index variceal bleed (Jalan and others 1997a). However, once the varices
have been eradicated. VBL may be as effective as a patent TIPSS in
preventing variceal rebleeding. Thus, following variceal eradication in a
patient with a TIPSS, it may not be necessary to continue TIPSS
surveillance to maintain TIPSS patency. It is not known whether terminating
angiographic TIPSS surveillance following successful VBL will
compromise the variceal rebleeding rate.
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We hypothesise that combining VBL and TIPSS with short-term
portographic surveillance will be as effective as a TIPSS alone with long-
term surveillance in the prevention of oesophageal variceal rebleeding.
Patients in the former group could benefit from the reduced need for
angiographic surveillance, and incidence of hepatic encephalopathy as the
TIPSS is allowed to occlude following variceal eradication. There may also
be cost advantages in using VBL instead of long-term TIPSS surveillance.
Therefore, the aim of this randomised controlled trial was to compare the
efficacy ofTIPSS plus VBL without long-term surveillance, with TIPSS
and long-term surveillance in the secondary prevention of oesophageal
variceal rebleeding. Other potential differences such as mortality,
encephalopathy, and costs were also explored.
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6.2 Methods.
The trial was undertaken with the approval of the local research ethics
committee, written informed consent of each subject, and in accordance
with the Declaration of Helsinki (1989) of the World Medical Association.
6.2.1 Patients selection.
Between December 1995 and August 2000, a total of 303 patients were
referred forTIPSS insertion from centres throughout Scotland. All TIPSS
procedures were performed in the Royal Infirmary, Edinburgh. All patients
presenting with bleeding oesophageal varices were considered for inclusion
into the trial. Exclusion criteria are as follows: 1) technical failure of TIPSS
insertion; 2) age < 18 or > 85; 3) bleeding gastric or ectopic varices; 4)
portal vein thrombosis; 5) Budd-Chiari Syndrome; 6) ascites as a primary
indication for TIPSS; 7) advanced cardiopulmonary disease; 8) malignancy
with prognosis that will affect study outcome; 9) inability to give informed
consent; 10) previous variceal haemorrhage; 11) pregnancy or women of
childbearing potential not taking contraception. Patients were recruited after
haemodynamic stabilisation.
6.2.2 Randomisation and treatments.
Prior to TIPSS, all patients were resuscitated with fluids and blood or blood
products, and underwent endoscopy with VBL or sclerotherapy using 5%
ethanolamine oleate if there was active bleeding. In some patients,
pharmacological intervention with octreotide or terlipressin was undertaken.
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Randomisation was performed following TIPSS insertion and only after
initial control of bleeding and haemodynamic stabilisation. Patients were
allocated to either Group 1 or Group 2 by the sealed envelope method (Peto
and others 1977).
Group 1: TIPSS alone (n = 39)
At the time of index endoscopy active variceal bleeding was noted in 23
patients. VBL was performed in 13 patients. VBL and sclerotherapy in 1
patient, and sclerotherapy in 6 patients. In 3 patients it was not possible to
control bleeding with endoscopic therapies requiring the use of balloon
tamponade. In 16 patients there was stigmata of recent bleeding but no
active bleeding, with 3 patients having VBL and 1 both VBL and
sclerotherapy. The remainder proceeded straight to TIPSS. All TIPSS
procedures in the recruited patients were performed or closely supervised by
a skilled interventional radiologist using a standard technique described
earlier. All patients were administered broad spectrum antibiotics pre- and
for 48 hours post-procedure. Ten to 14 mm diameter expandable metal
stents (Wallstent, Schneider, Switzerland) were used, with the aim of
reducing the PPG to < 12 mm Hg or by > 20%. This was achieved in 36
(92%) and 37 (93%) patients in groups 1 and 2 respectively. Two or more
stents were used, if necessary, to cover the entire length of the tract between
the hepatic vein and the portal vein.
Following creation, TIPSS function was assessed at one week by colour
Doppler ultrasound. Routine portographic follow up with intervention, if
required, to maintain shunt patency was undertaken at six monthly intervals
thereafter. However, additional TIPSS portography was also perfomed
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where there was clinical suspicion of TIPSS insufficiency such as
rebleeding.
Group 2: TIPSSplus VBL (n=40)
At the time of index TIPSS 28 patients were actively bleeding from varices.
Eighteen patients required VBL, 2 patients VBL and sclerotherapy, and 4
sclerotherapy. Four patients failed endoscopic therapy requiring balloon
tamponade and urgent TIPSS. In 12 patients there were stigmata of recent
bleeding but not active bleeding, with 6 patients having VBL, and the
remainder proceeding to TIPSS. TIPSS procedure was performed as above.
Following satisfactory haemodynamic stabilisation , VBL was undertaken
or closely supervised by an experienced endoscopist. One of two banding
devices was used (Speedbander, Boston Scientific, Herts or 6-Shooter Saeed
Multi-Band Ligator, Cook, Ireland), deploying 5 or 6 bands respectively.
Varices just above the gastro-oesophageal junction were banded using a
single band at a time. A varix was considered eradicated if the column had
disappeared, or if they could not be sucked into the banding device. It
should be noted that in patients with a patent TIPSS the varices often appear
collapsed, and therefore require suction for their size to be appreciated and
VBL to be performed.
Repeat endoscopy ± VBL was performed within a week ofTIPSS insertion
and at two weekly intervals until variceal eradication. Intervals were
extended to 3 and 6 months thereafter. Shunt function was assessed as
previously mentioned. Portographic follow up was continued for up to 12
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months following TIPSS insertion in all patients, but was discontinued
earlier in patients where variceal eradication was achieved.
6.2.3 Follow up.
All subjects were followed up until death, liver transplantation, or lost to
follow up. A specialist research nurse coordinated clinical follow up, with
full clinical examination and biochemical profile at 6 weeks post
randomisation and 4 monthly thereafter.
6.2.4 Outcomes.
The outcomes were assessed at 6, 12 and 24 months. The primary outcome
of the study was variceal rebleeding. Secondary outcomes were mortality,
incidence of encephalopathy, and orthotopic liver transplantation (OLT).
6.2.5 Sample size calculation.
Sample size was calculated to show that both treatments were equally
effective in preventing rebleeding (Blackwelder 1982). Assuming that both
treatments were expected to have a 10% variceal rebleeding rate, and with a
type I error (a) of 0.05 and type II error (B) of 0.2, 38 patients would be
required in each arm to demonstrate equivalence (assumed as < 17%
difference) of the two treatments. Once sufficient numbers were reached in
each arm, recruitment stopped and the study was terminated 4 months after
the last patient was recruited.
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6.2.6 Calculation ofcosts oftreatment.
Data regarding the time spent by each patient in a general, intensive care, or
high-dependency ward during the follow up period were retrieved. The costs
were based on data from the National Health Service, our Department of
Radiology, and our Endoscopy Unit. The costs are expressed as cost per
patient and also the cost per month survival. The latter is the overall cost per
patient divided by the follow up time in months (Table 4).
Costs ofward beds
The cost per day in a general ward was £350, high-dependency ward was
£500 and an intensive care ward was £1200. These costs include staff and
consumables.
Cost ofthe TIPSSprocedure andfollow up
The consumable cost of the TIPSS procedure is £1679. Follow up costs are
as follows; routine portography (£205), balloon angioplasty (£371), shunt
reduction (£753), insertion of a caval filter and coils for the purposes of
occluding the shunt (£785), shunt extension (£927), and insertion of parallel
shunt (£1462).
CostofVBL
The cost of the endoscopy session is £250. Where VBL is also required, the
overall cost increases to £350.
6.2. 7 Statistical analysis.
Data was analysed on an intention-to-treat basis. Baseline characteristics
were described in the 2 groups using summary statistics. Chi squared test
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was used to compare non-parametric data, and Student r-test was used to
compare parametric data. Kaplan-Meier graphs and log-rank tests were
applied to survival, rebleeding, encephalopathy, and shunt insufficiency.
Cox regression analysis was used to control of gender and PPG pre-TIPSS.
Significance was taken at the 5% level. The SPSS statistics packkage
(version 9, Chicago, Illinois, USA) was used for all statistical analyses.
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Figure 15: Flow diagram of patient recruitment. See text for exclusion
criteria. Patients who reached the end points after randomisation and
withdrawn from the trial had one of the following events: 1) Death; 2)




79 patients met the inclusion criteria, with 39 randomised to group 1 and 40
to group 2 (Figure 15). There were no patients excluded from the trial after
randomisation. The mean follow up period was 22.5 ± 17.2 (range 0.1 to
58.9) and 26.6 ± 18.1 (range 0.3 to 64.1) months for Groups 1 and 2
respectively.
6.3.2 Baseline characteristics.
There were more male patients and the PPG pre-TIPSS was higher in the
TIPSS alone arm. Clinical parameters of the 2 groups are shown in Table
16.
6.3.3 Procedures.
TIPSS insertion was complicated by an intraperitoneal bleed in 1 patient in
Group 1. In another patient in Group 2, there was a biliary leak leading to a
percutaneous fistula and suprahepatic abscess. This patient developed
respiratory failure and staphylococcal septicaemia requiring antibiotics,
vasoconstrictor therapy, and ventilation. The suprahepatic abscess was
drained percutaneously. The patient then made an uneventful recovery. In
73 (92%) patients, there was reduction in the PPG following TIPSS
insertion to < 12 mm Fig, and in all patients except one there was a > 20%
reduction in the PPG post-TIPSS. The mean diameter of the stents was
similar in the 2 groups.
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VBL post-TIPSS insertion was performed successfully in 38 patients in
Group 2. One patient rebled before VBL could take place, and another
refused banding. A total of 176 endoscopies were performed during the
follow up period. VBL was required in 69 endoscopies, with 47 (68%)
procedures performed in the first 3 sessions. Successful eradication of
varices was achieved in 28 patients following an average of 2.8 ± 0.3
sessions. Four patients rebled prior to eradication and were entered into a
regular long-term TIPSS surveillance program instead of regular VBL. Two
patients died before eradication could take place. Another 6 patients did not
complete the banding program either because they were lost to follow up, or
because they refused further banding. Post-banding ulceration occurred in
12 (30%) patients.
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Table 16: Characteristics of the 2 groups at baseline. Figures are mean
± SD unless stated otherwise.
Characteristic TIPSS TIPSS & VBL
(n = 39) (n = 40)
Mean age (years), min to max 53.9 ± 11.2 55.9 ± 11.4
(32 to 74) (30 to 82)
Male sex n (%) 30 (77%) 22 (55%)*
Child-Pugh Score (at baseline) 9.2 ±2.1 8.7 ±2.3
Aetiology
Alcoholic n(%) 28 (72) 35 (88)
Abstained from alcohol n(%) 8 (29) 10 (29)
Non-alcoholic n(%) 11 (25) 5(13)
PPG (mm Hg)
Pre-TIPSS 25.2 ±6.6 20.1 ±6.1**
Post-TIPSS 7.2 ±4.0 6.6 ±4.4
Requirement for mechanical ventilation
n(%)
Time from index bleed to
randomisation (days)
5 (13%) 6(15%)
8.1 ±6.8 6.3 ±5.5
Time from T1PSS insertion to
randomisation (days)
3.3 ±2.9 2.9 ±3.3
Blood transfusion at randomisation
(units)
3.5 ±4.2 2.7 ±2.6
Hypotensive at randomisation n(%) 6(15%) 4(10%)
PPG: Portal pressure gradient.
* : p = 0.040
** : p < 0.001
164
6.3.4 Rebleeding.
In Group 1, 3 episodes of variceal rebleeding occurred in 3 patients (8%)
during follow up, 2 with Child C and 1 with Child B disease (Table 17). In 2
patients rebleeding proved to be rapidly fatal, whilst in the third case the
shunt was insufficient with a PPG of 18 mm Hg, and evidence of hepatic
vein stenosis requiring shunt extension. This patient did not have a further
rebleed and made a satisfactory recovery. In addition, there were 4 patients
who rebled from non-variceal sources (2 from banding ulceration, 1 from
oesophagitis, and another from a Mallory Weiss Tear).
In Group 2 there were 9 episodes of variceal rebleeding in 6 patients (15%)
during follow up, 2 with Child A and 4 with Child C disease (Table 17).
Varices were eradicated in only two patients. In all cases there was evidence
of TIPSS insufficiency requiring re-stenting or balloon angioplasty. In all
cases except one, variceal rebleeding was controlled. One patient who
rebled from gastric varices initially responded to thrombin injection and
balloon angioplasty of the TIPSS. This patient had gastric varices at
randomisation. However, he rebled again within 24 hours from gastric
varices, despite a patent TIPSS. He unfortunately died from oesophageal
rupture secondary to balloon tamponade. Three patients rebled from non-
variceal sources (1 from oesophagitis, 1 from a duodenal ulcer, and another
from severe portal hypertensive gastropathy).
There was no significant difference in the cumulative risk of variceal
rebleeding by Kaplan Meier analysis (p = 0.440; relative hazard 0.58; 95%
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CI 0.15 to 2.33; Figure 16 and Table 17). The 2 groups were similar even
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Time (months) 0 6 12 18 24 30 36
TIPSS alone (n) 39 27 23 19 13 11 9
TIPSS plus VBL (n) 40 34 28 26 20 13 10
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6.3.5 Mortality.
In Group 1, there were 17 deaths (44%) in total during follow up (Table 17).
Early mortality occurred in 2 patients from multiorgan failure resulting from
the variceal bleed. The other causes of death were renal failure secondary to
gentamicin therapy for a presumed shunt infection (n = 1), cerebrovascular
accident (n = 2), liver failure following non-variceal rebleeding (n = 4), and
for the remainder multiorgan failure and sepsis.
In Group 2, there were 15 deaths (38%) in total during follow up (Table 17).
One patient died within 6 weeks of the index bleed from aspiration
pneumonia. The causes of death were liver failure following variceal
rebleeding (n = 2), oesophageal rupture following insertion of a Sengstaken
tube (n = 1), sepsis after a colectomy (n = 1), cerebrovascular accident (n =
2), multiorgan failure (n = 7), and pneumonia (n = 1).
There was no statistically significant difference in the cumulative survival
by the Kaplan Meier method between the two groups (p = 0.434; relative
hazard 1.31; 95% CI 0.66 to 2.61; Figure 17 and Table 17). The two groups
were similar even after controlling for PPG pre-TIPSS and gender (Table
17).
6.3.6 Encephalopathy
In Group 1,15 patients (39%) in total developed encephalopathy during
follow up (Table 17). Four patients experienced deterioration of pre-existing
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encephalopathy. Two patients responded to conservative therapy with
lactulose and protein restriction, whilst the other 2 patients died with severe
encephalopathy and liver failure. The remainder (28%) had de-novo
encephalopathy. These patients were treated conservatively, with 2 patients
requiring occlusion of the shunt with a filter, and subsequent entry into a
banding program.
In Group 2, 8 patients (20%) in total developed encephalopathy during
follow up (Table 17). Two patients were encephalopathic prior to T1PSS.
Both responded to conservative therapy. The remainder (15%) had de-novo
encephalopathy. Four responded to conservative therapy, and two required
occlusion of the shunt.
There was a significance difference (relative hazard 2.63; 95% CI 1.11 to
6.25; p = 0.023) in favour of group 2, in the cumulative risk of being free of
encephalopathy during the follow up period (Figure 18 and Table 17). This
difference did not maintain statistical significance after controlling for
gender and PPG pre-TIPSS (p = 0.136; Table 17). The cumulative risk of
developing de-novo encephalopathy was also significantly less in Group 2
(p = 0.041). Further analysis revealed that there was no statistical difference
(p = 0.386) in the incidence of hepatic encephalopathy in the first 6 months
in the 2 groups, the period when the number of portograms was similar in
groups 1 and 2 (25 versus 27 respectively). Flowever, the difference in
hepatic encephalopathy in favour of Group 2 remained statistically
significant (p = 0.028) when analysis was confined to the period from the
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end of the first 6 months follow up, when there were far fewer portograms
performed in Group 2(10 versus 21).
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Figure 17: Kaplan Meier analysis of cumulative survival.
Time (months)
Time (months) 0 6 12 18 24 30 36
TIPSS alone (n) 39 32 23 19 13 11 9
TIPSS plus VBL (n) 40 34 28 26 20 13 10
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6.3.7 Shunt function in the first year.
Since TIPSS portography was performed only for up to a year following
TIPSS insertion in Group 2, valid comparisons of shunt function between
the 2 groups can only be made for 12 months following TIPSS insertion.
In group I, a total of 46 TIPSS portograms were performed in the first year,
with 54% of these performed in the first 6 months. A total of 16 (41%)
patients developed shunt insufficiency. In the first 12 months, 59% of shunt
interventions were performed within the first 6 months following TIPSS
insertion.
In Group 2, a total of 37 TIPSS portograms were performed in the first year,
with 73% of these in the first 6 months. There were 17 (43%) cases of shunt
insufficiency in the first 12 months. There was no difference in the
cumulative risk of shunt insufficiency in the 2 groups by the Kaplan Meier
Method (Figure 19).
6.3.8 Orthotopic liver transplantation (OLT).
Four patients, all from Group 1, underwent OLT during the follow-up
period, between 9.1 and 40.4 months after TIPSS creation. Most patients in
both groups were unsuitable for OLT on account of the high incidence of
continued alcohol consumption (Table 16).
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6.3.9 Duration ofhospital stay.
Total requirements for in-patient care were similar in the two groups during
follow up: 46.5 ± 54.5 versus 58.0 ± 65.2 days in Groups 1 and 2
respectively (p = 0.396). There was also no difference in the intensive care
or high dependency care requirements (Table 18).
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39 33 28 23 20 17 12
TIPSS plus VBL (n) 40 35 30 24 23 22 11
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Table 18: Days spent in hospital during follow up.





General Ward 43.9 ±54.0
HDU 1.8 ±1.4







ITU: Intensive care unit.
HDU: High dependency unit.
No statistical difference was detected between the two groups.
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6.3.10 Costs of treatment.
Table 19 details the costs incurred in both groups following randomisation.
The difference in the total cost per patient did not reach statistical
significance (£19560 ± 19146 versus £24738 ± 24299, p = 0.297, in Groups
1 and 2 respectively).
6.3.11 Severity ofliver disease at the end offollow up.
The Child-Pugh score did not change significantly at the end of follow up
(8.9 ± 2.6 versus 9.2 ± 2.2, p = 0.609, Groups 1 and 2 respectively).
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Table 19: Costs of treatments following randomisation in both groups.
Cost per patient (£)
Procedures TIPSS TIPSS & VBL
II (n = 40)
TIPSS surveillance 877 ±930 805 ± 969
VBL - 1270 ±985
Ward treatment 17004 ±19154 20983 ±23823
Total cost 19560±19146 24738 ±24299
Cost per patient free of rebleeding 20633* 24520°
Cost per surviving patient 15922^ 20127**
Cost per month survived* 4576 6024
Mean ± SD.
*: n = 36. a:n = 34. *:n = 22. **:n = 24.
* : Total cost per patient divided by the follow up time in months.
There was no statistical difference in the costs between the two groups.
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6.4 Conclusions
T1PSS plus VBL without long-term surveillance is effective in preventing
oesophageal variceal rebleeding, and has the potential for low rates of
encephalopathy. Therefore, VBL with short-term TIPSS surveillance is a






The clinical studies presented in this thesis aim to clarify the following
questions:
1. The systemic and portal haemodynamic effects and patient tolerablility of 2 novel
pharamacological agents:
a. Is low dose carvedilol, a non-cardioselective vasodilating beta-blocker, as effective
in reducing portal pressure and better tolerated than higher doses?
b. Does modification of the renin-angiotensin system by using losartan, an angiotensin
1 receptor antagonist, result in reduction of portal pressure in patients with pre-ascitic
cirrhosis?
2. Is there any difference in the efficacy ofTIPSS for the management of gastric and
oesophageal variceal haemorrhage? What is the role of portal pressure in determining
clinical outcomes following TIPSS?
3. Can variceal band ligation replace long-term portographic surveillance following a
TIPSS for the management of oesophageal variceal bleeding?
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7.1 The role of low dose carvedilol in cirrhotic portal hypertension.
Our results clearly show that carvedilol at a dose of 12.5mg per day is a
potent portal hypotensive agent and is well tolerated. Its acute
administration significantly reduces portal pressure, an effect which is
maintained following chronic dosing. In all cases except 1 there was a
reduction in the HVPG of> 20%, and in 7 out of 9 patients the HVPG was
< 12mmHg with chronic administration. The reduction in portal pressure
observed in this study is one of the largest reported in literature to date, and
is comparable to that seen following the insertion of a transjuglular
intrahepatic portosystemic stent-shunt (TIPSS).
7.1.1 Effects ofcarvedilol on portal and systemic haemodynamics.
The reductions in the HVPG, CO, and MAP which we observed following
acute dosing are consistent with that observed in previous studies performed
in our unit using 25 mg of carvedilol (Forrest and others 1996a). We also
demonstrated a reduction in the HBF in a small number of patients, a
finding that was noted in one the previous studies (Banares and others
1999). These haemodynamic findings would be consistent with non¬
selective B-blockade as has been demonstrated with propranolol (Lebrec and
others 1982). In comparison with propranolol, carvedilol has less effect on
CO and HR compared with its effect on HBF, suggesting that the degree of
Pi blockade is less than propranolol, at least acutely (Banares and others
1999). However, chronic administration did not lead to a further significant
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fall in the CO and MAP despite a reduction in the HR. These findings are
similar to those previously demonstrated in our centre (Stanley and others
1999). Alpha-1 receptor antagonism and hence reduced intra-hepatic
resistance are likely to have contributed to the marked reduction in the
HVPG following chronic dosing. A reduction in the hepatic blood flow
noted in the small group of patients could have had an additional effect.
The acute haemodynamic effects of low dose carvedilol have been
investigated in 3 previous studies (Banares and others 1999; De and others
2002). A lOmg dose significantly reduced the HVPG by 15% at 60 minutes
and by 17% after 90 minutes in 10 patients, although only 50% of patients
had a greater than 20% reduction in the HVPG (Sekiyama and others 1997).
The 12.5 mg dose has been studied in a further smaller study, which did not
demonstrate an effect on the portal or systemic haemodynamics, although
there was a tendency to reduced HVPG and MAP (Banares and others
1999). A similar dose of carvedilol has been studied alongside propranolol,
in a recent study by De and colleagues (De and others 2002). Following
acute administration of 25 mg carvedilol, there was a 27.7% reduction in the
HVPG, compared with 23.0% for 80 mg propranolol (p=NS). The effect on
portal pressure was sustained after 7 days administration of once daily
12.5mg of carvedilol, and 80 mg propranolol. There was a significant
reduction in the MAP, with just 1 ascitic patient in the carvedilol arm
suffering symptomatic hypotension necessitating withdrawal from the trial.
An important finding in the study was the strong predictive value of the
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acute response to carvedilol in determining those that will respond after
chronic dosing.
A recent study showed that the reduction in the HVPG, MAP, HR, and CO
was greater with chronic administration of carvedilol than with propranolol
(Banares and others 2002). Hepatic blood flow was unchanged with
carvedilol, but decreased with propranolol. The authors expressed concern
about the significant reduction in the MAP. The dose of carvedilol used was
significantly greater than the dose used in our study (31mg vs 12.5 mg per
day), which may have been because Banares and colleagues titrated the dose
against HR. It is doubtful whether such high doses are required because we
have demonstrated in this and a previous study (Stanley and others 1999)
that a lower fixed dose can result in a similar magnitude of portal pressure
reduction with minimal side effects. These findings were mirrored in a
randomised study comparing carvedilol with propranolol over a mean
follow up of 11 weeks (Banares and others 2002). In addition, carvedilol
and propranolol both reduced the azygous blood flow with no effect on
renal function.
7.1.2 Bioavailability ofcarvedilol.
Concerns have been expressed regarding the effect of carvedilol on systemic
haemodynamics, in particular blood pressure, in patients with liver disease.
This stems from the fact that the bioavalability is very variable in patients
with hepatic impairment. Carvedilol undergoes extensive stereoscopic first
pass metabolism in the liver (Morgan 1994). The stereoisomer R-carvedilol
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has equal P and oq antagonism while S-carvedilol has only non-selective P
antagonism (Ruffolo and others 1990). In healthy individuals R-carvedilol
has twice the bioavailability of S-carvedilol, whereas patients with liver
disease have equal and increased availability of both stereoisomers
(Neugebauer and others 1990; Neugebauer and others 1992). This means
that P antagonism is greater in patients with liver disease, which could result
in undesirable systemic effects. These effects appear to be dose related and
our results indicate that despite the greater bioavailability, patients with
advanced liver disease experienced minimal systemic hypotension. In
particular patients with ascites, despite exhibiting similar reductions in
HVPG compared with patients without ascites, did not experience
significant systemic hypotension. Clearly this reinforces the need to adhere
to lower dose regimens in such patients, especially as we have demonstrated
carvedilol can still have a marked portal hypotensive effect at these doses.
In heart failure carvedilol should be started from such a low dose as
3.125mg bd for two weeks and titrated according to patient tolerance
(Frishman 1998). Our results indicate that the first dose of carvedilol had a
greater effect on systemic haemodynamics than subsequent doses. It would
therefore seem logical to introduce carvedilol in a stepwise fashion in
patients with liver disease with the dose titrated according to patient
tolerability, aiming for a target daily dose of 12.5mg.
7.1.3 Effects ofcarvedilol on renalfunction.
Previous studies have shown that carvedilol does not affect the renal blood
flow (Forrest and others 1996a), and our findings confirm that the renal
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function remains unaffected following chronic dosing with no evidence of
increased ascites formation. Therefore, it seems that additional non-selective
B-blockade helps to maintain renal blood flow and function. This may be
explained by previous observations of non-cardioselective beta-blockers
suppressing the increase in plasma renin activity and plasma aldosterone
that ocurrs following alpha blockade (Albillos and others 1995). Although
not included in our present study, we have previously shown that carvedilol
at a dose of 25mg has no effect on creatinine clearance, urine volume or
natiuresis (Stanley and others 1999). This is consistent with the observation
that none of the patients with ascites suffered from increased fluid retention.
7.1.4 Carvedilol in clinical practice.
These findings and the earlier observation that carvedilol appears to have
superior portal hypotensive effects than propranolol (Banares and others
1999), suggests that carvedilol should be assessed in large randomised
controlled trials for the primary prevention of variceal haemorrhage. If the
finding that more patients respond to carvedilol than propranolol holds true,
then it is plausible that carvedilol could be used as secondary prophylaxis
against variceal rebleeding or even during acute variceal haemorrhage as is
the case with terlipressin.
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7.2 Haemodynamic effects of chronic administration of
losartan.
The present study demonstrates that in patients with preascitic cirrhosis, oral
dosing of 25 mg losartan did not result in a significant reduction in the HVPG
despite a significant fall in the WHVP. Losartan significantly reduced the
MAP with one patient experiencing mild symptoms after the first dose, a
phenomenon that has been reported previously with ACE inhibitors
(Hodsman and others 1983).
7.2.1 Effect on systemic andportal haemodynamics: Comparison with other
studies.
The literature appears to be divided on the efficacy of Losartan in portal
hypertension. Schneider and colleagues reported a significant reduction in the
portal pressure approaching 45%, the largest reported to date for any
pharmacological agent. This is particularly impressive considering the
minimal effect on blood pressure, with only 1 patient experiencing
symptomatic hypotension. A recent paper, however, does not support the
observation by Schneider (Gonzalez-Abraldes and others 2001). This
randomised study revealed that propranolol produced a significantly greater
reduction in the HVPG than losartan following a variceal haemorrhage (10%
vs 2%). A concerning observation was a significant reduction in the
glomerular filtration rate in Childs B patients taking losartan. Adverse effects
related to therapy were similar in both groups. However, a recent randomised
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study demonstrated better efficacy with 25mg losartan compared to
propranolol even in non-ascitic patients (De and others 2003). The 80%
response rate in the losartan arm is also noteworthy.
Our results contrast with those of Schneider and colleagues (Schneider and
others 1999), but are in keeping with that ofGonzalez-Abraldes et al
(Gonzalez-Abraldes and others 2001). This is despite using the same dose of
losartan that resulted in activation of the renin-angiotensin system, as
evidenced by a significant increase in PRA. Our study design differs in a
number of ways from that of Schneider et al. First, we studied preascitic
cirrhotic patients. This was to minimise the potential risk of systemic
hypotension with ANG II blockade in patients with more advanced cirrhosis
(Arroyo and others 1981). Second, significant proportions of patients in
Schneider's study were on diuretics, both in the treatment and control groups.
Clearly, this will have an effect on circulating volume, and the degree of
activation of the renin-angiotensin system. Third, the timing of the
haemodynamic measurements is different. Schneider et al. performed the
measurements at 4 hours post dosing compared with 12 hours for our study. It
is known, however, that the pharmacological actions of losartan last up to 24
hours (Christen and others 1991). Losartan is a pro drug that is converted to
the active metabolite E-3174, whose maximum plasma levels are obtained
after 3—4 hours. This may explain why we saw no effect on the HVPG in the
3 patients in whom we repeated measurements 60 min after acute dosing. The
half-life of E-3174 is 6-9 hours and the levels in plasma in cirrhotics are 1.7
times those of healthy individuals (Mclntyre and others 1997). This may
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partly explain the difference in the results, but for a drug to be considered for
therapy it must have a sustained chronic effect on portal hypertension. The
third point also applies to the study by De and colleagues, in addition to the
fact that there were no assays of renin, angiotensin II or aldosterone. It is
therefore not clear the degree of activation of the renin angiotensin system nor
the effect of losartan. In the study by Gonzalez-Abraldes the timing of the
measurements is also not clear (Gonzalez-Abraldes and others 2001). Finally,
our sample size is smaller, and a larger sample size may have resulted in a
significant difference. Our study shows that the drug is biologically active in
cirrhotic patients as evidenced by a significant decrease in the MAP, and
increase in the renin activity. Although we cannot rule out that the inclusion
ofmore patients may result in a statistically significant effect on HVPG, we
feel it is unlikely to show greater clinical effect. One could argue that the
dosing may be inadequate, but our dosage was the same as used in the
Schneider study and was enough to cause sufficient blockage of ANG II
receptors as demonstrated by the significant increase in ANG II levels
following chronic dosing. Higher doses may not prove to be more effective,
and are likely to significantly increase the risk of adverse systemic side effects
as demonstrated by Gonzalez-Abraldes and colleagues (Gonzalez-Abraldes
and others 2001).
7.2.2 Effect ofon renalfunction.
Girgrah et al. have recently studied the renal effects of losartan in preascitic
cirrhotics (Girgrah and others 2000). This study demonstrated that the renin-
angiotensin system is activated even in early cirrhosis, a finding that is in
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keeping with that of our recent study (Helmy and others 2000). It was
suggested by the authors that losartan, at a dose of 7.5 mg per day, improved
natriuresis by blocking the sodium-retaining actions ofANG II proximal to
the distal tubule. Our findings are not in keeping with this observation, but the
sample size of the patients in whom the 24-hour sodium excretion was
measured was small. Our study also examined the chronic rather than acute
effect of losartan, and the dietary intake of sodium was not so strictly
regulated. Creatinine clearance was unaffected, suggesting that at this dose in
preascitic cirrhotic patients losartan appears to have no adverse renal effects.
In other patients with more severe liver disease, and especially those on
potassium-sparing diuretics, problems with renal function and electrolyte
imbalance may occur as demonstrated by Gonzalez-Abraldes and colleagues
(Gonzalez-Abraldes and others 2001).
7.2.3 Clinical implications oflosartan therapy.
Or results suggest that although low-dose losartan appears to be well tolerated
and has no adverse renal effects, there is no significant reduction in HVPG
following chronic dosing with losartan in well compensated cirrhotic patients.
Losartan therefore is unlikely to have a place in the management of patients
with cirrhosis and portal hypertension who are at risk of variceal
haemorrhage.
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7.3 The efficacy of TIPSS in the management of gastric and
oesophageal varices: Clinical and haemodynamic correlations.
Our findings show that TIPSS is equally effective in the prevention of
rebleeding from gastric and oesophageal variceal haemorrhage. Incidence of
shunt insufficiency and encephalopathy were similar in both groups. These
results are similar to that of an earlier study in our unit (Stanley and others
1997a). We have adopted a policy of referring patients with bleeding gastric
varices and a patent portal vein directly for TIPSS insertion. A further finding
is the significant numbers of patients that bleed at PPG of <12 mmHg, and
gastric varices accounting for a sizeable proportion of this group.
7.3.1 Portal pressure ofgastric varices.
It has been reported that patients with large gastric varices have a lower portal
pressure than those with oesophageal varices (Chao and others 1993), which
may be as a result of the development of gastro-renal porto-systemic shunts
(GRS) (Watanabe and others 1988). Portography at the time of index TIPSS
insertion was primarily performed in order to identify varices, and not
specifically to look for the presence ofGRS, although the splenic vein was
visualised if not always in its entirety. Given these limitations, we have
looked at the portograms of over 400 patients who have had a TIPSS for any
cause, and identified shunts in 18.3%. A wider portographic review and a
prospective MR angiography study will assist in identifying all those patients
with GRS. Wantabe and colleagues also demonstrated increased collateral
flow at the expense of reduced portal venous flow in patients with gastric
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varices. The authors proposed that reduced portocollateral resistance may
account for the latter finding. It is however unclear as to why patients bleed at
portal pressures of< 12 mmHg. Other factors such as the presence of red
spots, variceal size and that of gastritis may be important. Therefore
particularly in patients with gastric varices it would not be safe to regard
reducing the portal pressure gradient of< 12 mmHg as a therapeutic goal.
Indeed, for patients who bleed at PPG < 12 mmHg our results demonstrate
that PPG post TIPSS is not statistically different in patients who rebleed
compared with those that do not. However for patients who bleed at PPG > 12
mmHg, the post TIPSS PPG is greater for patients who rebleed with most of
these patients having a PPG post TIPSS of greater than 7 mmHg. These
results suggest that in group 2 i.e. predominantly oesophageal variceal
bleeders a therapeutic goal of a post TIPSS PPG < 7 mmHg would be
reasonable.
7.3.2 TIPSS as savage therapy in bleeding gastric varices.
TIPSS has recently been studied in the management of refractory variceal
bleeding either from gastric alone (Barange and others 1999) or gastric
compared with oesophageal varices (Chau and others 1998; Rees and others
2000). Our rebleeding rates are comparable to these studies. Chau and
colleagues also found that portal pressure in patients who had early rebleeding
before 7 days was lower in patients with GVB (Chau and others 1998). Rees
et al did not demonstrate significant differences in the PPG prior to TIPSS
which was >20 mmHg in both groups (Rees and others 2000). This study was
limited by small number of patients and a short follow up period.
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7.3.3 Survival following TIPSS: Gastric versus oesophageal varices.
An interesting finding in the present study is that of significantly better
survival in the GVB group, compared with the OVB group, despite the 2
groups being matched for age of patient, aetiology of liver disease, Child
Pugh score, and pre TIPSS encephalopathy. We have previously shown the
latter 2 parameters to strongly predict mortality post TIPSS (Jalan and others
1995a). It has also been observed that the mortality following a variceal
haemorrhage is highest in the first few days after the index bleed (Smith and
Graham 1982). Both the OVB and GVB groups were matched for the time of
intervention with TIPSS after the variceal bleed, thus there was no undue
selection of patients in either group who were likely to have a better survival.
The difference in mortality between the two groups appears to be confined to
patients who bleed at a portal pressure gradient of>12 mmHg, and is
particularly striking for long-term mortality. Older age of patient, high
bilirubin and low albumin in keeping with more advanced liver disease were
independent predictors ofmortality. The causes of death in both groups were
predominantly liver failure and sepsis. The earlier study in our unit (Stanley
and others 1997a) had demonstrated a trend towards improved survival
amongst the GVB group. The present study has a greater number of patients
and a longer follow up period, which may account for the now significant
findings. The longer follow up period in the GVB is likely to be as a result the
combination of reduced mortality and larger number of patients recruited
before or in 1995.
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7.3.4 Role ofportal pressure in determining clinical outcome.
It is important to highlight the observation of a significantly higher PPG prior
to TIPSS insertion in patients with OVB. We have previously shown that a
HVPG of >16 mmHg predicted mortality in patients with alcoholic cirrhosis
(Stanley and others 1998b). This finding was reinforced in a later study by
Patch and colleagues (Patch and others 1999). HVPG measurements made
within the first or second week had the greatest predictive value. Nearly all
our patients had their portal pressures measured at the time ofTIPSS within
the first 2 weeks of the index variceal bleed. A recent study by Moitinho and
colleagues (Moitinho and others 1999b) assessed the prognostic value of early
portal pressure measurements following an acute variceal bleed. The striking
finding in this study was that patients with a HVPG of>20 mmHg had a 1
year mortality of 64% compared with that of 20% for patients with HVPG
<20 mmHg (p<0.004). In our group all the patients who bled from
oesophageal varices had a mean PPG > 21 mmHg. It is therefore plausible
that the difference in PPG between the OVB and GVB groups may account
for the difference in the observed mortality, although the reason why PPG
affects mortality is not understood. We have not shown a difference in
rebleeding rates as the rebleeding rate is so low in both groups following
TIPSS insertion that much larger numbers may be needed to show any




Our study demonstrates that TIPSS is very effective in the prevention of
variceal rebleeding irrespective of whether patients have had an OVB or a
GVB. Mortality is significantly better in the GVB group who bleed at PPG >
12 mmHg, and warrants further study. The findings also highlight the
significant role ofGVB in patients who bleed at PPG < 12mmHg, and
challenges the use of this cut off value as a treatment goal particularly in
patients with gastric varices. Our results also suggest that clinicians should
aim for a PPG post TIPSS of < 7 mmHg for patients who have variceal
bleeding at PPG > 12 mmHg. TIPSS therefore has a major role in the
management ofGVB, which can be very difficult to control by other
measures. Further long-term prospective studies would assist in clarifying the
effect of TIPSS on mortality in the GVB group compared with OVB.
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7.4 Variceal band ligation versus long-term surveillance
following TIPSS insertion for the prevention of oesophageal
variceal rebleeding.
TIPSS has now become accepted as a method of treating variceal bleeding
refractory to endoscopic methods, and for the prevention of variceal
rebleeding. We have shown for the first time that VBL can replace long-term
TIPSS surveillance for patients who have required a TIPSS for bleeding
oesophageal varices.
7.4.1 Comparison ofvariceal rebleeding.
The rebleeding rates in the two groups were not significantly different even
after adjustment for gender and portal pressure, and are consistent with that
from previous trials (Papatheodoridis and others 1999). Although the absolute
cumulative risk of variceal rebleeding was higher in Group 2 (15% versus
8%), this did not reach statistical significance. The lack of statistical
difference needs to be interpreted with caution in view of the wide confidence
intervals, and the fact that the power calculations allow for large differences
in the 2 groups. However, it must be emphasised that the absolute risk of
variceal rebleeding in Group 2 appears less than that seen with VBL alone as
demonstrated in a recent study performed in our unit (Jalan and others 1997a).
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7.4.2 Comparison ofmortality.
Likewise, mortality was not different in the two groups even after adjusting
for the difference in gender and portal pressure at baseline, and is in keeping
with most of the previous studies comparing TIPSS and endoscopic
modalities ([Anon] 1995; Cabrera and others 1996; Cello and others 1997;
Rossle and others 1997; Jalan and others 1997a; Sauer and others 1997a;
Sauerand others 1997b; Sanyal and others 1997c; Merli and others 1998;
Sauer and others 1998; Papatheodoridis and others 1999; Luca and others
1999; Garcia-Villarreal and others 1999; Pomier-Layrargues and others
2001). The 2 groups were well matched for degree of liver disease, age,
alcoholic aetiology, requirement for mechanical ventilation, time to
randomisation from the index bleed, and encephalopathy pre-TIPSS; all
variables which our unit and others have shown to predict mortality post-
TIPSS (Smith and Graham 1982; Jalan and others 1995a; Tyburski and others
1997; Williams and others 1998). (Smith and Graham 1982; Tyburski and
others 1997; Williams and others 1998)
198
7.4.3 Comparison ofhepatic encephalopathy.
Encephalopathy, both overall and de novo, was significantly less in the Group
2 and is similar to that seen with VBL alone when used for secondary
prophylaxis of variceal haemorrhage (Papatheodoridis and others 1999). This
difference is maintained when the first 6 months of follow up is excluded,
following which time there are fewer interventions in Group 2 to maintain
shunt patency. However, in the first 6 months following TiPSS insertion, the
period of maximum and equivalent shunt interventions in both groups, there
was no difference in the incidence of hepatic encephalopathy. Since the shunt
patency in Group 1 was maintained by regular portographic surveillance and
intervention throughout the study period, the fact this group had greater
episodes of encephalopathy would be expected. The rate of encephalopathy
(39%) seen in Group 1 is similar to that published in recent literature
(Papatheodoridis and others 1999), with de-novo encephalopathy being
significantly less frequent (Blackwelder 1982). The majority of the patients
responded to conservative measures with just 4 (5%) patients in total
requiring blockage of the TIPSS. The statistically significant difference in
encephalopathy was not maintained after controlling for PPG pre-TIPSS and
gender. However, there did not appear to be any detrimental effects ofTIPSS
combined with VBL, and this treatment modality certainly has the potential to
reduce the rate of hepatic encephalopathy.
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7.4.4 Change in Child-Pugh score duringfollow up.
The severity of liver disease, quantified by the Child-Pugh score, did not
change significantly in both groups during follow up. This may be explained
by the fact that most patients had alcoholic liver disease, with most patients
continuing to consume alcohol. A recent study demonstrated an improvement
in the Child-Pugh score following TIPSS (Escorsell and others 2002), but
there were fewer patients with alcoholic cirrhosis and it is not clear how many
people abstained.
7.4.5 Shunt function and surveillance.
We have shown that the rates of shunt insufficiency in the first year are
similar in the two groups, with most episodes occurring in the first six months
following TIPSS creation. This important observation suggests that
portographic follow up is ofmost value for the first few months following
TIPSS insertion and may not be required for 1 year. However, at the time of
study design, we were more conservative with respect to TIPSS surveillance.
In all cases of variceal rebleeding, where portography was performed, there
was evidence of shunt insufficiency.
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7.4.6 Cost implications.
There was a trend to higher costs in the TIPSS + VBL group, the lack of
statistical significance being due to high standard deviation in costs, and the
small sample size. With longer follow up, the costs differences may lessen
since the patients in the TIPSS and VBL group will only be followed up by
endoscopy and VBL if required. One could even put forward a case for no
surveillance at all in Group 2, provided every attempt was made to eradicate
varices early. This could significantly reduce the costs, and increase the use of
TIPSS since follow up after TIPSS insertion can occur in any hospital with
endoscopy and banding facilities.
7.4.7 Clinical implications.
Our findings suggest that VBL can replace long-term TIPSS surveillance, and
still maintain low rates of variceal rebleeding with the potential to reduce the
rates of post-TIPSS encephalopathy. Therefore, in patients who have bled
from oesophageal varices, combining TIPSS and short-term surveillance with
VBL is a suitable alternative to TIPSS with long-term surveillance in the
prevention of variceal rebleeding. The recent introduction of covered stents
promises excellent patency without the need for long-term surveillance, but
controlled trials are lacking.
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Epilogue
What of the future?
The studies comprising this thesis have important implications for further
research. These are briefly summarised:
The role of haemodynamic measurements in cirrhosis
The measurement of HVPG remains an important research tool. Clearly as
demonstrated in chapter 5, the haemodynamic goals of therapy for portal
hypertension may have to be revised particularly for patients who bleed
from gastric varices. It is worth noting that the measurement of HVPG is not
so widely available and is invasive. Future research should focus on non¬
invasive means ofmeasuring portal pressure.
Pharmacological agents for portal hypertension
Clearly of the 2 drugs studies, carvedilol appears to be more effective. The
excellent tolerability is particularly impressive, since up to a third of
patients on propranolol withdraw due to side effects. We are currently
running a randomised controlled trial comparing carvedilol with VBL in the
primary prevention of variceal haemorrhage.
Transjugular intrahepatic portosystemic stent-shunt
Despite TIPSS being utilised for the management of the complications of
portal hypertension for almost 15 years, there are relatively few controlled
studies. In this thesis, we have shown that TIPSS can effectively be
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combined with VBL to reduce invasive portography and potentially reduce
hepatic encephalopathy. The hot topic at the moment is the introduction of
PTFE covered stents, with the potential for excellent shunt patency. There
are few studies at the moment using these stents, but early data from our
unit is very encouraging. We hope to publish these soon. The studies so far
have not demonstrated any survival benefit ofTIPSS over endoscopic
therapies in the management of variceal bleeding. The potential superiority
of PTFE covered stents over standard stents leads one to ask whether these
stents would not only lead to reduced variceal rebleeding, but also improved
survival when compared with endoscopic therapies. Therefore, it would be
very interesting to compare PTFE covered stents with VBL for the
prevention of variceal bleeding in a controlled trial.
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SUMMARY
The development of varices is a major complication of
cirrhosis, and variceal haemorrhage has a high mortality.
There have been major advances in the primary and
secondary prevention of variceal haemorrhage over the
last 20 years involving endoscopic, radiological and
pharmacological approaches. This review concentrates
principally on drug therapy, particularly on the
numerous haemodynamic studies. Many of these drugs
have not been studied in clinical trials, but provide data
about the underlying pathogenesis of portal
hypertension.
Also covered in this review are the randomized
controlled trials and meta-analyses that involve a large
number of patients. These trials involve relatively few
drugs such as non-selective beta-blockers and nitrates.
Correlations between haemodynamic and clinical
parameters are discussed.
Despite the recent increase in the use of alternative
endoscopic therapies, an effective and well tolerated
drug remains a clinically important research goal.
INTRODUCTION
Cirrhosis is the main cause of portal hypertension in
North America and Europe. Common causes include
alcohol abuse, hepatitis C, primary biliary cirrhosis and
autoimmune disease. The major life threatening com¬
plication of portal hypertension is the development of
gastro-oesophageal varices that have the potential to
bleed torrentially. At the time of diagnosis of cirrhosis
varices are present in 30% of compensated and 60% of
decompensated patients.1 In a third of these patients the
varices will bleed, with an inhospital mortality of
approximately 50%. Seventy to one-hundred per cent
of survivors will re-bleed over 1-2 years, with a 20%
mortality for each survivor that re-bleeds.2 These dismal
statistics have led to the search for primary prophylaxis
against variceal bleeding, and secondary prophylaxis
against re-bleeding. Although a variety of strategies
Correspondence to: Dr D. Tripathi, liver Unit. Department of Medicine,
Royal Infirmary, Lauriston Place, Edinburgh, EH 3 9YW, UK.
E-mail: d.tripatlii@ed.ac.uk
including surgical and endoscopic techniques have been
proposed, drug therapy has been the strategy most
explored. Bearing in mind that the majority of patients
will not bleed, pharmacological agents, especially for
primary prophylaxis, seem to be the most attractive
option. This review aims to present the evidence for the
current use of drug therapy in patients with portal
hypertension and varices (Table 1). The treatment of an
acute variceal haemorrhage will not be covered.
Prophylaxis against the formation of varices has been
little studied and does not appear to be promising.3
PATHOPHYSIOLOGY OF PORTAL HYPERTENSION
Propranolol was the first drug used to reduce portal
pressure in 1981 by Didier Lebrec. Since then an
improved understanding of the mechanisms behind
portal hypertension has led to the use of a variety of
pharmacological agents that act by altering portal
haemodynamics favourably.
Normal portal pressure is between 1 and 4 mmHg. The
cirrhotic liver leads to an increase in resistance to
© 2001 Blackwell Science Ltd 291
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Prazosin and /i-blockers or isosorbide-5-mononitrate
sinusoidal blood flow, which in turn leads to the
development of collaterals that should decompress the
portal system und minimize portul hypertension. flow
ever increased inflow in the splancnic circulation leads
to increased portal inflow, which maintains portal
pressure.
Many studies have looked at the hepatic vein pressure
gradient (HVPG) as a prognostic marker and as a guide
to the efficacy of pharmacological agents. The HVPG is
the difference between the wedged hepatic venous
pressure (WHVP) and free hepatic venous pressure
(FHVP). The HVPG correlates with the true portal
pressure in patients with alcoholic cirrhosis,4 hepatitis
B' and hepatitis C,6 but underestimates the true portal
pressure in conditions such as primary biliary cirrhosis
and chronic active hepatitis.4
The aim of pharmacological therapy is to prevent or
reduce the risk of variceal bleeding and because this is
unusual if the HVPG is less than 12 mmHg this has been
adopted as a haemodynamic target.' A reduction in the
portal pressure of greater than 20% has also been
proposed as a therapeutic goal.8 In clinical practice it is
also important to combine drug efficacy with tolerability.
HAEMODYNAMIC STUDIES
P~blockers
A number of /^-blockers have been studied in patients
with portal hypertension and varices, although only
propranolol and nadolol have been studied in large
randomized trials.
Propranolol. In 1982 Lebrec and colleagues investigated
the portal hypotensive effect of propranolol in a placebo
controlled haemodynamic study in alcoholic cirrhotic
patients.9 Other studies have corroborated these find¬
ings reporting reductions in the HVPG of between 10
and 31% (Table 2). The fall in portal pressure is
produced by a combination of reduced cardiac output
(Pi antagonism) and reduced splancnic blood flow
(p2 antagonism). Changes in portal blood flow are
probably mainly a result of pi blockade.1" It was also
observed by others that propranolol consistently
reduced azygous blood flow, which was elevated in
patients with portal hypertension." It has been postu¬
lated that a reduction in collateral llow, indirectly
measured by azygous blood flow, might bo an important
mechanism of action in reducing variceal bleeding risk.
Others have found that there appeared to be a
reciprocal relationship between severity of liver disease
and response to propranolol.21 It seemed that although
all patients with liver disease responded to propranolol,
the response of the collateral circulation to propranolol
administration in Child's C patients was significantly
diminished. Child's C patients had higher baseline
azygous blood flow, and despite a fall in the azygous
blood flow, a higher fraction of the cardiac output was
distributed to the azygous venous bed following prop¬
ranolol administration. This was described as a pooling
of blood in the collateral circulation, and the authors
suggest stratification of patients according to the degree
of liver disease. This is not universally supported.11 Most
of the haemodynamic studies have included prodomin
antly Child's A and B patients, possibly because Child's
C patients were less tolerant of the drug or were too
unwell to be included in such studies.
The first paper to examine the effect of chronic
administration of propranolol on portal pressure was
published by Vorobioff and colleagues.1 ' Here the acute
and chronic effects on alcoholic cirrhotics with oeso¬
phageal varices were studied over an average of 106
days. A portal hypotensive effect of 2 5% was main¬
tained chronically. However 30% of patients failed to
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Table 2. The effect of propranolol on portal and systemic haemodynamics
Hepatic
Mean Cardiac venous Estimated
Acute/ arterial output/ pressure hepatic Azygous
Child's chronic pressure cardiac gradient blood blood
Study Dose Class study (MAP)* index* (HVPG)* (low* flow
Lebrec el al.9 40 mg All A Acute Not stated 31 23 12 Not stated
Bosch et al.11 83 mg Not stated Acute 2 22.6 11.5 13.4 34.2
Mastai et al.'2 10 mg i.v. A/B/C: 9/3/0 Acute NS 17 10 NS 31
VorobiolT et al.1J 40 mg Not stated Acute NS 21 17.6 Not stated Not stated
158+ mg Not stated Chronic NS 27 22.5 Not stated Not stated
Westaby et al.'4 > or =2 mg i.v. A/B: 2/7 Acute Not stated 13 31 21 Not stated
Braillon et 10 mg i.v. Mean score: 5.3 Acute NS 26 15 NS 36
Garcia-I'agan et al.16 i.v. 0.1 mg/kg A/B/C: 9/10/1 Acute NS 24 13 12.8 38
bolus
2 mg/h 30 min
infusion
Groszmann et al. 132 mg+ Mean score: 8 Chronic NS 22 29 Not stated NS
Garcia-Pagan et al.1' +(actual doses Mean score: 6.9 Chronic NS 10 10 25 29
not stated)
Bendtsen et al.ls 160 mg+ A/B/C: 7/5/2 Chronic NS 20 24 39 47
Aramaki et al.19 90 mg A/B/C: 7/4/0 Chronic NS 14 12 NS Not stated
VorobiofT et al.2" 140 mgt Mean score: 7 Chronic NS 38 12.5 Not stated Not stated
*Measured as the percentage decrease from the baseline.
tDose required to reduce the mean pulse to 25% of baseline.
NS - not significant.
respond after chronic dosing. This paper highlighted the
considerable non-response rate of portal pressure to
propranolol confixmed by later studies. This may be
explained by a portal hypertensive model demonstra¬
ting that a rise in the portocollatcral resistance
accompanies the reduction in portal blood flow thus
reducing the overall portal hypotensive response to
propranolol.22 It has been shown than in healthy
subjects S-propranolol, which is the haemodynamically
active component, is present in higher concentrations
than R-propranolol on account of reduced first pass
metabolism.25 In patients with liver disease the con
centration of the S-propranolol is greatly elevated.
Stereoisomer concentrations, however, do not appear to
predict the haemodynamic response to propranolol, and
there is no difference in the relative concentrations of
both stereoisomers in propranolol responders and
nonrespondorc.
Another chronic study with a longer follow-up period of
1 year failed to demonstrate a sustained fall in portal
pressure gradient when propranolol was compared with
placebo, despite significant reductions in hepatic blood
flow, azygous blood flow and cardiac index.Ix The inves¬
tigators suggested that the splancnic hyperdynamic
circulation observed in cirrhotics might be partly revers¬
ible in some patients, without drug therapy. This may be
explained by the fact that patients in the second study
were clinically better and had reduced sympathetic tone,
but probably more importantly all had stopped drinking
alcohol. Patients who were not studied after 1 year due to
bleeding episodes or death could introduce selection bias
despite the initial haemodynamic parameters being
comparable to that of the group who were studied. The
findings add weight to the hypothesis that reduction in
collateral blood How and therefore variceal blood flow is
the mechanism behind the beneficial effect ofpropranolol
in preventing bleeding. Feu and colleagues investigated
the concept of reduced variccal flow using a non invasive
pressure sensitive endoscopic technique.2' Their findings
suggested that even in patients in whom the HVPG did
not fall significantly there appeared to be a fall in variceal
pressure, of similar magnitude to those patients that
responded to propranolol.
Croszmann and associates looked at a larger number
of patients in a randomized double-blind placebo-
controlled trial to investigate whether lowering the
HVPG with propranolol protects against a variceal bleed
over a 2-year follow-up period.' They found that a
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HVPG of less than 12 rnmHg protected patients from
variccal haemorrhage and improved survival. It is of
note that in this study almost all patients bled within
the first year and that treatment with propranolol did
not result in a greater portal pressure reduction than
placebo after 3 months of treatment, suggesting prop
ranolol had a protective effect earlier on. The authors
did point out that this might have been due to a greater
drop-out rate of patients with the highest pressures in
the placebo group from terminating events such as
variceal bleed and death. Fifty-one patients were studied
in both groups and after 24 months the final number
was nine and 12 in the placebo and propranolol groups
respectively. It is questionable whether these small
numbers allow meaningful analysis. Values for HVPG
were higher in the pationts who dropped out of the
placebo group at 3-12 months. However recent papers
by McCormick et al.2h and Stanley et al.2/ have sup¬
ported this observation. The latter study concluded that
the HVPC was the only haomodynamic parameter that
predicted death or bleeding. Interestingly it has been
demonstrated that bleeding may occur at pressures
below the threshold level of 12 mmHg,2s although the
numbers quoted in Ibis study are quite small.
Nadolol. Nadolol is also a non-selective /1-blocker, which
was first studied by Gatta and colleagues.29-52 These
studies suggested a similar mechanism of action and
efficacy to propranolol. Nadolol, unlike propranolol, has
low hepatic metabolism and lipid solubility resulting in
a longer half life. The main chronic effects at a dose that
reduced the heart rate by 25% were of significant
reductions in HVPG (19-22%), cardiac output and
effective hepatic blood flow. Mean arterial pressure, liver
function and renal function were unaffected. Recent
studies also suggest that nadolol therapy results in a
significant reduction in portal blood flow.5 5 This paper
also suggested that nadolol results in a slight fall in
renal blood flow
Timolol. This is a non-selective /?-blocker that has only
been studied in one haemodynamic study.54 The mean
reduction in the portal pressure gradient was 20%, which
is comparable to the that of propranolol and nadolol. The
drug has not been studied in any clinical trials.
Atenolol. Hillon and colleagues, in a comparative hae¬
modynamic study with propranolol, first investigated
atenolol, a selective /h receptor antagonist in portal
hypertensive patients with cirrhosis.5,5 They found a
16% reduction in HVPG, which significantly correlated
with cardiac output. Propranolol produced a greater
reduction of portal pressure, although the reduction in
cardiac output was similar to that of atenolol. It was
postulated that the extra cardiac effects of propranolol
were responsible for the difference.
Another comparative study looked at the effect of
atenolol, propranolol and prazosin (a blocker) on portal
haemodynamics in a chronic study with an 8-week
follow-up period.56 Atenolol resulted in a non-significant
1 5% reduction in HVPG compared with a significant
25% reduction in HVPG with propranolol. The findings
again suggested again suggested a significant correla¬
tion between cardiac output and portal pressure with
atenolol but not with propranolol. Both /i blockers were
well tolerated.
Atenolol therefore appears less effective at reducing
portal pressure than propranolol, which suggests that
the pz receptor blockade has a major role to play in tho
mechanism of action propranolol.
Metoprolol. Metoprolol is another /G selective jS-blocker.
Initial haemodynamic studies suggested that it was of
equal efficacy to propranolol in reducing portal pres¬
sure.5, The study also demonstrated significant falls in
cardiac output in both groups, but a reduced hepatic
blood flow only in the propranolol group. The latter
finding led the authors to conclude that mctoprolol may
even be preferable to propranolol in patients with
advance liver disease. It has, however, been little
studied.
[>2 receptor antagonists. ICI 11855 is a selective /G
antagonist, which was studied by Bihari et al. in 1 7
patients.58 There was a significant reduction in the
portal pressure 60 min following administration of the
drug, which was accompanied by significant reductions
in the heart rate and cardiac index, both of which were
not related to the fall in the portal pressure.
Another selective p2 antagonist mepindolol was com¬
pared with intravenous propranolol in patients with
cirrhosis and portal hypertension by Brallion and
colleagues.59 The effect on the HVPG and systemic
circulation was similar to that of propranolol, but at the
expense of significantly reduced hepatic blood flow,
which was not the case with propranolol. Clearly both
these drugs have a significant effect on the systemic
circulation, and mepindolol offers no benefit over
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propranolol in reducing portal pressure. This may
explain why they have not been studied further.
Carvedilol. Carvedilol is a novel vasodilating non¬
selective ^-blocker with weak ai receptor antagonism
and calcium channel antagonism. It has a rapid onset
of action with 2-4 times greater ^-blocking action
than propranolol.
Forrest and colleagues performed the first acute
haemodynamic study on cirrhotic patients using
25 mg oral carvedilol.40 A 20% fall in HVPG from 17
to 14 mmHg was achieved mainly due to a fall in wedge
hepatic venous pressure. A significant fall in MAP of
10% was noted particularly in ascitic patients. Hepatic
blood flow, azygous blood flow and renal blood flow
were unaffected. This effect of carvedilol on HVPG was
similar to that of propranolol as demonstrated in
previous studies (Table 2).
The chronic effect of carvedilol was investigated by
Stanley et «/.41 A 21% drop in HVPG was maintained
chronically. The fall in HVPG was mainly as a result of a
significant drop in the wedge hepatic venous pressure.
There was no change in renal function or hepatic blood
flow. Poor tolerability was noted in three out of the 17
patients who experienced dizziness, breathlessness or
hypotension,
A recent study compared carvedilol with intravenous
propranolol and placebo.42 Carvedilol at a dose 25 mg
was used and resulted in a 21% drop in the HVPG. A
lower dose of 12.5 mg carvedilol did not lead to a
significant drop in the portal pressure in this series.
Propranolol in this study was not as effective in
lowering HVPG with only a 1 3% reduction. Both drugs
significantly reduced cardiac output, hepatic blood flow
and azygous blood flow. Once again carvedilol caused a
significant reduction in the mean arterial pressure of
17% compared with 3.4% with propranolol.
A lower dose of carvedilol has been studied in our
center and the findings were published in abstract
form.4' The acute and chronic effects of 12.5 mg of
carvedilol were studied in six patients. A significant
40% reduction in (he HVPG was noted. The drug was
very well tolerated.
All these studies seemed to suggest that carvedilol
has a portal hypotensive effect greater than propran¬
olol, and that lower doses may avoid significant
systemic effects. To date there are no clinical studies
looking at the effect of carvedilol in preventing
variceal bleeding.
Nitrates
Isosorbide-5-mononitrate is a long acting organic
nitrate. The mononitrate, either as native drug or
formed from the denitration of isosorbide dinitrate in the
lever,44 is the active component, and undergoes mini¬
mal first class pass metabolism unlike isosorbide
dinitrate,4' thus assisting in appropriate dosing for
patients with liver disease and portal shunting. Isosor¬
bide mononitrate reaches peak concentrations within
an hour of oral dosing, and has a half-life of approxi¬
mately 5 h. Only 1-2% of an orally administered dose is
excreted unchanged in the urine, with the remainder
being eliminated as inactive metabolites. Its pharmaco¬
kinetic properties are unchanged in the elderly and in
patients with renal failure, or liver cirrhosis.46 It is
therefore preferred to isosorbide dinitrate in such
patients. To date it is the only nitrate to be used in
large randomized controlled trials for preventing vari¬
ceal bleeding.
The molecular mechanism of action of nitrates is
uncertain. It is thought the vasodilatory actions may be
a result of enhanced production of intrahepatic nitric
oxide or cyclic-GMP.4'
There have been a number of haemodynamic studies
using isosorbide-5-mononitrate in patients with portal
hypertension (Table 3). All the studies with the excep¬
tion of one, 49 which included predominantly Childs A
patients, demonstrated significant reductions in the
HVPG. This appears to have been achieved by a fall in
the HVWP. Three studies looking at the chronic effects
show that the effect of reduced portal pressure is
sustained.'1 ~5 5 Indeed the portal hypotensive effect
seemed to be amplified after rechallenge following
chronic dosing, confirming lack of tolerance.
Pronounced effects on other parameters may help to
explain the mechanism underlying the fall in HVPG,
which is comparable to that of propranolol. Fjarly
studies48 noted that the hepatic blood flow fell acutely,
and this along with an increase in systemic vascular
resistance index (SVRI) suggested that a baroreceptor-
mediated splancnic vasoconstriction may be responsible
for the fall in portal pressure rather than portal venous
dilation. However recent work" demonstrated a signi¬
ficant fall in the portal pressure gradient without
affecting the portal blood flow in patients with a
transjugular intrahepatic portosystemic stent shunt
(TIPSS). It was clear, therefore, that in the study group
of patients reflex baroreceptor-mediated vasoconstric-
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tion of the splancnic bed could not be the case and that
any vasoconstrictive effect to account for the rise in
SVRI was limited to the periphery. The observed
findings were attributed to reduced intrahepatic vascu¬
lar resistance rather than a reduction in the liver blood
flow (which would be undesirable). Chronic adminis¬
tration resulted in no change or even an increase in the
hepatic blood How1"' 51 and may reflect the buffer
response of hepatic artery blood flow to a decrease in
portal flow.56
Isosorbide-5-mononitrate also reduces the cardiac
preload and hence the cardiac output, at least acutely.
Significant correlation between the reduction in portal
pressure gradient and cardiac output suggests that this
may partly be responsible for the reduced portal blood
flow observed in (his study.48 In all cases the mean
arterial pressure fell acutely. It is interesting to note that
chronic administration does not appear to have a
significant effect on cardiac output or mean arterial
pressure.
Azygous blood flow has already been demonstrated as
a useful indicator of variceal blood flow in patients with
cirrhosis.3/ Azygous blood flow responds in a variable
fashion to isosorbide-5-mononitrate. Jones and col¬
leagues5® demonstrated no significant change in the
azygous blood flow in response to varying doses of
nitrates, both acutely and following chronic dosing.
However, a relationship was noted between baseline
azygous blood flow and the response to nitrates, with
those patients with a high azygous blood flow respond¬
ing by reducing their flow and vice versa. The dose did
not seem to influence the azygous blood How.
Nitrate tolerance is clearly documented in cardiovas¬
cular medicine.58' 39 However, of the studies looking at
the chronic effects of isosorbide-5-mononitrate therapy
only one has reported partial tolerance in live out of 11
patients,51 with others reporting no tolerance.52' 3® The
exact mechanism behind why patients with cirrhosis do
not develop nitrate tolerance is unknown. It has been
suggested that patients with cirrhosis may not be able to
develop compensatory mechanisms that are necessary
to bring about nitrate tolerance.5®
An important observation with nitrate monotherapy
has been the deleterious effect on renal function.61'
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Activation of the renin-angiotensin system was felt to be
a major factor. In particular, patients with ascites
suffered from a reduced glomerular filtration rate,
sodium excretion and renal plasma flow. It is interesting
that combination therapy with other portal hypotensive
agents abolished these undesirable renal effects. The
combination therapies will be covered later.
Drugs acting on alpha adrenergic receptors
Prazosin. Prazosin is an ai receptor blocker, which was
initially studied by Mills and colleagues56 in a compar¬
ative haemodynamic study with propranolol and ateno¬
lol over an 8-week follow-up period. An 18% reduction
of the hepatic venous pressure gradient was obtained
with prazosin compared with 25% with propranolol.
Prazosin did not affect the cardiac index or hepatic blood
How. and had no effects on renal function or sodium
handling. It acts by reducing intra-hepatic resistance. In
a recent study61 impressive results were obtained with
acute and chronic reductions in the HVPG of 25.7% and
19.1% respectively, which are comparable to propran¬
olol. However this was accompained by a significant fall
in the MAP and systemic vascular resistance. An
important finding in this study was the tendency to
increased ascites and oedema as a result of a reduction in
sodium excretion and expansion of the plasma volume.
Tolerance was also felt likely to have occurred following
chronic administration. Hepatic blood flow and liver
function, as quantified by indocyanide green clearance
and galactose elimination, were noted to have improved.
These findings were mirrored in a subsequent study62
and thus the use of prazosin in clinical practice was not
an attractive proposition. There are at present no clinical
trials using prazosin in primary or secondary prophy¬
laxis of variceal haemorrhage.
Clonidine. Clonidine is a centrally acting a2 agonist that
acts by reducing peripheral noradrenaline outflow and
thus the sympathetic tone in patients with cirrhosis.6 5~("
A fall in the hepatic venous wedge pressure was
believed to occur secondary to reduced post sinusoidal
hepatic vascular resistance. Azygous blood flow was
reduced, but hepatic blood flow remained unaffected.
The change in hepatic haemodynamic parameters was
unrelated to changes in the systemic haemodynamics,
where there was a reduction in the cardiac output and
mean arterial pressure. The hepatomesenteric circula¬
tion was more sensitive to the actions of clonidine in
cirrhotic patients compared with healthy controls.
Clonidine resulted in a greater fall in the portal pressure
compared with propranolol66 and a recent study
looking at the effects of clonidine and propranolol in
cirrhotic patients found that only propranolol or a
combination of propranolol and clonidine resulted in a
fall in the portal blood flow.67 Despite these results,
there are no randomized clinical trials using clonidine
for primary or secondary prophylaxis in patients with
varices. The effect on systemic haemodynamics may
limit its use.
Drugs acting on the renin-angiotensin system
Losartan. This is an angiotensin II receptor antagonist
that is used in the treatment of systemic hypertension.
In cirrhotic patients it is known that the levels of
angiotensin II are elevated6* and in vitro studies have
shown that angiotensin II can cause a rise in the portal
pressure.69 The only published human study demon¬
strated impressive reductions in the portal pressure of
over 20% in response to Losartan'0 with minimal effects
on the systemic circulation.
Irbesartan. This is another angotensin II receptor ant¬
agonist that has been studied by Debernardi-Venon and
colleagues with the results published in abstract form.'1
A mean reduction in portal pressure of 20.7% after 2
months in 10 patients is similar to that demonstrated
with Losartan. One patient experienced symptomatic
hypotension. There was no adverse effect on renal
function.
If other studies corroborate these findings, and they
were proved not to have deleterious effects on renal
function, sodium handling and systemic haemodynam¬
ics, angiotensin II receptor antagonists could be ideal
agents for use in large randomized clinical trials. Caution
is necessary however, because of the deleterious effect on
renal function demonstrated in the past with captopril.'2
Drugs acting on the seretonin S2 receptors
It has been shown in an experimental model that portal
hypertensive animals are more sensitive to the vaso¬
constrictor effects of seretonin on mesenteric veins, and
that administration of ketanserin, a 5HT2 receptor
blocker with a adrenergic antagonist activity, resulted
in significant reductions in the portal venous inflow and
portal pressure.'5 The reduction in portal pressure
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caused by kelanserin was due mainly to a decrease in
portal venous inflow secondary to a decreased cardiac
output, which was only seen in portal hypertensive rats.
This would be consistent with venous dilatation and
pooling of blood in the portal venous system secondary
to 5HT2 receptor blockade. These finding led to human
studies investigating the effect of 5HT2 receptor block¬
ade on portal pressure.
Early trials in cirrhotic patients demonstrated a
significant reduction of 23% in the HVPG following
ketanserin administration, which was accompanied by
reductions in the azygous blood flow and mean arterial
pressure with the hepatic blood flow remaining unaf¬
fected.'4 Subsequent studies corroborated these find¬
ings. ' '6 The chronic administration of ketanserin was
associated with a sustained drop in the portal pressure
of 14.6%, a reduction in the cardiac index, and a drop
in the mean arterial pressure.'6 This study also
demonstrated that 50% of patients developed reversible
portosystemic encepahlopathy. Hypotension probably
results from a receptor blockade.
Combination treatments have also been studied.
Ketanserin in combination with propranolol, both
administrated intravenously, has been shown to reduce
the HVPG in patients who did not initially respond to
propranolol." Ritanserin, a more selective serotonin S2
blocker, was combined with propranolol in a study
investigating the haemodynamic effects of the chronic
dosing of these agents.'8 An initial reduction in the
portal pressure was noted, but this effect was not
sustained during follow up.
These agents have not been studied in randomized
controlled trials for the prevention of variceal bleeding
or for the treatment of variceal bleeding. The high
incidence of encepahlopathy observed with monother¬
apy, and the potential for systemic hypotension may
limit their clinical use. Combination therapy with non¬
selective /(-blockers seems more promising.
Drugs affecting plasma volume
The expansion of plasma volume leading to increased
cardiac index is believed to play a major role in
sustaining portal hypertension.'4 Thus diuretics or a
low sodium diet may in theory help to reduce portal
pressure. Early studies suggested that spironolactone
had the potential to be as potent a portal hypotensive
agent as propranolol.80 A significant reduction in the
portal pressure of between 10 and 1 5% was shown to be
accompanied by reductions in plasma volume, cardiac
output, mean arterial pressure and azygous blood
flow.81-83 Hepatic blood flow was unaffected. Although
there was no significant correlation between the plasma
volume and HVPG, a significant inverse relationship
between post treatment serum aldosterone levels and
the HVPG was noted, thus confirming the mode of
action of aldosterone.81 The reductions in the HVPG
following spironolactone administration were not affec¬
ted by dietary sodium content suggesting that a low
sodium diet alone is not sufficient to reduce the portal
pressure.82' 81 In clinical practice the use of spirono¬
lactone, like propranolol, may be limited by its side
effects, particularly painful gynaecomastia which was
present in 55% of male patients in one series.84 There
are no published clinical trials assessing the efficacy
of spironolactone in preventing variceal bleeding,
although an ongoing study is comparing nadolol
monotherapy with nadolol and spironolactone combi¬
nation therapy in the primary prevention of variceal
bleeding.85 Initial results show no differences in the
bleeding rate in the two groups.
Combination therapy
Combination therapy was first used for the treatment of
portal hypertension using nitrates and vasopression.86, 8'
Enhancement of the portal hypotensive effect was
observed. Studies using propranolol, as already dis¬
cussed, have revealed that 30% of patients failed to
reduce portal pressure.1 1 This observation and the fact
that nitrate monotherapy consistently reduced portal
pressure led to studies to investigate the effect of
combined nitrate and /(-blocker therapy (Table 4), a
combination that was first investigated in vitro by
Kroeger and Groszmann.88 In general there is an
enhanced portal hypotensive effect of the combination
therapy using isosorbide-5-mononitrate leading to a
further 13-16% fall in the HVPG. This effect is
particularly striking in those patients who did not
respond to a /(-blocker alone.16 The mechanism pro¬
posed has been that of a decrease in the outflow
resistance.41 It is of note that 1 year after combination
therapy with nadolol there did not seem to be any
additional effect of the nitrate either in the hepatic or
systemic haemodynamics43 despite there being a sus¬
tained effect after 3 months of therapy. This may be
partly explained by a study by Bendsten and associates
who demonstrated that placebo treatment had an equal
© 2001 Blackwell Science Lid. Aliment Pharmacol Titer 15. 291-310
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effect to propranolol after 1 year suggesting that portal
hypertension improves spontaneously in some
patients.18 Although studies looking at the short term
effect of nitrates failed to demonstrate tolerance,,2' 51
nitrate tolerance could still be an explanation for the lack
of effect due to a longer follow-up period in this study.93
The hepatic blood flow and liver metabolic activity are
unaffected, but the azygous blood flow decreased in
most cases with the effect being less pronounced with
longer duration of treatment. Mean arterial blood
pressure and cardiac output both fell, again with the
effect most pronounced following acute administration.
Renal function and ascites formation have been the
focus of some of the studies,89- 90- 92 particularly as
isosorbide-5-mononitrate has been associated with
deteriorating renal function.81' The findings suggest
that the combination of isosorbide-5-mononitrate with
either propranolol or nadolol had no detrimental effect
on renal function in patients with or without ascites,
despite significant effects on hepatic haemodynamics.
These encouraging findings have led to a number of
clinical trials using such combinations.
Other combination therapies have also been studied,
but none of them have been studied in large clinical
trials. One combination therapy worth noting is that of
prazosin and propranolol.92 This study showed a
greater portal hypotensive effect of prazosin and prop¬
ranolol than isosorbide-5-mononitrate and prazosin,
with no effect on hepatic or renal function. Undesirable
systemic effects unfortunately offset the impressive
hepatic haemodynamic results with more patients
experiencing symptomatic hypotension in the prazosin
arm of the study, thus limiting its use in clinical
practice.
CLINICAL APPLICATION OF DRUGS IN PORTAL
HYPERTENSION
Primary prophylaxis
P-blockers versus placebo. Propranolol and nadolol have
been compared with placebo in nine randomized
controlled trials in patients with varices (Table 5),
although two of these were published in abstract
form.99' 100 Another large trial involving 319 patients
treated with either placebo or propranolol is not
comparable with the other trials.103 Here patients were
unselected with regard to the presence of cirrhosis and
varices. This accounts for the low event rate with just
11 patients bleeding and probably explains why no
difference was found in the two groups.
The results of meta-analyses of these trials 104-106 are
very favourable for the treatment group, with reduc¬
tions in the number of bleeding episodes approaching
50%. Overall deaths due to bleeding were significantly
reduced by 45% in one of these studies and overall
deaths by 22% (P = 0.05 2).104 The other two analyses
did not show any benefit on overall survival, although
in one mortality from bleeding episodes was reduced by
50%. 05 This analysis also demonstrated that the
presence of ascites was associated with greater mortality
and bleeding risk. One of the main problems with many
of the trials is the low number of patients, resulting in
insufficient power to detect a reduction in bleeding risk
and especially mortality. The study by Colman et «I.100
is unique in showing an increase in bleeding rate in the
treatment group. However the sample size of this study
is low and the very low event rate in the control group
suggests that patient selection may have been respon¬
sible.





Bleeding rate (%) Death rate (%)
Control Treatment Control Treatment Control Treatment
Pascal et al.94 Propranolol 112 118 24 61 26 49 28
Italian9' Propranolol 89 85 42 41 26 49 41
Conn et al96 Propranolol 51 51 16 22 4 22 16
I'ROVA97 Propranolol 72 68 15 18 18 19 10
Anreani et a/.98 Propranolol 41 42 24 39 6 46 34
Strauss et at." Propranolol 16 20 24 25 20 44 35
Colman et al.mo Propranolol 25 23 24 8 35 28 26
Ideo et al."" Nadolol 49 30 24 30 6 18 10
Lebrec et al.'"2 Nadolol 53 53 12 20 17 19 19
© 2001 Blackwell Science Ltd. Aliment Pharmacol Titer 15, 291-310
REVIEW: PREVENTION OF VARICEAL HAEMORRHAGE 301
A recent trial by Cales and colleagues involving 206
patients with no or only small (< 5 mm) varices was
performed to investigate whether propranolol prevents
the development of varices.' One-hundred and four
patients were randomized to receive placebo and 102 to
receive long acting propranolol (160 mg/day). After a
2-year follow-up period 31% of patients in the prop¬
ranolol arm and 14% of patients taking placebo
developed large varices (P < 0.05). There was no
difference in the rate of bleeding or mortality in the
two groups. The low bleeding rate in the placebo group
may reflect the small numbers of patients in Child's C
class (13%). However the high incidence of the
development of varices in the propranolol group is
striking. The authors postulated that above a certain
portal pressure the development of varices is not directly
related to portal pressure and other 'non-haemodynam-
ics' play a part. Another mechanism proposed was that
of increased vascular resistance in the collateral circu¬
lation following propranolol administration, although it
is not clear what the relationship between collateral
resistance and the development of varices is. Clearly
further studies would assist in elucidating the exact
mechanisms. This may involve the measurement of
portal pressure in the two groups. Until further studies
are performed it is not recommended that propranolol
be prescribed for the prevention of the development of
varices and bleeding in cirrhotic patients with small or
no varices.
Studies have shown propranolol to be safe in long term
use in patients with cirrhosis, but up to a third of
patients are intolerant of the side effects resulting in
discontinuation of the drug.2' The dosage in most of the
studies is that required to reduce the resting heart rate
by 25%. This usually means starting therapy with a
dose 40 mg twice daily and working up to an average
maintenance dose of 160 mg/day. Nadolol is typically
administered at a dose of 80 mg/day. Fatigue is the
most important side effect. Compliance can be a major
problem, especially in patients with alcoholic liver
disease.
Isosorbide-5-mononitrate. There is only one published
randomized controlled trial comparing ISMN with
placebo.10' Forty-two cirrhotic patients were random¬
ized to either ISMN (n = 23) or placebo (n = 19).
Both groups were followed up for an average of 43-49
weeks. There was a tendency towards reduced bleeding
and death in the ISMN group, although the results did
not reach statistical significance. It is also of note ISMN
was well tolerated.
A recent randomized double-blinded study published in
abstract form comparing ISMN (in patients intolerant of
/^-blockers) with placebo in 13 3 consecutive cirrhotic
patients with gastro-oesophageal varices, reported a
higher first bleeding rate in the treatment group (29%)
than in the placebo group (14%) following a 2-year
follow-up period.108 There was no signiiicant difference
in survival. The presence of ascites, larger variceal size
and red signs were associated with a greater incidence
of the first bleed. A greater withdrawal from the study
because of side effects was noted in the ISMN group.
There was no effect on the development of new ascites
or worsening of existing ascites in the treatment arm.
The incidence of bleeding in the placebo group was
lower than in most other studies. The full paper will
need to be published before conclusions can be made
from this study.
Others have compared ISMN with propranolol.109 This
was a large randomized trial over a 7-year follow-up
period involving 118 patients. The probability of
bleeding was identical in both the groups. Mortality
was significantly greater in the nitrate group, but this
was only in patients above 50 years of age.
A smaller study demonstrated that ISMN was less
effective than nadalol in preventing bleeding in 30
patients with ascites.110 Mortality was unaffected, but
sodium excretion was reduced by almost 50% in the
nitrate group. The small size of this study makes it
difficult to draw conclusions from the findings.
It appears that ISMN is at least as effective as
propranolol in the prevention of gastrointestinal hae¬
morrhage. However the reduced mortality seen with
propranolol is not present in the nitrate group. Caution
is needed in prescribing nitrate monotherapy on
account of the potential for deterioration in renal
function and the increased mortality seen in the older
age group.109 This may explain why there are not so
many trials using nitrate monotherapy and many more
looking at combination therapy.
Combination therapy. As discussed earlier, combination
therapy has been shown to be effective in producing a
sustained portal hypotensive response. The only com¬
bination that has been studied in large randomized
trials is that of nitrates and /I-blockers.
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Nadolol monotherapy has been compared with nadalol
and ISMN dual therapy by Merkel and colleagues
with the results of long-term follow-up published
recently.111, 112 Initial results following a 30-month
follow-up period in 146 patients demonstrated a
significant reduction of greater than 50% in the
cumulative risk of variceal bleeding in the combination
treatment group compared with nadolol alone. There
was a non-significant trend towards reduced mortality
in the combination therapy group. However there was a
high incidence of side effects in the combination group
(51%), which were severe enough to cause withdrawal
from the study in 11% of patients. This compares with
4% in the nadalol only group.
Long-term follow-up of these patients over 7 years has
revealed a sustained effect of combination therapy in
preventing variceal haemorrhage."2 Survival was
unaffected. A larger sample size would be required to
show up any survival differences. Two significant
findings are of note. First, long-term administration
did not result in further side-effects leading to with¬
drawal from the study. Thus side-effects usually occur
early, after the initial doses for nitrates, and in the first
few months in the case of /I-blockers. Second, there was
no significant effect on (he occurrence of de novo ascites
in the two groups. Previous studies have shown a
deleterious effect on renal function and sodium hand¬
ling when using nitrate monotherapy.60
Another two double-blind placebo-controlled random¬
ized studies have been published in abstract form.115114
The first of these compared propranolol and placebo with
propranolol and ISMN in 349 patients of whom 57% had
> 5 mm size varices.115 Low bleeding rates at 2 years in
both the groups were 13% and 10% respectively. The
bleeding rates were similar in patients with only large
varices. Mortality was similar in both groups, but there
were significantly more side-effects in the combination
group (36.5% vs. 24.7%, P < 0.05). Development of
ascitps and renal function were unaffected.
The second study114 involved fewer patients. Patients
with large oesophageal varices and red colour signs were
randomized to either nadolol and placebo (n = 27) or
nadolol and ISMN (n = 30). There was no significant
difference in the bleeding rate or mortality following a 2-
year follow-up. Side-effects were significantly more
common in the combination group (53% vs. 26%,
P = 0.03) with 40% in the combination group with¬
drawing as a result, compared with 15% in the nadalol
monotherapy group (P = 0.034). However the study
was terminated early on account of excess mortality in
patients treated with nadolol and ISMN in a parallel trial
for the prevention of rebleeding.115 Thus it is not
appropriate to make valid conclusions based on this trial.
Beta-blocker and ISMN combination therapy, in par¬
ticular nadolol and ISMN, appears to be more etfective
than nadolol monotherapy in preventing the first
variceal bleed. Until further studies are performed there
does not appear to be any advantage in adding ISMN to
propranolol. The side-effect profile of combination ther¬
apy is considerably worse, and this is likely to limit its
clinical application. Outside of clinical trials patients and
clinicians may not be so vigilant in continuing therapy
that leads to so many side-effects when alternatives such
as endoscopic treatments are available.
Pharmacological agents compared with endoscopic treat¬
ments. Sclerotherapy has been compared with placebo
and propranolol in two studies9'" 9S and the efficacy of
sclerotherapy and propranolol combination therapy
assessed in one of these and a further study.9'' 116
One study revealed that bleeding from a portal hyper¬
tensive source was significantly less in the propranolol
group than the sclerotherapy group (4.7% vs. 21.4%,
P < 0.00 3).98 None of the studies showed differences in
variceal bleeding or mortality when propranolol was
compared with sclerotherapy.
A recent trial, which selected patients with high intra-
oesophageal variceal pressures, randomized patients to
propranolol (42 patients) or to propranolol plus sclero¬
therapy (44 patients).116 After a 2-year follow-up
period, 23% of the patients in the combination group
bled due to varices or congestive gastropathy as
compared with 14% in the propranolol group (not
significant). Fifty-two per cent in the combination group
developed complications as compared with 19% in the
propranolol group (P = 0.002). The mortality rate was
similar in both groups. The findings are similar to those
in an oarlicr study where patients were unsclcctcd with
regard to the characteristics of varices.9'
Endoscopic band ligation is a recent technique that
has been compared with sclerotherapy in a meta¬
analysis,1 1' and was found to be superior to sclerotherapy
in the secondary prophylaxis against variceal rebleeding
with fewer complications and quicker eradication of
varices. Band ligation has been compared with prop¬
ranolol for the primary prophylaxis of variceal bleeding
in two published trials'1 x' 119 and also a recent abstract
from our center.120 In the first study,118 30 patients
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with grade III or higher varices were studied over a 17-
month follow-up period. There was no difference in the
bleeding rate in the two groups. Sarin and colleagues119
studied 89 patients with greater than 5 mm varices and
observed that over a 17-month period the probability of
bleeding was 43% in the propranolol group and I 5% in
the ligation group (P = 0.04). There was no difference
in mortality. The very high bleeding rate in the
propranolol group contrasts with that observed in other
trials. The dose of propranolol was also lower than in
other trials. A recent multicenter trial involving 172
patients compared propranolol, ISMN and band ligation
over a mean follow up of 20 months.120 Banding was
superior to ISMN but similar to propranolol in prevent¬
ing the tirst bleed. There was no difference in the overall
mortality in the three groups. A very significant
proportion of patients had to withdraw from drug
therapy as result of side-effects.
Clearly, of the two modes of endoscopic treatments,
banding is preferable to scelotherapy because there are
fewer iatrogenic complications and it has been shown to
be at least as good as if not better than propranolol.
Banding is particularly useful where patients are
intolerant of drug therapy. Sclerotherapy combined
with propranolol does not offer any further benefit over
propranolol monotherapy. It remains to be seen whe¬
ther this is also the case with banding. It therefore
appears that banding is at least as good as propranolol
in the primary prevention of variceal bleeding and will
probably be widely employed, because of its lack
of dependence on compliance and the attraction of
eradicating oesophageal varices.
Secondary prophylaxis
It is clear that secondary prevention following a variccal
bleed is essential in view of the high rate of rebleeding
without intervention.2 There is a greater choice of
endoscopic, pharmacological, radiological and surgical
therapies for secondary prophylaxis than for primary
prophylaxis.
ji-blockers versus placebo. There were several trials in the
1980s, and a meta-analysis of these performed in our
center revealed significant benefits of propranolol ther¬
apy.104 In a population of 1080 patients there was a
39% reduction in rebleeding episodes, a 40% reduction
in deaths from bleeding and a 25% reduction in total
mortality in the propranolol groups. Heterogeneity was
significant for rebleeding episodes, but not when deaths
from bleeding or overall mortality were assessed.
Although not all of these trials were randomized or
placebo controlled, further analysis of selected trials that
met more strict criteria, and in those where there was
no significant heterogeneity, demonstrated significant
benefits from propranolol therapy in the reduction of
bleeding and improved mortality rates.
There are 12 published randomized controlled trials
comparing /(-blockers with placebo against variceal
rebleeding (Table 6). Propranolol was assessed in 11,
nadalol in one and atenolol in one study which also
included propranolol.128 The latter study found atenolol
to be less effective than propranolol at reducing
rebleeding and improving patient survival. A meta¬
analysis of these trials 06 demonstrated a significant
Table 6. /i-blocker therapy in the secondary prophylaxis against variceal rcblecding
Number of patients Rebleeding rate (%) Death rate (%)
Trial Drug Control Treatment (months) Control Treatment Control Treatment
Burroughs et al.12' Propranolol 22 26 21 59 54 23 1 5
Lebrec et al.122 Propranolol 36 38 24 64 21 22 8
Villeneuve et al.'" Propranolol 37 42 24 81 76 38 45
Carbelaud et al.'24 Propranolol 50 50 24 78 40 33 26
Queuniet et al.'25 Propranolol 48 51 18 64 57 21 23
Gatta et al.'26 Nadalol 12 12 33 67 25 25 8
Kobe et al.'27 Propranolol 28 26 16 46 38 32 2 3
Colombo et al128 Propranolol 30 32 11 47 25 23 12
Colombo et al.'29 Atenolol 30 32 11 47 31 23 9
Sheen et al.150 Propranolol 18 18 24 55 28 11 0
Garden et al."' Propranolol 43 38 24 77 47 44 37
Colman et al.132 Propranolol 26 26 24 50 35 4 4
Rossi et al.'53 Propranolol 27 27 19 63 48 33 26
© 2001 Blackwell Science Ltd, Aliment Pharmacol Tlwr 15, 291-310
304 D. TRIPATH1 & P. C. HAYES
reduction in the rebleeding rate from 66% in the
placebo group to 44% in the treatment group (pooled
odds ratio of 0.4). There was no significant effect of drug
therapy on survival, which may reflect the heterogen¬
eity of the study populations, particularly with respect
to aetiology, severity of the liver disease and the time to
treatment from the index bleed. Only two of these
studies included a significant proportion of Child's C
patients,125' 151 and benefit for the Child's C patients
was seen in one.151
A recent meta-analysis also revealed that there was a
significantly greater reduction in the variceal rebleeding
rate in the /(-blocker treated patients than in the placebo
group (20% mean improvement rate, P < 0.001).154
However this study also demonstrated that there was a
significant improvement in the survival rate in the
treatment group with a mean improvement of 5.5%
(P = 0.05), with this being more marked in patients
with more advanced liver disease. The methods of
analysis did not reveal any significant heterogeneity
amongst the trials. It would therefore seem appropriate
that /(-blocker therapy for secondary prophylaxis can be
recommended for patients regardless of the degree of
liver disease. Although the prevalence of adverse events
was significantly higher in the treatment group,
because adverse events were only mentioned in some
of the studies it remains somewhat unclear of the
impact of this on practice.
Combination therapy. There is only one published trial
assessing the effect of combination drug therapy in
preventing variceal rebleeding.151 In this randomized
study involving 95 patients, after a 2-year follow-up
period, overall rebleeding and survival was not
improved by the addition of ISMN to propranolol
compared with propranolol alone. However there was
a significant reduction in the risk of rebleeding when
patients were stratified according to age, i.e. less than
50 years old versus over 50 year olds or by adding an
extra year of follow up. It is also of note that more
patients experienced side-effects leading to discontinu¬
ation of medication with the combination therapy.
However no adverse events concerning renal function
or effect on ascites was observed with the combination
therapy.
Another two studies published in abstract form
reinforce the findings of the above study that combining
/?-blockers with ISMN offers no additional benefit in
reducing the overall rebleeding rate and mortality.15h'15/
In fact one of these studies reported greater mortality in
patients treated with nadolol and ISMN than nadolol
alone (32% vs. 14%, P = 0.02).156 Clearly the full
paper would need to be published and analysed before
firm conclusions can be made.
It seems, therefore, that combination therapy may
have a role in secondary prophylaxis, but adverse side-
effects may limit its clinical use. Further studies are
necessary before confident recommendations can be
made.
Pharmacological agents compared with endoscopic treat¬
ments. There have been several trials comparing scle¬
rotherapy with /(-blockers alone or /(-blockers combined
with sclerotherapy. Meta-analysis of these studies104
demonstrated a small benefit of sclerotherapy over
propranolol on the rebleeding rate but no effect on
survival. Sclerotherapy was associated with a greater
number and severity of complications. Propranolol
combined with sclerotherapy was found to be better
than sclerotherapy in reducing the rebleeding rate, but
there was no difference in survival. The rationale being
that the addition of propranolol reduces the risk of
rebleeding in the first few months before the varices are
completely eradicated. However the meta-analysis
revealed significant heterogeneity in all these trials,
which makes firm conclusions difficult. A recent
abstract found that propranolol and sclerotherapy were
significantly more effective at reducing the rebleeding
rate than sclerotherapy alone (11/35 vs. 16/30
patients, P < 0.001).158 It is interesting that most of
the difference was accounted for by a greater incidence
of bleeding from gastric varices and congestive gastr-
opathy in the sclerotherapy only group.
Propranolol in combination with sclerotherapy was
found to be superior, in terms of rebleeding rate and
survival, to propranolol alone based on the results of
two studies. In the meta-analysis the odds ratios for
rebleeding in the above trial comparisons were not as
low as that when comparing propranolol with placebo.
The trials comparing the latter were also of a higher
quality with a longer follow-up period. Another meta¬
analysis comparing propranolol with sclerotherapy
mirrors these findings in that sclerotherapy was more
effective at reducing variceal rebleeding, but was
associated with more iatrogenic adverse events.159
Survival was similar in the two groups.
The combination of nadolol and ISMN was found to be
superior to sclerotherapy in a recent trial.140 Rebleeding
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rate and treatment related complications were signifi¬
cantly lower than in sclerotherapy. Overall survival
was, however, identical in the two groups. It is
interesting that patients in whom the hepatic venous
wedge pressure fell by 20% or more had far fewer
episodes of rebleeding.
Banding has been compared with /I-blocker and ISMN
combination therapy in preventing recurrent variceal
bleeding in three studies all published in abstract
form.141-143 The results suggest that drug therapy is
better than band ligation in reducing the risk of
rebleeding, although there was no effect on mortality.
The full report of these trials is awaited.
It seems, therefore, that further trials with a longer
follow-up and including banding combined with prop¬
ranolol are necessary before combination drug or
endoscopic therapy can be recommended for the
secondary prophylaxis against variceal rebleeding.
Pharmacological agents compared with transjugular intra¬
hepatic portosystemic stent shunt (TIPSS). The only
publication is a study published in abstract form that
randomized patients to either TIPSS only (;i = 47) or
propranolol and isosorbide-5-mononitrate combination
therapy (n = 44).144 The TIPSS arm had significantly
fewer episodes of rebleeding (11% vs. 32%, P = 0.02),
but encepahlopathy was significantly higher in the
shunted group (38% vs. 11%, P = 0.004). Mortality
was similar for both groups. The cost of TIPSS was more
than twice that of drug therapy. Full publication of the
report is awaited.
There is no doubt that TIPSS is very effective at
reducing rebleeding and has been demonstrated in a
recent meta-analysis to be more effective than endo¬
scopic therapy, although overall survival is similar.14:1
Encephalopathy often responds to simple measures and
in most cases improves or resolves over time.146 There is
now more of a case for TIPSS to be used early in the
secondary prevention of variceal bleeding in patients
with more advanced disease. Further studies with drug
therapy are needed before conclusions can be made
about its efficacy compared with TIPSS in the preven¬
tion of variceal rebleeding.
CONCLUSIONS
There have been many studies investigating the effect of
pharmcological agents on portal hypertension with
varying results. Of these agents non-selective /f-blockers
and isosorbide-5-mononitrate alone and in combination
seem to be the most promising. The haemodynamic
response to drug therapy also has been shown to
correlate with the risk of bleeding, and monitoring the
haemodynamic response to medical therapy may assist
in appropriate dosing and choice of agent. Newer
preparations such as carvedilol and losartan deserve
further study following very encouraging initial results.
Large randomized clinical trails remain the gold
standard for testing the efficacy of these agents in
preventing the initial variceal bleed and rebleeding. The
first choice for primary prevention are non-selective ft-
blockers, although recent evidence suggests a role for /?-
blockers in combination with isosorbide-5-mononilrate.
Endoscopic variceal ligation also compares favourably
with drug therapy especially where drugs are not
tolerated.
For secondary prevention non-selective /i-blockers are
also effective and similar to sclerotherapy. As band
ligation replaces sclerotherapy the relative efficacy of
drug therapy versus band therapy should be studied.
Following initial encouraging results further studies
looking at combination therapy for secondary preven¬
tion are needed. TIPSS is also very effective at reducing
the rebeleeding rate compared with endoscopic therapy,
and has a place in the management of patients with
more advanced liver disease. It is currently unclear how
TIPSS compares with pharmacological agents.
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SUMMARY
Background: Carvedilol is a non-selective vasodilating
^-blocker with weak a, receptor antagonism. Recent
studies have demonstrated its potential as a portal
hypotensive agent.
Aim: To assess the haemodynamic effects and patient
tolerability of the acute and chronic administration of
low-dose carvedilol.
Methods: Haemodynamic measurements were per¬
formed in ten cirrhotic patients before and 1 h after
the administration of 12.5 mg oral carvedilol. The study
was repeated 4 weeks after daily administration of
12.5 mg carvedilol.
Results: After acute administration of carvedilol, there
was a 23% reduction in the hepatic venous pressure
gradient from lb.37 ± 2.14 to 12.56 ± 3.91 mmHg
(P < 0.05), with significant falls in the heart rate,
mean arterial pressure and cardiac output. Chronic
administration resulted in a further fall in the hepatic
venous pressure gradient from a baseline of 16.37 ±
0.71 to 9.27 ± 1.40 mmHg (P < 0.001) with the
mean arterial pressure being unaffected. The drug
was well tolerated with only one patient experiencing
asymptomatic hypotension.
Conclusions: The results show that low-dose carvedilol
is an extremely potent portal hypotensive pharmacolo¬
gical agent, and is worthy of further investigation in
large randomized trials to assess its effect in preventing
variceal haemorrhage.
INTRODUCTION
The haemodynamic effects of propranolol have been
well studied. Lebrec et al. demonstrated a greater than
20% reduction in the hepatic venous pressure gradient
(HVPG) following the acute administration of propran¬
olol,1 but up to one-third of patients do not exhibit a
portal hypotensive response.2 This may be explained by
a portal hypertensive model demonstrating that a rise in
the portocollateral resistance accompanies the reduc-
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tion in portal blood flow, thus reducing the overall
portal hypotensive response to propranolol." Current
evidence suggests that the goal of pharmacotherapy in
reducing the risk of variceal haemorrhage is to achieve
a fall in the HVPG to < 12 mmHg4 or a 20%1 reduction
from baseline values.
The role of non-selective /i-blockers in the primary
prevention of variceal haemorrhage has been exten¬
sively studied.6-14 Meta-analysis of these trials has
clearly shown the benefit of these drugs when compared
with placebo.1^ However, many patients are intolerant
to drug side-effects.10' 15
ot-i antagonism has been investigated in three haemo¬
dynamic studies.1,1-1 ,s Impressive reductions in the
HVPG were achieved and these were comparable with
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those of propranolol. It was postulated that prazosin
exerted its effect by reducing the intrahepatic resist¬
ance. However, patients suffered from symptomatic
hypotension and a worsening of renal function and
ascites. Prazosin in combination with propranolol was
found to achieve a greater reduction in the portal
pressure than a combination of propranolol and
isosorbide-5-mononitrate.14 It is interesting that the
combination of an a blocker and a non-selective
/i-blocker had no effect on renal function. A drug
which combines the properties of these two agents is
worth investigating.
Carvedilol is a vasodilating non-selective /^-blocker
with weak ai receptor and calcium channel antagon¬
ism. It has a rapid onset of action with 2-4 times
greater /3-blocking action than propranolol.20 Studies
have shown that carvedilol at a dose of 25 mg daily is
effective in reducing the HVPG in cirrhotic sub¬
jects,21'22 both acutely and after chronic use. A
recent study has demonstrated that carvedilol is more
effective in reducing the portal pressure than intra¬
venous propranolol or placebo when administered
acutely.2 5 However, all of these studies reported a
significant incidence of systemic hypotension, which
was dose related, whilst renal function was unaffected.
A 1 5% fall in HVPG was reported following the acute
administration of 10 mg carvedilol, but to date there
has been no investigation of the haemodynamic effects
of low-dose carvedilol following chronic administra¬
tion.24 The aim of this study was to investigate the
acute and chronic effects of low-dose carvedilol on
portal and systemic haemodynamics and the patient
tolerability at this dose.
PATIENTS AND METHODS
Ten patients, seven male and three female, with a mean
age of 53 ± 4.07 years, were recruited, all of whom had
either biopsy-proven or clinical, biochemical and ultra¬
sonographic evidence of cirrhosis. Eight patients had
alcoholic liver disease, one patient had primary biliary
cirrhosis and one patient had hepatitis C virus-related
cirrhosis. Seven patients had Child-Pugh grade B
disease, one grade A and two grade C. Six patients
had ascites at the time of the study or in the past. All
patients had gastro-oesophageal varices, with none
having bled. All patients gave informed consent and the
study was approved by the Lothian Medicine and
Oncology Ethics Committee. The study protocol was in
accordance with the ethical guidelines of the 1975
Declaration of Helsinki.
All patients had baseline haemodynamic measure¬
ments performed following an overnight fast. They were
then given 12.5 mg of oral carvedilol (Roche Pharma¬
ceuticals) and haemodynamic measurements were
repeated after 1 h as per our previous protocols using
this drug.21'22 After completion of the acute study,
patients were instructed to take 12.5 mg of carvedilol
daily at 09.00 h for 4 weeks, after which time the
haemodynamic measurements were repeated before
and 1 h after the administration of 12.5 mg carvedilol
as per the initial protocol. There was no change in the
observed alcohol consumption for the duration of the
study. There were no detectable serum ethanol levels
prior to each study or during follow-up.
Haemodynamic study protocol
All measurements were performed in the Liver Hae¬
modynamics Suite. Blood for baseline biochemical and
haematological measurements was obtained from a
peripheral vein. All haemodynamic measurements
were performed in the supine position. After infiltra¬
tion with 10 mL 2% lignocaine (lidocaine), a 7 FG
venous introducer (Cordis, USA) was inserted into the
right femoral vein using the Seldinger technique.
Under fluoroscopic guidance, a Swan-Ganz catheter
(Baxter Healthcare Corporation, USA) was inserted
through the introducer to measure cardiac output
(CO) and right atrial pressure (RAP) in the standard
manner. Using the same catheter, or a Sidewinder II
torque balloon catheter (Cordis Corporation, USA), the
main right hepatic vein was then catheterized for the
measurement of the free (FHVP) and wedge (WHVP)
hepatic venous pressures. The HVPG was derived from
WHVP - FHVP. All haemodynamic measurements
were taken in triplicate, with the mean of the values
being used for analysis. The mean arterial pressure
(MAP) was measured using an automatic sphygmo¬
manometer (Hewlett Packard series 54 model
78 339A) and was calculated as (pulse pressure/
3) + diastolic blood pressure. The systemic vascular
resistance (SVR) was calculated as (79.96 (MAP -
RAP)/CO).
The hepatic blood flow (HBF) was derived from
measurements of the indocyanine green (Akorn)
clearance and extraction. Indocyanine green was
infused at the beginning of the study as a 10 mg
© 2002 Blackwell Science Lid, Aliment Pharmacol Ther 16, 373-380
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intravenous bolus via a peripheral cannula, followed
by an infusion of 0.2 mg/min indocyanine green.
After an equilibration time of 40 min, three samples
were taken simultaneously from the right hepatic vein
and femoral vein. The HBF was calculated using the
following equation (provided that the hepatic excre¬
tion exceeded 10%):
HBF = (indocyanine green clearance/
indocyanine green extraction)/(1 — haematocrit)
Statistical analysis
All results are expressed as the mean ± S.E.M. Para¬
metric data were analysed using the paired Student's
t-test and Pearson's correlation. The Wilcoxon signed
rank test and Spearman correlation were used for
non-parametric data. Significance was taken at the
5% level. Microsoft Excel 2000 and SPSS packages
(version 9, Chicago, IL, USA) were used for statistical
analysis.
RESULTS
Nine patients completed both the acute and chronic
studies. One male patient with Child's C disease, who
had a hypotensive reaction to acute dosing with
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carvedilol and developed an alcoholic hepatitis, comple¬
ted only the acute phase of the study.
Portal haemodynamics
Following the acute administration of carvedilol, there
was a 23.9 ± 5.6% reduction in HVPG (from
16.37 ± 2.14 to 12.56 ± 3.91 mmHg: P < 0.05),
due principally to a reduction in WHVP (from
22.03 ± 1.28 to 16.86 ± 1.15 mmHg: P < 0.01) with
no significant change in FHVP (Table 1). Chronic
administration resulted in a sustained and even greater
fall in HVPG from the baseline average value of
16.37 ± 0.71 to a pre-dosing value following chronic
dosing of 9.27 ± 1.40 mmHg (P < 0.001, 43.4 ±
9.2%). In all cases except one, there was a > 20%
reduction in HVPG after chronic dosing. There was no
additional effect on HVPG following re-challenge with
carvedilol (Figures 1-4).
Hepatic blood flow
Indocyanine green clearance and extraction were
measured in five patients (Table 1). In the acute phase
of the study, there was a significant reduction in HBF
from 1725 ± 435 to 718 ± 179 mL/min (P < 0.05,
n = 5) following acute administration. Following chro¬
nic dosing, one patient had an initial indocyanine
Acute dosing After chronic dosing
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green extraction of < 10%, and therefore HBF could
not be calculated. There was no further significant
reduction in HBF following chronic administration or
re-challenge with carvedilol (n = 4).
Systemic haemodynamics
MAP fell acutely from 90.33 ± 4.95 to 81.56 ±
5.84 mmHg (P < 0.01), but with chronic administra¬
tion and re-challenge there was no additional change.











Figure 1. Effect on hepatic venous pressure gradient (HVPG)
following chronic dosing. Each patient is represented by a symbol.
chronic dosing or re-challenge. The heart rate fell
with acute and chronic dosing, but was unaffected
following re-challenge with carvedilol. RAP fell acutely
and following re-challenge. SVR was unaffected. The
changes in HVPG did not correlate with changes in
MAP, CO. heart rate or RAP.
Liver function tests and renal function
The serum alanine aminotransferase, bilirubin, creati¬
nine and clotting parameters were unaffected by
chronic administration.
Tolerability
No side-effects were reported, except in one patient who
experienced palpitations, and no patients were with¬
drawn because of side-effects. The patient who became
hypotensive after acute dosing experienced a fall in
MAP from 64 to 57 mmHg. He successfully completed
the acute study and remained asymptomatic. His blood
pressure normalized after 3 h and following colloid
administration.
There were six patients with a history of ascites,
although only four had ascites at the time of the
study, which limited valid statistical analysis. These
patients exhibited a similar reduction in HVPG
following acute and chronic dosing of 26.41% and
38.38%, respectively. There was no significant reduc¬
tion in MAP (- 1.2 3%). No patients experienced
Figure 2. Overall effect on hepatic venous
pressure gradient (HVPtl).
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deterioration in ascites or renal function during
follow-up.
DISCUSSION
These results clearly show that carvedilol, at a dose of
12.5 mg/day, is a potent portal hypotensive agent and
is well tolerated. Its acute administration significantly
reduces portal pressure, an effect which is maintained
following chronic dosing.
The acute haemodynamic effect of low-dose carvedilol
has been investigated in two previous studies.23, 24 A
10 mg dose significantly reduced HVPG by 15% after
60 min and by 17% after 90 min in 10 patients,
although only 50% of patients had a greater than 20%
reduction in HVPG.24 The 12.5 mg dose has been
investigated in a smaller study, which did not demon¬
strate an effect on the portal or systemic haemodynam-
ics, although there was a tendency to reduce HVPG and
MAP.'3 The reductions in HVPG, CO and MAP observed
following acute dosing in this study are consistent with
those observed in previous studies performed in our unit
using 25 mg of carvedilol.21, 22 We also demonstrated a











Figure 3. Acute haemodynamic effects
of carvedilol. CO. cardiac output: HVPG. -25
hepatic venous pressure gradient: MAP.
mean arterial pressure; PR, pulse rate;
SVR, systemic vascular resistance. Bars
(left to right): MAP. PR, HVPG, CO,
SVR. -35
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finding that was noted in one of the previous studies.25
These haemodynamic findings are consistent with non¬
selective /(-blockade, as demonstrated with propran¬
olol.1 In comparison with propranolol, carvedilol has
less of an effect on CO and heart rate compared with its
effect on HBF, suggesting that the degree of /h blockade
is less than that of propranolol, at least acutely.23
However, chronic administration did not lead to a
further significant fall in CO and MAP despite a
reduction in the heart rate. These findings are similar
to those previously demonstrated in our centre.22 a-\
receptor antagonism, and hence reduced intrahepatic
resistance, is likely to have contributed to the marked
reduction in HVPG following chronic dosing. A reduc¬
tion in HBF noted in a small group of patients could
have had an additional effect.
A recent abstract has shown that the reduction in
HVPG, MAP, heart rate and CO is greater with chronic
administration of carvedilol than with administration
of propranolol.21 HBF was unchanged with carvedilol,
but decreased with propranolol. The authors expressed
concern about the significant reduction in MAP. The
dose of carvedilol used was significantly greater than
that used in our study (31 vs. 12.5 mg/day), which


















Figure 4. Haemodynamic effects of carv-
edilol following chronic dosing. CO. cardiac
output: HVPG, hepatic venous pressure
gradient: MAP. mean arterial pressure: PR,
pulse rate: SVR, systemic vascular resist¬
ance. Bars (left to right): MAP. PR, HVPG.
CO, SVR.
may have been because Banares et al. titrated the dose
against the heart rate. It is doubtful whether such high
doses are required, because we have demonstrated in
this and a previous study22 that a lower fixed dose can
result in a similar magnitude of portal pressure
reduction with minimal side-effects. Prazosin has been
shown to have detrimental effects on sodium handling,
resulting in an increased tendency to ascites forma¬
tion. 6 However, combination therapy with propran¬
olol did not affect renal function.19 Previous studies
have shown that carvedilol does not affect the renal
blood flow,21 and our findings confirm that the renal
function remains unaffected following chronic dosing,
with no evidence of increased ascites formation.
Therefore, it seems that additional non-selective
/J-blockade helps to maintain renal blood flow and
function. This may be explained by previous observa¬
tions that non-cardioselective /^-blockers suppress the
increase in plasma renin activity and plasma aldoster¬
one that occurs following a blockade.1' Although not
included in our present study, we have previously
shown that carvedilol at a dose of 2 5 mg has no effect
on creatinine clearance, urine volume or natriuresis.22
This is consistent with the observation that none of the
patients with ascites suffered from increased fluid
retention.
Concerns have been expressed regarding the effect of
carvedilol on systemic haemodynamics, in particular
blood pressure, in patients with liver disease. This
stems from the fact that the bioavailability is very
variable in patients with hepatic impairment. Carv¬
edilol undergoes extensive stereoscopic first-pass meta¬
bolism in the liver.2'1 The stereoisomer R-carvedilol has
equal j] and oq antagonism, while s-carvedilol has only
non-selective ji antagonism.27 In healthy individuals,
R-carvedilol has twice the bioavailability of s-carvedilol,
whereas patients with liver disease have equal and
increased availability of both stereoisomers.28' 29 This
means that /I antagonism is greater in patients with
liver disease, which could result in undesirable sys¬
temic effects. These effects appear to be dose related
and our results indicate that, despite the greater
bioavailability, patients with advanced liver disease
experience minimal systemic hypotension. In partic¬
ular, patients with ascites, despite exhibiting similar
reductions in HVPG compared with patients without
ascites, do not experience significant systemic hypo¬
tension. Clearly, this reinforces the need to adhere to
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lower dose regimens in such patients, especially as we
have demonstrated that carvedilol can still have a
marked portal hypotensive effect at these doses. In
heart failure, carvedilol should be started from a low
dose, such as 3.125 mg b.d., for 2 weeks and titrated
according to patient tolerance.50 Our results indicate
that the first dose of carvedilol has a greater effect on
systemic haemodynamics than subsequent doses. It
would therefore seem logical to introduce carvedilol in
a stepwise fashion in patients with liver disease, with
the dose titrated according to patient tolerability,
aiming for a target daily dose of 12.5 mg.
In conclusion, our study demonstrates that low-dose
carvedilol leads to a significant reduction in portal
pressure with minimal effects on systemic haemody¬
namics. In all cases except one, there was a reduction
in HVPG of > 20%, and in seven out of nine patients
HVPG was <12 mmHg with chronic administration.
The reduction in portal pressure observed in this
study is one of the largest reported in the literature to
date, and is comparable to that seen following the
insertion of a transjugular intrahepatic portosystemic
stent-shunt. These findings, and the earlier observa¬
tion that carvedilol appears to have superior portal
hypotensive effects to propranolol,2 5 suggest that
carvedilol should be assessed in large randomized
controlled trials for the primary prevention of variceal
haemorrhage.
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LIVER DISEASE
The role of the transjugular intrahepatic portosystemic
stent shunt (TIPSS) in the management of bleeding gastric
varices: clinical and haemodynamic correlations
D Tripathi, G Therapondos, E Jackson, D N Redhead, P C Hayes
Cut 2002;51:270-274
Background: The transjugular intrahepatic portosystemic stent shunt (TIPSS) is effective in the manage¬
ment of both oesophageal and gastric variceal bleeding. Although it has been reported that gastric
varices can bleed at pressures of S12 mm Hg, this phenomenon has been little studied in the clinical
setti ng.
Aims: To assess the efficacy of TIPSS on rebleeding and mortality following gastric and oesophageal
variceal bleeding, and the importance of portal pressure in both groups.
Methods: Forty eligible patients who had bled from gastric varices and 232 from oesophageal varices
were studied. Patients were also subdivided into those whose portal pressure gradients (PPG) prior to
TIPSS were S 1 2 mm Hg (group 1) and >1 2 mm Hg (group 2).
Results: There was no difference in Child-Pugh score, age, sex, or alcohol related disease between
patients bleeding from gastric or oesophageal varices. Patients who bled from gastric varices had a
lower PPG pre-TIPSS (15.8 (0.8) v 21.44 (0.4) mm Hg; p<0.001). There was no difference in the
rebleeding rate (20.0% v 14.7%; NS). There was a significant difference (p<0.05) in favour of the
gastric varices group in the one year mortality (30.7% v 38.7%) and five year mortality (49.5% v
74.9%), particularly in those patients in group 2. Gastric variceal bleeding accounted for significantly
more cases in group 1 than in group 2 (36.8% v 10.2%; p<0.001). Most patients in group 2 who
rebled had a PPG post-TIPSS of >7 mm Hg.
Conclusions: TIPSS is equally effective in the prevention of rebleeding following gastric and oesopha¬
geal variceal bleeding. A significant proportion of gastric varices bleed at a PPG sS 1 2 mm Hg. The
improved mortality in patients with gastric variceal bleeding is seen only in those that bleed at a PPG
>12 mm Hg, and warrants further study.
See end of article for
authors' affiliations
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Variceal haemorrhage is a major cause of mortality andmorbidity in patients with cirrhosis and portalhypertension.' Studie have eport d an association
between portal pressure and the risk of variceal bleeding.2' It
has been reported that varices rarely bleed if the portal
pressure gradient (PPG) is less than 12 mm Hg and many
advocate this as a therapeutic goal."
The management of bleeding gastric varices has been a par¬
ticular challenge to clinicians. It is known that the natural
history of bleeding gastric varices differs from that of
oesophageal varices. Although the risk of bleeding from
gastric varices is less than that of oesophageal varices, the
outcome once bleeding has occurred is worse, particularly for
isolated gastric varices.5 Various endoscopic methods, includ¬
ing standard sclerotherapy" and injection of tissue adhesives,7
have resulted in good initial hacmostasis but arc limited by a
high rebleeding rate. Results using thrombin are more prom¬
ising in uncontrolled studies." "The use of a transjugular intra¬
hepatic portosystemic stent shunt (TIPSS) has been studied
extensively for oesophageal variceal bleeding (OVB) and more
recently for the management of gastric variceal bleeding
(GVB). We have previously shown TIPSS to be equally effective
in the management of gastric varices, a finding which has
been confirmed by other centres, particularly in emergency or
refractory GVB.10"12
Despite reports that varices bleed almost exclusively at por¬
tal pressures of greater than 12 mm Hg,*1 we have shown pre¬
viously that a minority of patients with directly measured PPG
<12 mm Hg remain at risk of variccal bleeding." Further¬
more, it is recognised that gastric varices occur at lower portal
pressures than oesophageal varices."
The aim of this study was to analyse retrospectively the
clinical outcome of patients who have bled from gastric varices
and in whom a TIPSS procedure was undertaken. These
patients were compared with a group of patients who bled
from oesophageal varices. Haemodynamic and clinical corre¬
lations were made, and patients who bled at a PPG of S 12 mm
Hg were studied to identify whether they differed from the
group who bled at higher portal pressures with regard to site
of variccal bleed, rebleeding, and survival.
PATIENTS AND METHODS
Patients
During the period between September 1991 and August 2000,
436 patients underwent a TIPSS procedure in our centre. In
377 patients the primary indication was variccal haemorrhage
with the remainder having ascites (n=44), portal hyperten¬
sive gastropathy (n=9), or other indication (n=6). Patients
were excluded if the TIPSS procedure had failed (n=24), if
they had participated in a trial comparing TIPSS versus TIPSS
and banding and were randomised to the TIPSS and banding
arm (where TIPSS angiographic surveillance was performed
for the first year after TIPSS only, n=40), or if there were
insufficient data (n=21). After exclusions there were a total of
292 patients from which the study populations were selected.
Abbreviations: TIPSS, transjugular intrahepatic portosystemic stent
shunt; PPG, portal pressure gradient; GVB, gastric variceal bleeding;
OVB, oesophageal variceal bleeding; HVPG, hepatic venous pressure
gradient.
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varices (n= 12) (n=8)
Age (y)
Sex
50.9(1.6) 53.6 (0.8) 45.4 (5.4) 52.5 (4.0)
Male 22 (55.0%) 150 (64.7%) 6 (50%) 4 (50%)
Female 18 (45.0%) 82 (35.3%) 6 (50%) 4 (50%)
Aetiology
Alcoholic liver disease 28 (70.0%) 140 (60.3%) 5 (41.8%) 5 (62.5%)
Primary biliary cirrhosis 1 (2.5%) 2 (12.1%) 1 (8.3%) 0
Hepatitis C 1 (2.5%) 16 (6.9%) 2 (16.7%) 0
Cryptogenic cirrhosis 7 (17.5%) 18 (7.8%)** 1 (8.3%) 1 (12.5%)
Autoimmune 1 (2.5%) 8 (3.4%) 0 0
Cystic fibrosis 0 5 (2.2%) 1 (8.3%) 0
Primary sclerosing cholangitis 1 (2.5%) 4 (1.7%) 1 (8.3%) 2 (25%)
Hepatitis B 1 (2.5%) 4 (1.7%) 1 (8.3%) 0
Other 0 9 (3-9%) 0 0
Child-Pugh score 9.3 (0.5) 9.8 (0.2) 9.3 (0.7) 10.9 (0.9)
Portal pressure gradient (mm Hg)
Pre-TIPSS 15.8 (0.8) 21.4 (0.5)** 22.5 (3.0)* 15.6 (2.5)
Post-TIPSS 6.7 (0.6) 7.2 (0.3) 7.1 (1.4) 6.9 (1.9)
Reduction post-TIPSS 9.2 (0.8) 14.2 (0.5)** 15.4 (3.5)* 8.8 (2.1)
Median follow up (months) 36.7 (5.1) 19.8 (13)** 16.8 (5.1) 8.1 (4.9)*
TIPSS, transjugular intrahepatic portosystemic stent shunt; PPG, portal pressure gradient.
*p<0.05, **p<0.001 compared with gastric varices.
Table 2 Patient characteristics depending on the portal pressure gradient (PPG) at










Alcoholic liver disease 27 (71.1%)
Primary biliary cirrhosis 3 (7.9)
Hepatitis C 0
Cryptogenic cirrhosis 5 (13.2%)
Autoimmune 1 (2.6%)
Cystic fibrosis 0
Primary sclerosing cholangitis 1 (2.6%)
Hepatitis B 1 (2.6%)
Other 0
PPG (mm Hg)
Pre-TIPSS 9.8 (0.4) 22.1 (0.4)
Post-TIPSS 4.2 (0.5) 7.6 (0.3)
Reduction post-TIPSS 5.6 (0.5) 14.6 (0.5)
Child-Pugh score 9.1 (0.5) 9.9 (0.2)
Indication
Oesophageal variceal bleeding 20 (52.6%) 212 (83.5%)
Gastric variceal bleeding 14 (36.8%) 26 (10.2%)
Gastric and oesophageal variceal bleeding 2 (5.3%) 10 (3.9%)
Ectopic variceal bleeding 2 (5.3%) 6 (2.4%)











































In the eligible patients, 40 patients had a TIPSS performed
for GVB, 232 for OVB alone, 12 for both GVB and OVB, and
eight for ectopic variceal bleeding. All varices were thought to
have arisen because of portal hypertension secondary to
parenchymal liver disease. In 38 cases of GVB, bleeding was
believed to have been from varices in the fundus or cardia, and
two cases from varices along the lesser curve. Table 1
illustrates the baseline characteristics of these patients. There
were more patients with cryptogenic cirrhosis in the OVB
group.
In order to make hacmodynamic and clinical correlations,
patients were further divided into two groups according to the
direct PPG at the time of TIPSS. Group I included those
patients with PPG SI2 mm Hg (n = 38) and group 2 those
patients with a PPG >12 mm Hg (n=254). The baseline char¬
acteristics of these patients are detailed in table 2. There was
no difference in the age, sex, aetiology of liver disease, or
Child-Pugh score between the two groups.
TIPSS procedure
All patients were referred for TIPSS from within the Royal
Infirmary, Edinburgh, or from other hospitals within Scot¬
land. Our unit operates a 24 hour facility for emergency TIPSS
insertion. TIPSS insertion was performed by an experienced
radiologist using an established technique." Where the origi¬
nal pressure was >12 mm Hg, the aim was to reduce the PPG
to below 12 mm Hg. The patency of the TIPSS shunt was
assessed by Dopplcr ultrasound within a week of insertion,
www.guljnl.com
























20 40 60 80 100
Time (months)
Time (months) 0 10 20 30 40 50 60
months months months months months months months
Gastric 40 25 17 17 15 14 9
varices
Oesophageal 232 114 85 52 37 22 6
varices
Figure 1 Kaplan Meier graph of rebleeding for all patients who
bled from gastric and oesophageal varices treated with a
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Time (months)
p = 0.046
Time (months) 0 10 20 30 40 50 60
months months months months months months months
Gastric 40 25 22 20 18 16 11
varices
Oesophageal 232 128 101 60 40 25 8
varices
Figure 2 Kaplan Meier graph of survival for all patients who bled
from gastric and oesophageal varices treated with a transjugular
intrahepatic portosystemic stent shunt.
and by portogram at three months then six monthly thereaf¬
ter or whenever there were clinical features suggestive of
shunt insufficiency.
Follow up
Patients were followed up clinically at three monthly intervals
to assess their clinical condition with emphasis being placed
on any episodes of encephalopathy and variceal reblceding.
Early mortality was defined as death within four weeks of the
variceal haemorrhage. Variceal reblceding was defined as sub¬
sequent variccal bleeding manifested by hacmatemesis and/or
mclaena, requiring an unscheduled endoscopy, and accompa¬
nied by a reduction in haemoglobin concentration by 20 g/1 or
more. Shunt insufficiency (defined as an increase in PPG S 12
mm Hg or a 20% rise above the immediate post-TIPSS PPG)
was assessed based on the results of routine follow up angio¬
graphic surveillance. Any episodes of shunt insufficiency were
treated by balloon angioplasty, shunt extension, or parallel
shunt placement, as required to maintain patency. Follow up
time was defined as the time interval in months between the
initial TIPSS insertion to cither the most recent clinic review,
liver transplantation, or death.
Statistical analysis
All results arc expressed as mean (SEM) or percentage, where
indicated. Statistical significance for parametric data was
determined using Student t tests, and for non-parametric data
using the X ar>d Mann Whitney U tests. The Kaplan-Meier
method was used to analyse patient survival, and cumulative
reblecding risk, with comparison between the two groups, was
determined by the log rank test. Univariate and multivariate
relations between survival and variables of interest in those
patients who bled from gastric varices and oesophageal varices
at a PPG >12 mm Hg was performed using Cox regression
analysis. These variables were: aetiology of cirrhosis (alcoholic
or non-alcoholic), site of bleeding (from gastric or oesophageal
varices), sex and age of the patients, encephalopathy, ascites,
bilirubin, prothrombin time, albumin, and the time interval
between the index bleed and TIPSS insertion. Significance
was taken at p<0.05 for all tests. All statistical analysis was
performed using the SPSS package (version 10; SPSS Inc.,
Chicago, Illinois, USA).
RESULTS
PPG before and after TIPSS
PPG prc-TIPSS was significantly higher in patients who bled
from oesophageal varices compared with GVB (21.4 (0.5) v
15.8 (0.8) mm Hg; p<0.001). Following TIPSS insertion, all
patients who had bled from gastric varices had PPG reduced to
<12 mm Hg, while in 22 (9.5%) patients who bled from
oesophageal varices the post-TIPSS PPG was >12 mm Hg.
However, mean PPG post-TIPSS was similar in the GVB and
OVB groups (table 1).
Rebleeding
The mean follow up period was 19.8 (1.3) and 36.7 (5.1)
months in the OVB and GVB groups, respectively (p < 0.01).
The longer follow up time in the GVB group may reflect the
greater proportion of patients recruited in or prior to 1995
compared with the OVB group (62.5% v 29.7%; p<0.001). In
this time, 34 (14.7%) patients in the OVB group rebled and
eight (20%) patients in the GVB group reblcd. The cumulative
risk of rcbleeding was similar in both groups (fig I). In 31
(73.5%) cases of variceal rcbleeding there was evidence of
TIPSS dysfunction.
Mortality
During this follow up period there was a significant difference
in the cumulative risk of death in favour of the GVB group
(p<0.05 by Kaplan-Meier method). This was true for 30 day
mortality (15% v 23.8%), one year mortality (30.7% v 38.6%),
and five year mortality (49.5% v 74.9%) (fig 2). There was no
significant difference in the time interval to TIPSS from the
variceal bleed (5.4 (0.9) days v 4.9 (0.4) days for the GVB and
OVB groups, respectively; NS). The principal cause of death
was similar in both groups, with liver failure or sepsis
accounting for 82 (64.1%) deaths in the OVB group and 12
(75%) deaths in the GVB group.
Encephalopathy
The rate of encephalopathy prior to TIPSS insertion was simi¬
lar in the OVB and GVB groups (27.6% v 30.0%; NS). There was
no significant difference in episodes of new or worsening
encephalopathy in the oesophageal and gastric varices groups
(16.35% v 17.5% respectively; NS) All episodes of encepha¬
lopathy were managed initially with lactulose and protein
reduction. In three cases the shunt was reduced in size, and in
eight cases it was necessary to block the shunt with a filter
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Time (months)
Time (months) 0 10 20 30 40 50 60
months months months months months months months
Gastric 26 14 14 14 12 11 8
varices
Oesophageal 212 114 87 54 37 23 8
varices
Figure 3 Kaplan Meier graph of survival for all patients who bled
from gastric and oesophageal varices at a portal pressure gradient
of greater than 1 2 mm Hg.
Shunt insufficiency
There was no difference in the incidence of shunt insufficiency
between the two groups (42.67% v 55% in the OVB and GVB
groups, respectively). In one patient in the GVB group
problems with maintaining TIPSS patency resulted in elective
surgery with the creation of a distal splenorenal shunt.
Orthotopic liver transplantation
Twenty one patients required an orthotopic liver transplanta¬
tion, 19 (8.2%) in the oesophageal varices group and two (5%)
in the gastric varices group (NS).
Correlations between portal pressure and clinical
outcome
When patients with a prc-TIPSS PPG ^ 12 mm Hg were ana¬
lysed, it was clear that GVB accounted for many more cases
than for those patients who bled at a PPG >12 mm Hg (36.8%
v 10.2%; p<0.001) (table 2). However, there was no overall
difference in the reblccding rate and mortality in the two
groups. Rates of shunt insufficiency and encephalopathy were
also similar in the two groups. In group I, the final PPG post-
TIPSS was similar in those patients that rebled (n = 9)
compared with those that did not rebleed (n=29) (5.1 (0.1)
mm Hg and 3.9 (0.5) mm Hg, respectively; p=0.2). In group 2,
PPG post-TIPSS was significantly higher in patients who
rcbled post-TIPSS (n = 35) compared with those that did not
rebleed (n=219) (9.4 (0.8) mm Hg and 7.3 (0.3) mm Hg,
respectively; p<0.005). In addition, 75% of patients in group 2
who rebled had a PPG post-TIPSS of >7 mm Hg.
When patients who bled from either oesophageal varices or
gastric varices with a PPG pre-TIPSS of >12 mm Hg were
analysed, there was a significant difference in mortality in
favour of gastric varices (p=0.02 by Kaplan-Meier method).
Thirty day mortality (12% v24.2%), one year mortality (33.8%
v40.4%), and five year mortality (39.4% v 79.1%) were all sig¬
nificantly better in the gastric varices group (fig 3). Univariate
analysis showed that the following variables were associated
with higher mortality in patients who bled from gastric or
oesophageal varices at a PPG >12 mm Hg: increasing age
(p<0.01), bleeding from oesophageal varices (p=0.04), high
prothrombin time (p<0.05), high bilirubin (p<0.001), low
albumin (p=0.001), presence of ascites (p<0.001), and
encephalopathy (p<0.05). Multivariate analysis of these vari¬
ables revealed that older age of patients (p<0.05), high
bilirubin (p<0.05), and a low albumin (p<0.001) were inde¬
pendent variables predicting mortality. There was no differ¬
ence in the reblceding rate. Mortality and rebleeding rates
were similar in the GVB and OVB groups who bled at a PPG
€ 12 mm Hg.
DISCUSSION
Historically, the management of GVB has been suboptimal.
Endoscopic measures have met with varying degrees of
success6 although current UK guidelines recommend endo¬
scopic treatment as the first line in the management of the
acute gastric variceal bleed.'"*" " Iatrogenic complications
such as embolic phenomena and the potential for equipment
damage may limit the use of tissue adhesives." " Thrombin
seems to be promising but large multicentre controlled trials
have yet to emerge. Previous studies have used bovine
thrombin which has the potential risk of prion
transmission* * although our experience with human
thrombin has been promising so far.*" Surgical shunts may be
of value in patients with early liver disease*'"*1 but have the
disadvantage of high mortality in patients with advanced liver
disease, particularly in the emergency setting.*4
Our findings show that TIPSS is equally effective in the pre¬
vention of rebleeding from gastric and oesophageal variceal
haemorrhage. Incidences of shunt insufficiency and encepha¬
lopathy were similar in both groups. These results arc similar
to those of an earlier study in our unit.1* We have adopted a
policy of referring patients with bleeding gastric varices and a
patent portal vein directly for TIPSS insertion. A further find¬
ing is the significant numbers of patients that bleed at a PPG
of < 12 mm Hg, and gastric varices account for a sizeable pro¬
portion of this group.
It has been reported that patients with large gastric varices
have a lower portal pressure than those with oesophageal
varices," which may be as a result of the development of
gastro-rcnal porto-systcmic shunts.14 Watanabe et al also dem¬
onstrated increased collateral flow at the expense of reduced
portal venous flow in patients with gastric varices. The authors
proposed that reduced portocollatcral resistance may account
for the latter finding. It is however unclear as to why patients
bleed at portal pressures of < 12 mm Hg. Other factors such as
the presence of red spots, variceal size, and that of gastritis
may be important. Therefore, particularly in patients with
gastric varices, it would not be safe to regard reducing a PPG
of < 12 mm Hg as a therapeutic goal. Indeed, for patients who
bleed at a PPG S 12 mm Hg, our results demonstrate that PPG
post-TIPSS is not statistically different in patients who reblccd
compared with those that do not. However, for patients who
bleed at a PPG > 12 mm Hg, the post-TIPSS PPG is greater for
patients who rcblecd, with most of these patients having a
PPG post-TIPSS of >7 mm Hg. These results suggest that in
group 2 (that is, predominantly oesophageal variccal bleeders)
a therapeutic goal of a post-TIPSS PPG <7 mm Hg would be
reasonable.
TIPSS has recently been studied in the management of
refractory variceal bleeding cither from gastric alone" or gas¬
tric compared with oesophageal varices.*6 " Our rebleeding
rates are comparable with these studies. Chau et al also found
that portal pressure in patients who had early rebleeding
before seven days was lower in patients with GVB.*6 Rees and
colleagues*' did not demonstrate significant differences in PPG
prior to TIPSS which was >20 mm Hg in both groups. This
study was limited by a small number of patients and a short
follow up period.
An interesting finding in the present study is that of
significantly better survival in the GVB group compared with
the OVB group, despite the two groups being matched for age,
aetiology of liver disease, Child-Pugh score, and prc-TIPSS
encephalopathy. We have previously shown the latter two
parameters to strongly predict mortality post-TIPSS.** It has
also been observed that mortality following a variceal
haemorrhage is highest in the first few days after the index
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bleed.39 Both the OVB and GVB groups were matched for the
time of intervention with TIPSS after the variccal bleed and
thus there was no undue selection of patients in either group
who were likely to have a better survival. The difference in
mortality between the two groups appears to be confined to
patients who bleed at a PPG >12 mm Hg, and is particularly
striking for long term mortality. Older age of the patient, high
bilirubin, and low albumin in keeping with more advanced
liver disease were independent predictors of mortality. The
causes of death in both groups were predominantly liver failure
and sepsis. The earlier study in our unit13 had demonstrated a
trend towards improved survival among the GVB group. The
present study had a greater number of patients and a longer
follow up period, which may account for the now significant
findings. The longer follow up period in the GVB group is likely
to be a result of the combination of reduced mortality and
larger numbers of patients recruited before or in 1995.
It is important to highlight the observation of a significantly
higher PPG prior to TIPSS insertion in patients with OVB. We
have previously shown that a hepatic venous pressure gradient
(HVPG) of >16 mm Hg predicted mortality in patients with
alcoholic cirrhosis.50 This finding was reinforced in a later study
by Patch and colleagues.51 HVPG measurements made within
the first or second week had the greatest predictive value. Nearly
all of our patients had their portal pressures measured at the
time of TIPSS within the first two weeks of the index variccal
bleed. A recent study by Moitinho and colleagues53 assessed the
prognostic value of early portal pressure measurements follow¬
ing an acute variceal bleed. The striking finding in this study
was that patients with a HVPG of >20 mm Hg had a one year
mortality of 64% compared with 20% for that of patients with
HVPG <20 mm Hg (p<0.004). In our group, all patients who
bled from oesophageal varices had a mean PPG >21 mm Hg. It
is therefore plausible that the difference in PPG between the
OVB and GVB groups may account for the difference in the
observed mortality, although the reason why PPG affects
mortality is not understood. We have not shown a difference in
rebleeding rates as the rcblceding rate was so low in both groups
following TIPSS insertion that much larger numbers may be
needed to show any differences. This illustrates the impressive
efficacy of TIPSS in preventing variceal rebleeding.
In conclusion, our study demonstrates that TIPSS is very
effective in the prevention of variceal rebleeding irrespective of
whether patients have had an OVB or a GVB. Mortality is sig¬
nificantly better in the GVB group who bleed at a PPG >12
mm Hg, and warrants further study. The findings also
highlight the significant role of GVB in patients who bleed at
a PPG 12 mm Hg, and challenges the use of this cut off value
as a treatment goal, particularly in patients with gastric
varices. Our results also suggest that clinicians should aim for
a PPG post-TIPSS of <7 mm Hg for patients who have variceal
bleeding at a PPG > 12 mm Hg. TIPSS therefore has a major
role in the management of GVB, which can be very difficult to
control by other measures. Further long term prospective
studies would assist in clarifying the effect of TIPSS on
mortality in the GVB group compared with OVB.
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Randomised controlled trial of long term portographic
follow up versus variceal band ligation following
transjugular intrahepatic portosystemic stent shunt for
preventing oesophageal variceal rebleeding
D Tripathi, H F Lui, A Helmy, K Dabos, E Forrest, A J Stanley, R Jalan, D N Redhead, P C Hayes
Gut 2004;53:431-437. doi: 10.1136/gut.2003.013532
Background/aims: Transjugular intrahepatic portosystemic stent shunt (TIPSS) is effective in the prevention
of variceal rebleeding but requires invasive portographic follow up. This randomised controlled trial aims
to test the hypothesis that combining variceal band ligation (VBL) with TIPSS can obviate the need for long
term TIPSS sup/eillance without compromising clinical efficacy, and can reduce the incidence of hepatic
encephalopathy.
Patients/methods: Patients who required TIPSS for the prevention of oesophageal variceal rebleeding
were randomised to either TIPSS alone (n = 39, group 1) or TIPSS plus VBL (n = 40, group 2). In group 1,
patients underwent long term TIPSS angiographic surveillance. In group 2, patients entered a banding
programme with TIPSS surveillance only continued for up to one year.
Results: There was a tendency to higher variceal rebleeding in group 2 although this did not reach
statistical significance (8% v 15%; relative hazard 0.58; 95% confidence interval (CI) 0.15-2.33;
p = 0.440). Mortality (47% v40%; relative hazard 1.31; 95% CI 0.66-2.61; p = 0.434) was similar in the
two groups. Hepatic encephalopathy was significantly less in group 2 (20% v 39%; relative hazard 2.63;
95% CI 1.11-6.25; p = 0.023). Hepatic encephalopathy was not statistically different after correcting for
sex and portal pressure gradient (p = 0.136).
Conclusions: TIPSS plus VBL without long term surveillance is effective in preventing oesophageal variceal
rebleeding, and has the potential for low rates of encephalopathy. Therefore, VBL with short term TIPSS
surveillance is a suitable alternative to long term TIPSS surveillance in the prevention of oesophageal
variceal rebleeding.
See end of article for
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Variccal bleeding is a serious complication of portalhypertension with inhospital mortality of 30-50%depending on the severity of liver disease.' Mortality
following variceal rebleeding is as high as 78% in patients
with advanced hepatic decompensation.2 Transjugular intra¬
hepatic portosystemic stent shunt (TIPSS) is superior to
variceal band ligation (VBL) in the prevention of variceal
rebleeding although patients are more likely to develop
hepatic encephalopathy and patient survival is unaffected.'-"
Long term patency of TIPSS is also a clinical problem. Studies
indicate that without regular TIPSS surveillance and inter¬
vention, approximately 50% of stents will occlude after one
year.12-" Regular invasive portographic surveillance, which is
essential for maintaining shunt patency, is not available in all
centres, and places an additional burden on resources.
Moreover, non-invasive methods of assessing TIPSS patency
such as Dopplcr ultrasound arc not as sensitive as regular
portography,and lead to a higher rebleeding rate.' In any
case, Doppler ultrasound does not allow for interventions,
such as balloon angioplasty and rc-stcnting, or for measure¬
ment of portal pressures.
VBL has replaced injection sclerotherapy in most centres as
the favoured endoscopic treatment for the prevention of
variccal reblecding. VBL is associated with a high rate of
rebleeding, particularly in the month following the index
variccal bleed.7 However, once the varices have been
eradicated, VBL may be as effective as a patent TIPSS in
preventing variccal rebleeding. Thus following variceal
eradication in a patient with a TIPSS, it may not be necessary
to continue TIPSS surveillance to maintain TIPSS patency. It
is not known whether terminating angiographic TIPSS
surveillance following successful VBL will compromise the
variceal rcblecding rate.
We hypothesised that combining VBL and TIPSS with
short term portographic surveillance would be as effective as
TIPSS alone with long term surveillance in the prevention of
oesophageal variceal rebleeding. Patients in the former group
could benefit from the reduced need for angiographic
surveillance and incidence of hepatic encephalopathy as
TIPSS is allowed to occlude following variccal eradication.
There may also be cost advantages in using VBL instead of
long term TIPSS surveillance.
Therefore, the aim of this randomised controlled trial was
to compare the efficacy of TIPSS plus VBL without long term
surveillance, with TIPSS and long term surveillance in the
secondary prevention of oesophageal variceal reblceding.
Other potential differences such as mortality, encephalo¬
pathy, and costs were also explored.
METHODS
The trial was undertaken with the approval of the local
research ethics committee, written informed consent of each
subject, and in accordance with the Declaration of Helsinki
(1989) of the World Medical Association.
Abbreviations: PPG, portal pressure gradient; TIPSS, transjugular
intrahepatic portosystemic stent shunt; VBL, variceal band ligation; OLT,
orthotopic liver transplantation
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Patients selection
Between December 1995 and August 2000, a total of 303
patients were referred for TIPSS insertion from centres
throughout Scotland. All TIPSS procedures were performed
at the Royal Infirmary, Edinburgh. All patients presenting
with bleeding oesophageal varices were considered for
inclusion into the trial. Exclusion criteria are as follows: (I)
technical failure of TIPSS insertion; (2) age <18 or
>85 years; (3) bleeding gastric or ectopic varices; (4) portal
vein thrombosis; (5) Budd-Chiari syndrome; (6) ascites as a
primary indication for TIPSS; (7) advanced cardiopulmonary
disease; (8) malignancy with prognosis that will affect study
outcome; (9) inability to give informed consent; (10)
previous variccal haemorrhage; and (II) pregnancy or
women of childbearing potential not taking contraception.
Patients were recruited after hacmodynamic stabilisation.
Randomisation and treatments
Prior to TIPSS, all patients were resuscitated with fluids and
blood or blood products, and underwent endoscopy with VBL
or sclerotherapy using 5% ethanolamine oleate if there was
active bleeding. In some patients, pharmacological interven¬
tion with octreotide or tcrlipressin was undertaken.
Randomisation was performed following TIPSS insertion
and only after initial control of bleeding and haemodynamic
stabilisation. Patients were allocated to cither group 1 or
group 2 using the sealed envelope method."
Group 1: TIPSS alone
At the time of the index endoscopy, active variccal bleeding
was noted in 23 patients. VBL was performed in 13 patients,
VBL and sclerotherapy in one patient, and sclerotherapy in
six patients. In three patients it was not possible to control
bleeding with endoscopic therapies requiring the use of
balloon tamponade. In 16 patients there were stigmata of
recent bleeding but no active bleeding, with three patients
having VBL and one both VBL and sclerotherapy. The
remainder proceeded straight to TIPSS. All TIPSS procedures
in recruited patients were performed or closely supervised by
a skilled interventional radiologist using a standard techni¬
que described elsewhere.2" All patients were administered
broad spectrum antibiotics pre- and for 48 hours post¬
procedure. Ten to 14 mm diameter expandable metal stents
(Wallstcnt, Schneider, Switzerland) were used with the aim
of reducing the portal pressure gradient (PPG) to
<12 mm Hg or by 3=20%. This was achieved in 36 (92%)
and 37 (93%) patients in groups 1 and 2, respectively. Two or
more stents were used, if necessary, to cover the entire length
of the tract between the hepatic vein and portal vein.
Following creation, TIPSS function was assessed at one
week by colour Doppler ultrasound. Routine portographic
follow up with intervention, if required, to maintain shunt
patency was undertaken at six monthly intervals thereafter.
However, additional TIPSS portography was also performed
where there was clinical suspicion of TIPSS insufficiency,
such as reblccding.
Group 2: TIPSS plus VBL
At the time of the index TIPSS, 28 patients were actively
bleeding from varices. Eighteen patients required VBL, two
patients VBL and sclerotherapy, and four sclerotherapy. Four
patients failed endoscopic therapy requiring balloon tampo¬
nade and urgent TIPSS. In 12 patients there were stigmata of
recent bleeding but not active bleeding, with six patients
having VBL, and the remainder proceeding to TIPSS. The
TIPSS procedure was performed as above. Following satis¬
factory haemodynamic stabilisation of the patient, VBL was
undertaken or closely supervised by an experienced endosco¬
pist. One of two banding devices was used (Spccdbandcr,
Boston Scientific, Herts, UK; or 6-Shootcr Saecd Multi-Band
Ligator, Cook, Ireland), deploying 5 or 6 bands, respectively.
Varices just above the gastro-oesophageal junction were
banded using a single band at a time. A varix was considered
eradicated if the column had disappeared or if they could not
be sucked into the banding device. It should be noted that in
patients with a patent TIPSS, varices often appear collapsed
and therefore require suction for their size to be appreciated
and VBL to be performed.
Repeat endoscopy with or without VBL was performed
within a week of TIPSS insertion and at two weekly intervals
until variccal eradication. Intervals were extended to three
and six months thereafter. Shunt function was assessed as
previously mentioned. Portographic follow up was continued
for up to 12 months following TIPSS insertion in all patients
but was discontinued earlier in patients where variceal
eradication was achieved.
Follow up
All subjects were followed up until death, liver transplanta¬
tion, or lost to follow up. A specialist research nurse
coordinated clinical follow up, with full clinical examination




Reblccding was defined as subsequent hacmatcmcsis or
melacna with a 20 g/1 reduction in haemoglobin requiring an
unscheduled endoscopy.
Early mortality
This was defined as death within six weeks of the index
variccal bleed.
Hepatic encephalopathy
This was assessed prior to and during follow up, as already
mentioned, and was classified as de novo or deterioration of
pre-existing encephalopathy using the criteria of Parson-
Smith and colleagues.22
Shunt insufficiency
This was defined as an increase in PPG to >12 mm Hg or an
increase in PPG of more than 20% of the immediate post-
TIPSS value.'4
Outcomes were assessed at 6, 12, and 24 months. The
primary outcome of the study was variceal reblceding.
Secondary outcomes were mortality, incidence of encephalo¬
pathy, and orthotopic liver transplantation (OLT).
Sample size calculation
Sample size was calculated to show that both treatments
were equally effective in preventing rcblceding.21 Assuming
that both treatments were expected to have a 10% variceal
rcblecding rate, and with a type I error (a) of 0.05 and a type
II error (P) of 0.2, 38 patients would be required in each arm
to demonstrate the equivalence (assumed as <17% differ¬
ence) of the two treatments. Once sufficient numbers were
reached in each arm, recruitment stopped and the study was
terminated four months after the last patient was recruited.
Calculation of costs of treatment
Data regarding the time spent by each patient in a general,
intensive care, or high dependency ward during the follow up
period were retrieved. Costs were based on data from the
National Health Service, our Department of Radiology, and
our Endoscopy Unit. Costs are expressed as cost per patient
and also the cost per month survival. The latter is the overall
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Table 1 Characteristics of the two groups at baseline
Characteristic TIPSS (n = 39) TIPSS+VBL (n = 40)
Age (y) (range) 53.9(11.2] (32-74) 55.9(11.4) (30-82)
Male sex (n {%)} 30 (77%) 22 (55%)'
Child-Pugh score (at baseline) 9.2(2.1) 8.7(2.3)
Aetiology (n (%))
Alcoholic 28(72%) 35 (88%)
Abstained from alcohol 8(29%) 10(29%)
Non-alcoholic 11 (25%) 5(13%)
PPG (mm Hg)
Pre-TIPSS 25.2 (6.6) 20.1 (6.1)"
Post-TIPSS 7.2 (4.0) 6.6 (4.4)
Requirement for mechanical ventilation (n (%}} 5(13%| 6(15%)
Time from index bleed to randomisation (days) 8.1 (6.8) 6.3 (5.5)
Time from TIPSS insertion to randomisation (days) 3.3 (2.9) 2.9(3.3)
Blood transfusion at randomisation (units) 3.5 (4.2) 2.7 (2.6)
Hypotensive at randomisation (n (%)) 6(15%) 4(10%]
Values are mean (SD) unless stated otherwise.
TIPSS, transiugular intrahepatic portosystemic stent shunt; VBL, variceal band 1 gation; PPG, portal pressure
gradient.
*p = 0.040; "p<0.001.
cost per patient divided by the follow up time in months
(table 4).
Costs of ward beds
The cost per day in a general ward is £350, high dependency
ward is £500, and an intensive care ward is £1200. These
costs include staff and consumables.
Cost of TIPSS procedure and follow up
The consumable cost of the TIPSS procedure is £1679. Follow
up costs are as follows: routine portography (£205), balloon
angioplasty (£371), shunt reduction (£753), insertion of a
caval filter and coils for the purposes of occluding the shunt
(£785), shunt extension (£927), and insertion of a parallel
shunt (£1462).
Cost of VBL
The cost of the endoscopy session is £250. Where VBL is also
required, the overall cost increases to £350.
Statistical analysis
Data were analysed on an intention to treat basis. Baseline
characteristics were described in the two groups using
summary statistics. The y2 test was used to compare non-
parametric data, and the Student's t test was used to compare
parametric data. Kaplan-Meier graphs and log rank tests
were applied to survival, rcblceding, encephalopathy, and
shunt insufficiency. Cox regression analysis was used to
control for sex and PPG pre-TlPSS. Significance was taken at
the 5% level. The SPSS statistics package (version 9; Chicago,
Illinois, USA) was used for all statistical analyses.
RESULTS
Patients recruited
Seventy nine patients met the inclusion criteria, with 39 were
randomised to group 1 and 40 to group 2 (fig I). There were
no patients excluded from the trial after randomisation.
Mean follow up period was 22.5 (17.2) months (range 0.1-
58.9) and 26.6 (18.1) months (range 0.3-64.1) in groups I
and 2, respectively.
Baseline characteristics
There were more male patients and PPG prc-TIPSS was
higher in the TIPSS alope arm. Clinical parameters of the two
groups are shown in table 1.
Procedures
TIPSS insertion was complicated by an intraperitoneal bleed
in one patient in group 1. In another patient in group 2, there-
was a biliary leak leading to a percutaneous fistula and
suprahepatic abscess. This patient developed respiratory
failure and staphylococcal septicaemia requiring antibiotics,
vasoconstrictor therapy, and ventilation. The suprahepatic
abscess was drained pcrcutaneously. The patient then made
an uneventful recovery. In 73 (92%) patients there was a
reduction in PPG following TIPSS insertion to <12 mm Hg,
and in all patients except one there was a >20% reduction in
PPG post-TIPSS. Mean diameter of the stents was similar in
the two groups.
VBL post-TIPSS insertion was performed successfully in 38
patients in group 2. One patient rebled before VBL could take
place and another refused banding. A total of 176 endosco¬
pies were performed during the follow up period. VBL was
required in 69 endoscopies, with 47 (68%) procedures
performed in the first three sessions. Successful eradication
Figure 1 Flow diagram of patient recruitment (see text for exclusion
criteria). Patients who reached the end points after randomisation and
withdrew from the trial had one of the following events: (1) death; (2)
liver transplantation; or (3) variceal rebleeding.
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Table 2 Details of trial outcomes
TIPSS/TIPSS VBL relative hazard over entire
TIPSS TIPSS+VBt follow up (95% CI)* p Value*
Mortality (n (%)) 1.31 (0.66-2.611/1.10(0.53-2.28) 0.434/0.803
6 month 5(13%) 2(5%)
1 2 month 8 (21%) 6(15%)
24 month 14(36%) 11 (28%)
Variceal rebleeding (n (%)) 0.58 (0.15-2.331/0.39(0.09-1.77) 0.440/0.221
6 month 0 3 (8%)
1 2 month 1 (3%) 5(13%)
24 month 3 (8%) 6(15%)
Hepatic encephalopathy (n (%}) 2.63 (1.11-6.25)/2.10 (0.79-5.58) 0.023"/0.136
6 month 5(13%) 3(8%)
1 2 month 10(26%) 3(8%)
24 month 14(26%) 7(18%)
*TIPSS versus TIPSS+VBL. The first value refers to uncontrolled analysis. The second value refers to analysis controlled for sex and pre-TIPSS portal pressure
gradient.
**p = 0.386 for comparisons in the first six months of follow up only.
of varices was achieved in 28 patients following an average of
2.8 (0.3) sessions. Four patients reblcd prior to eradication
and were entered into a regular long term TIPSS surveillance
programme instead of regular VBL. Two patients died before
eradication could take place. Another six patients did not
complete the banding programme either because they were
lost to follow up or because they refused further banding.
Post-banding ulceration occurred in 12 (30%) patients.
Rebleeding
In group 1, three episodes of variceal reblecding occurred in
three patients (8%) during follow up, two with Child C and
one with Child B disease (table 2). In two patients reblecding
proved to be rapidly fatal while in the third case the shunt
was insufficient with a PPG of 18 mm Hg and evidence of
hepatic vein stenosis requiring shunt extension. This patient
did not have a further rcblced and made a satisfactory
recovery. In addition, there were four patients who rcbled
from non-variccal sources (two from banding ulceration, one
from oesophagitis, and another from a Mallory Weiss tear).
In group 2 there were six episodes of variccal rcblceding in
six patients (15%) during follow up, two with Child A and
four with Child C disease (table 2). Three of these patients
had one further episode of variccal reblccding during follow
up. Varices were eradicated in only two patients. In all cases
there was evidence of TIPSS insufficiency requiring rc-
stenting or balloon angioplasty. In all eases except one,
variceal rcbleeding was controlled. One patient who rebled
from gastric varices initially responded to thrombin injection
and balloon angioplasty of TIPSS. This patient had gastric
varices at randomisation. However, he reblcd again within
24 hours from gastric varices, despite a patent TIPSS. He
unfortunately died from oesophageal rupture secondary to
balloon tamponade. Three patients rcbled from non-variceal
sources (one from oesophagitis, one from a duodenal ulcer,
and another from severe portal hypertensive gastropathy).
There was no significant difference in the cumulative risk
of variceal reblccding by Kaplan-Meier analysis (p = 0.440;
relative hazard 0.58; 95% confidence interval (CI) 0.15-2.33)
(fig 2, table 2). The two groups were similar even after
controlling for PPG prc-TIPSS and sex (table 2).
Mortality
In group I, there were 17 deaths (44%) in total during follow
up (table 2). Early mortality occurred in two patients from
multiorgan failure resulting from the variccal bleed. The
other causes of death were renal failure secondary to genta-
micin therapy for a presumed shunt infection (n=l),
cerebrovascular accident (n = 2), liver failure following
non-variccal reblecding (n = 4), and for the remainder,
multiorgan failure and sepsis.
In group 2, there were 15 deaths (38%) in total during
follow up (table 2). One patient died within six weeks of the
index bleed from aspiration pneumonia. The causes of death
were liver failure following variccal rebleeding (n = 2),
oesophageal rupture following insertion of a Sengstakcn
tube (n = I), sepsis after a colectomy (n = 1), cerebrovascular
accident (n = 2), multiorgan failure (n = 7), and pneumonia
(n = 1).
There was no statistically significant difference in the
cumulative survival by the Kaplan-Meier method between
the two groups (p = 0.434; relative hazard 1.31; 95% CI 0.66-
2.61) (fig 3, table 2). The two groups were similar even after
controlling for PPG pre-TIPSS and sex (table 2).
Encephalopathy
In group 1, 15 patients (39%) in total developed encephalo¬
pathy during follow up (table 2). Four patients experienced
deterioration of pre-existing encephalopathy. Two patients
responded to conservative therapy with lactulose and protein
restriction while the two other patients died with severe
encephalopathy and liver failure. The remainder (28%) had
dc novo encephalopathy. These patients were treated
conservatively, with two patients requiring occlusion of the
shunt with a filter and subsequent entry into a banding
programme.
In group 2, eight patients (20%) in total developed
encephalopathy during follow up (table 2). Two patients
were enccphalopathic prior to TIPSS. Both responded to
conservative therapy. The remainder (15%) had de novo
encephalopathy. Four responded to conservative therapy and
two required occlusion of the shunt.
There was a significance difference (relative hazard 2.63;
95% CI 1.11-6.25; p = 0.023) in favour of group 2 in the
cumulative risk of being free of encephalopathy during
the follow up period (fig 4, table 2). This difference did
not maintain statistical significance after controlling for
sex and PPG prc-TIPSS (p = 0.136; table 2). The cumulative
risk of developing de novo encephalopathy was also
significantly less in group 2 (p = 0.041). Further analysis
revealed that there was no significant difference
(p = 0.386) in the incidence of hepatic encephalopathy in
the first six months in the two groups, the period when
the number of portograms was similar in groups 1 and 2 (25 v
27, respectively). However, the difference in hepatic ence¬
phalopathy in favour of group 2 remained statistically
significant (p = 0.028) when the analysis was confined to
the period from the end of the first six months of follow up.
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Figure 2 Kaplan-Meier analysis of variceal rebleeding in the
transjugular intrahepatic portosystemic stent shunt (TIPSS) alone group
and in the TIPSS plus variceal band ligation group (TIPSS+VBL).
where there were far fewer portograms performed in group 2
(10 v 21).
Shunt function in the first year
As TIPSS portography was performed only for up to one year
following TIPSS insertion in group 2, valid comparisons of
shunt function between the two groups can only be made for
the 12 months following TIPSS insertion.
In group 1, a total of 46 TIPSS portograms were performed
in the first year, with 54% of these performed in the first six
months. A total of 16 (41%) patients developed shunt
insufficiency. In the first 12 months, 59% of shunt interven¬
tions were performed within the first six months following
TIPSS insertion.
In group 2, a total of 37 TIPSS portograms were performed
in the first year, with 73% of these in the first six months.
There were 17 (43%) cases of shunt insufficiency in the first
12 months. There was no difference in the cumulative risk of
shunt insufficiency in the two groups by the Kaplan-Meier
Method (fig 5).
Orthotopic liver transplantation (OLT)
Four patients, all from group 1, underwent OLT during the
follow up period, between 9.1 and 40.4 months after TIPSS
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Figure 3 Kaplan-Meier analysis of cumulative survival in the
transjugular intrahepatic portosystemic stent shunt (TIPSS) alone group
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Figure 4 Kaplan-Meier analysis of encephalopathy in the transjuaular
intrahepatic portosystemic stent shunt (TIPSS) alone group and in the
TIPSS plus variceal band ligation group (TIPSS+VBL).
OLT on account of the high incidence of continued alcohol
consumption (table 1).
Duration of hospital stay
Total requirements for inpatient care were similar in the two
groups during follow up: 46.5 (54.5) versus 58.0 (65.2) days
in groups 1 and 2, respectively (p = 0.396). There was also no
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TIPSS alone (n) 39 33 28 23 20 17
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Figure 5 Kaplan-Meier analysis of 12 month shunt insufficiency in the
transjugular intrahepatic portosystemic stent shunt (TIPSS) alone group
and in the TIPSS plus variceal band ligation group (TIPPS+VBL).
Table 3 Days spent in hospital during follow up
Ward
Days in hospital per patient
TIPSS (n = 39) TIPSS+VBL (n = 40)
General ward 43.9 (54.0) 55.0 (64.2)
HDU 1.8 (1.4) 1.9 (1.9)
ITU 0.8(2.1) 1.1 (3.3)
Total 46.5 (54.5) 58.0 (65.2)
Values are mean (SD).
TIPSS, transjugular intrahepatic portosystemic stent shunt; VBL, variceal
band ligation; ITU, intensive care unit; HDU, high dependency unit.
No significant difference was detected between the two groups.
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Table 4 Costs of treatments following randomisation in both groups
Cost per patient (£)





Cost per patient free of rebleeding
Cost per surviving patient














Values are mean (SD).
*Total cost per patient divided by the follow up time in months.
fn = 36; Jn = 34; §n = 22; *n = 24.
There was no significant difference in costs between the two groups.
Costs of treatment
Table 4 details the costs incurred in both groups following
randomisation. The difference in total cost per patient did not
reach statistical significance (£119 560 (19 146) v £24 738
(24 299), p = 0.297, in groups 1 and 2, respectively).
Severity of liver disease at the end of follow up
The Child-Pugh score did not change significantly at the end
of follow up (8.9 (2.6) v 9.2 (2.2), p = 0.609, groups I and 2,
respectively).
DISCUSSION
TIPSS has now become accepted as a method of treating
variceal bleeding refractory to endoscopic methods, and for
the prevention of variccal reblccding. We have shown for the
first time that VBL can replace long term TIPSS surveillance
for patients who have required a TIPSS for bleeding
oesophageal varices.
The rebleeding rates in the two groups were not
significantly different, even after adjustment for sex and
portal pressure, and are consistent with previous trials.'
Although the absolute cumulative risk of variceal rebleeding
was higher in group 2 (15% v 8%), this did not reach
statistical significance. The lack of statistical difference needs
to be interpreted with caution in view of the wide confidence
intervals (table 2), and the fact that the power calculations
allow for large differences in the two groups. However, it
must be emphasised that the absolute risk of variceal
reblceding in group 2 appears less than that seen with VBL
alone, as demonstrated in a recent study performed in our
unit.7
Likewise, mortality was not different in the two groups,
even after adjusting for differences in sex and portal pre¬
ssure at baseline, and is in keeping with most of the
previous studies comparing TIPSS and endoscopic modal¬
ities.'"" 2'"2" The two groups were well matched for degree of
liver disease, age, alcoholic aetiology, requirement for
mechanical ventilation, time to randomisation from the
index bleed, and encephalopathy pre-TIPSS; all variables
which our unit and others have shown to predict mortality
post-TIPSS.27"'0
Encephalopathy, both overall and de novo, was signifi¬
cantly less in group 2 and is similar to that seen with VBL
alone when used for secondary prophylaxis of variceal
haemorrhage (fig 4).' This difference is maintained when
the first six months of follow up is excluded, following which
time there arc fewer interventions in group 2 to maintain
shunt patency. However, in the first six months following
TIPSS insertion, the period of maximum and equivalent
shunt interventions in both groups, there was no difference
in the incidence of hepatic encephalopathy. As shunt patency
in group 1 was maintained by regular portographic surveil¬
lance and intervention throughout the study period, the fact
that this group had greater episodes of encephalopathy would
be expected. The rate of encephalopathy (39%) seen in group
1 is similar to that published in the recent literature,' with de
novo encephalopathy being significantly less frequent.2" The
majority of patients responded to conservative measures,
with only four (5%) patients in total requiring blockage of the
TIPSS. The significance of the difference in encephalopathy
was not maintained after controlling for PPG pre-TIPSS and
sex (table 2). However, there did not appear to be any
detrimental effects of TIPSS combined with VBL, and this
regimen certainly has the potential to reduce the rate of
hepatic encephalopathy.
The severity of liver disease, quantified by the Child-Pugh
score, did not change significantly in both groups during
follow up. This may be explained by the fact that most
patients had alcoholic liver disease, with most patients
continuing to consume alcohol. A recent study demonstrated
improvement in Child-Pugh score following TIPSS" but there
were fewer patients with alcoholic cirrhosis and it is not clear
how many people abstained.
We have shown that the rates of shunt insufficiency in the
first year were similar in the two groups, with most episodes
occurring in the first six months following TIPSS creation.
This important observation suggests that portographic follow
up is of most value for the first few months following TIPSS
insertion and may not be required for one year. However, at
the time of the study design, we were more conservative with
respect to TIPSS surveillance. In all cases of variceal
rebleeding, where portography was performed, there was
evidence of shunt insufficiency.
There was a trend towards higher costs in the TIPSS+VBL
group, the lack of statistical significance being due to a high
standard deviation in costs (table 4) and the small sample-
size. With longer follow up, the costs differences may lessen
as patients in the TIPSS+VBL group will only be followed up
by endoscopy and VBL if required. One could even put
forward a case for no surveillance in group 2, provided every
attempt was made to eradicate varices early. This could
significantly reduce costs and increase the use of TIPSS as
follow up after TIPSS insertion can occur in any hospital with
endoscopy and banding facilities.
In conclusion, for the first time, our findings suggest that
VBL can replace long term TIPSS surveillance and still
maintain low rates of variccal rebleeding with the potential to
reduce the rates of post-TIPSS encephalopathy. Therefore, in
patients who have bled from oesophageal varices, combining
TIPSS and short term surveillance with VBL is a suitable-
alternative to TIPSS with long term surveillance in the
prevention of variceal rebleeding.
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Chronic Administration of Losartan, an Angiotensin II
Receptor Antagonist, is not Effective in Reducing Portal
Pressure in Patients with Preascitic Cirrhosis
Dhiraj Tripathi, M.R.C.P., George Thcrapondos, M.R.C.P., Hock F. Lui, M.R.C.P,
Neil Johnston, MSc, F.I.B.M.S., David J. Webb, F.R.C.P, M.D., D.Sc., and Peter C. Hayes, F.R.C.P., M.D., Ph.D.
liver Unit, Department ofMedicine, Royal Infirmary, Edinburgh; and Clinical Pharmacology Unit, Department
ofMedical Sciences and Centrefor Cardiovascular Science, The University ofEdinburgh, Western General
Hospital, Edinburgh, UK
OBJECTIVES: Plasma angiotensin II (ANG II) concentrations are elevated in cirrhosis and have been implicated as
a cause of portal hypertension. We aimed to study both the systemic and portal hemodynamics,
and tolerability after chronic administration of losartan, an ANG II receptor antagonist.
METHODS: Twelve patients with preascitic cirrhosis were studied: mean age of 53.8 ± 3.3 yr; average
Child-Pugh score of 5.8 ± 0.3; alcohol etiology (5), hepatitis B/C (1/3), primary biliary cirrhosis (3).
No patients were on diuretics or vasoactive medication. Hemodynamic measurements were
performed at baseline and 4 weeks after daily administration of 25 mg losartan.
RESULTS: There was no significant change in the hepatic venous pressure gradient (15.4 ± 1.5 to 13.6 ±
1.6 mmHg, —11.7%, p = NS), despite a significant reduction in the wedge hepatic venous pressure
(20.3 ± 1.8 to 17.3 ± 1.8 mmHg, —14.8%, p < 0.05). Cardiac output, hepatic blood flow,
systemic vascular resistance, creatinine clearance, and natriuresis were unaffected. The plasma
renin activity increased significantly from 2.7 ± 0.4 to 5.2 ± 1.1 ng/ml/h (p < 0.05). There was a
significant reduction in the mean arterial pressure from 96.9 ± 3.3 to 89.3 ± 3.5 mmHg, —7.8 ±
3.0% (p = 0.02), with 1 patient experiencing symptomatic hypotension.
CONCLUSIONS: Chronic administration of low-dose losartan does not lead to a significant reduction in the portal
pressure gradient. Losartan is unlikely to be useful in the management of patients with early
cirrhosis, who are at risk of variceal bleeding.
INTRODUCTION
Portal hypertension is a serious complication of cirrho¬
sis, and can result in life-threatening variceal hemorrhage
with an in-hospital mortality of between 30% and 40% de¬
spite current therapeutic interventions (1). There have been
many studies investigating the effects of pharmacological
agents on portal hypertension in cirrhotic patients (2). Non-
cardio-selcctive beta-blockers remain the drugs of choice in
preventing variceal hemorrhage and have been studied in
several randomized controlled trials (3-6). However, up to
a third of the patients do not respond to these drugs (7),
and a similar proportion are intolerant due to side effects (8).
There has been increasing interest in alternative agents, which
act via different pathways and promise better efficacy and
tolerability.
The renin-angiotensin system has been the focus of sev
eral studies in patients with cirrhosis. It is known that the
system is activated in cirrhosis and portal hypertension, and
that the degree of activation increases with the severity of
portal hypertension (9).
Angiotensin II (ANG II), acting via ATI receptors, may
cause portal hypertension by increasing intrahepatic resis¬
tance, portocollateral resistance, and portal blood flow (10-
12). We have also shown ANG II to play an important role in
mediating peripheral vascular tone, particularly in advanced
cirrhosis (13). Inhibiting the actions of ANG II at any of
these sites may result in a reduction of portal pressure, thus
offering a therapeutic alternative for the treatment of portal
hypertension.
Losartan is a specific ATI receptor antagonist with no ag¬
onist activity (14). It is licensed for the treatment of systemic
hypertension. Schneider and colleagues studied the effects of
losartan in patients with varying degrees of portal hyperten¬
sion, and demonstrated an impressive and significant portal
hypotensive response in excess of 40% (15). This was ac¬
complished with minimal effects on the systemic circulation.
Irbesartan, another ATI receptor antagonist with no agonist
activity but a longer half-life, was also found to have signif¬
icant portal hypotensive effects (16, 17). However, a recent
study failed to confirm the findings of Schneider in a large
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Table 1. Baseline Characteristics
Characteristic (n = 12)
Sex (M/F) 7/5
Age (yr) 53 ±3
Child's class (A/B) 9/3




Primary biliary cirrhosis 3
group of cirrhotic patients, and also reported significant side
effects with losartan (18). Therefore, there remains some un¬
certainty about the efficacy and tolerability of such agents in
cirrhosis.
The aim of the current study is to investigate the effect
of the chronic dosing of losartan in patients with cirrhosis
and portal hypertension. The patients, unlike those in pre¬
vious studies, all had early cirrhosis and were not on va¬
soactive medication or diuretics, thus the activation of the
renin-angiotensin system was minimal.
PATIENTS AND METHODS
Twelve patients with biopsy, radiological, biochemical, or
clinical evidence of cirrhosis were recruited. The baseline
characteristics are summarized in Table 1. All the patients
were preascitic, and were on no diuretics or other vasoactive
medication prior to and throughout the study period. Of the
7 patients who had esophageal varices, 6 had Grade II and 1
had Grade III varices, with none having bled in the past. All
patients gave written informed consent, and the local research
ethics committee approved the study. The study protocol was
in accordance with the ethical guidelines of the Declaration
of Helsinki.
Baseline hemodynamic measurements were performed
at 09:00 hours following an overnight fast. The patients
were then instructed to take 25 mg of losartan (Cozaar,
Merck Sharp & Dohme Ltd, NJ, USA) at 21:00 hours for
4 weeks. Schneider and colleagues (15) demonstrated a
significant effect on portal hypertension with the 25 mg
dose, hence the use of this dose. Patients were followed
up at 2 wk in the clinic for the assessment of side ef¬
fects, blood pressure, serum creatinine, liver function, and
compliance from the history. After 4 wk of treatment, the
hemodynamic measurements were repeated as in the ini¬
tial protocol. There was no change in the observed alcohol
consumption for the duration of the study. There were no de¬
tectable serum cthanol levels prior to each study or during
follow-up.
Hemodynamic Study Protocol
All measurements were performed in the hepatic hemody¬
namics suite. All hemodynamic measurements and blood
sampling were performed in the supine position. After in¬
filtration with 10 ml 2% lidocaine a 7FG venous introducer
(Cordis, USA) was inserted into the right femoral vein us¬
ing the Seldingcr technique. Under fluoroscopic guidance a
Swann Ganz catheter (Baxter Healthcare Corporation, USA)
was inserted through the introducer to measure cardiac output
(CO) and right atrial pressure (RAP) in the standard manner.
Using the same catheter or a Sidewinder II torque balloon
catheter (Cordis Corporation, USA) the main right hepatic
vein was then catheterized for the measurement of the free
and wedge hepatic venous pressures (FHVP andWHVP). The
hepatic venous pressure gradient (FIVPG) was derived from
these values as [WHVP-FHVP]. All hemodynamic measure¬
ments were taken in triplicate. The mean arterial pressure
(MAP) was measured using an automatic sphygmomanome¬
ter (Hewlett Packard series 54 model 78339A) and was cal¬
culated as (pulse pressure/3) + diastolic blood pressure. The
systemic vascular resistance (SVR) was calculated as (79.96
(MAP-RAP)/CO).
Measurement ofHepatic Blood Flow
Hepatic blood flow (HBF) was derived from measurements
of the indocyanine green (ICG, Akorn, IL) clearance and ex¬
traction (19). ICG was infused at the beginning ofthe study as
a 10 mg intravenous bolus via a peripheral cannula followed
by an infusion of0.2 mg/min ICG. After an equilibration time
of 40 min three samples were taken simultaneously from the
right hepatic vein and femoral vein. Hepatic blood flow was
calculated using the following equation (provided the hepatic
excretion exceeded 10%):
HBF = (ICG Clearance/ICG Extraction)/! I — Hematocrit)
Blood Sampling and Analysis
Venous blood was sampled after the patient was in the supine
position for 30 min for baseline biochemical and hematolog¬
ical measurements. In addition, ANG II concentration and
plasma renin activity (PRA) were measured by techniques
described previously (13). Aldosterone levels were also mea¬
sured by radioimmunoassay (20).
Assessment ofRenal Function
Prior to the first dose of losartan, urine was collected over
a 24-h period to measure creatinine clearance and urinary
sodium excretion. After 4 wk of administration of losartan,
the urinary measurements were repeated.
Statistical Analysis
All results are expressed as mean ± SEM. Parametric data
were analyzed using the paired Student's /-test and the
Pearson's correlation. Wilcoxon signed rank test and Spear¬
man correlation were used for nonparametric data. Signifi¬
cance was taken at the 5% level. The SPSS package (version 9,
Chicago, IL) was used for statistical analysis.
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Table 2. Effects on Hemodynamic and Humoral Mediators Follow¬
ing Chronic Dosing
Baseline After 4 wk
HVPG (mmHg) 15.4 ±1.5 13.6 ±1.6
WHVP (mmHg) 20.3 ±1.8 17.3 ±1.8*
FHVP (mmHg) 4.9 ± 0.6 3.7 ± 0.7
HR (bpm) 88.3 ± 5.8 79.1 ±4.9
MAP (mmHg) 97 ±3 89 ±4*
CO (1/min) 5.8 ± 0.3 5.7 ±0.3
SVR (dyn.Cm) 1324 ±48 1240 ±97
PRA (ng/ml/h) 2.7 ± 0.4 5.2 ± 1.1*
ANG 11 (pg/ml) 8.0 ± 1.8 24.2 ± 8.5**
Aldosterone (pg/ml) 52.5 ± 12.8 77.5 ± 27.4
*p < 0.05 compared with baseline, ** p = 0.08 compared with baseline.
HVPG: Hepatic venous pressure gradient; WHVP: Wedge hepatic venous pressure;
FHVP: Free hepatic venous pressure; HR: Heart rate; MAP: Mean arterial pressure;
CO: Cardiac output, SVR: Systemic vascular resistance, PRA: Plasma renin activity.
Following chronic dosing
A: mean HVPG ± SEM predosing
B: mean IIVPG ± SEM postchronic dosing
Values in the center of the chart refer to individual patient data.
Figure 1. Effect on HVPG following chronic dosing.
RESULTS
All patients completed the study.
Hepatic Hemodynamics and Function
After administration of losartan for 4 wk there was no sig¬
nificant reduction in the HVPG (15.4 ± 1.5 to 13.6 ±
1.6 mmHg, -11.7%, p = 0.1), despite a significant reduc¬
tion in the WHVP (20.3 ± 1.8 to 17.3 ± 1.8 mmHg,-14.8%,
p < 0.05) (Table 2). In five cases there was a >20% reduction
in the HVPG, while in three cases there was a reduction in
the HVPG to <12 mmHg in patients with a HVPG of >12
mmHg at baseline (n — 10). (Fig. 1) There were two pa¬
tients, one with ALU and the other with hepatitis G, in whom
the HVPG increased. These patients had similar baseline
characteristics compared with the rest of the group. Patients
with ALD, despite a higher baseline HVPG, experienced a
similar reduction in the HVPG from 19.8 ± 1.8 to 17.4 ±
2.1 mmHg (— 12.1%, p = NS, n = 5) compared with pa¬
tients with other etiologies (12.3 ± 1.1 to 10.8 ± 1.8 mmHg,
— 12.2%, p = NS, n = 7). In the first three patients repeat
hemodynamic measurements performed at sixty min post
dosage did not demonstrate any acute effect on the HVPG.
It was not possible to calculate the hepatic blood flow in
three patients where the hepatic extraction of ICG was < 10%.
In the remaining patients there was no change in the hepatic
blood flow (552.5 ± 72.9 to 559.7 ± 106.6 ml/min, n = 9,
p = NS).
The liver function tests in all patients were unaffected
Systemic Hemodynamics
There was a significant reduction in the MAP (97 ± 3 to 89 ±
4.0 mmHg, —7.8 ± 3.0%, p 0.02). There was no change in
the heart rate, CO, or SVR (Table 2).
Renal Function
The creatinine clearance was unaffected (90±14 to 93±19
ml/min, p = NS, n = 7), as was the 24-hour urinary sodium
excretion (154 ± 61 to 122 ± 36 mmol/day, p = NS,
n = 5).
Effect on the Renin-Angiotensin System
There was a significant increase in the serum plasma renin ac¬
tivity from 2.7 ± 0.4 to 5.2 ± 1.1 ng/ntl/h after chronic dosing
(p --- 0.05) confirming activation ofthe renin-angiotensin sys¬
tem. There was a strong trend toward increased serum ANG
II levels (8.0 ± 1.8 to 24.2 ± 8.5 pg/ml, p = 0.08). Serum
aldosterone levels were unaffected (Table 2).
Tolerability
One patient experienced symptomatic hypotension after the
first dose of losartan, but elected to continue with the study
and experienced no further symptoms. During follow-up
he was noted to have a 35% reduction in the MAP from
122 to 79 mmHg. This patient was subsequently diagnosed
as having systemic hypertension and commenced on drug
therapy. There were no other side effects reported during
follow-up.
DISCUSSION
The present study demonstrates that in patients with preascitic
cirrhosis, oral dosing of 25 mg losartan did not result in a
significant reduction in the HVPG despite a significant fall
in the WHVP. Losartan significantly reduced the MAP with
one patient experiencing mild symptoms after the first dose,
a phenomenon that has been reported previously with ACE
inhibitors (21).
The interest in ANG II receptor antagonism stems from the
observation that there is activation of the renin-angiotensin
system in cirrhosis, the degree of which is proportional to
the severity of cirrhosis, and portal hypertension (9). Stud¬
ies have shown that ANG II has a direct effect on por¬
tal pressure, via ATI type receptors (11). Animal models
demonstrate that ANG II mediates vasoconstriction of the
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portosystemic collaterals leading to increased portocollateral
resistance (11), and to have diminished vasoconstrictive ef¬
fects on the splanchnic circulation leading to increased portal
blood flow (10). Recent interest has concentrated on the role
of the activated hepatocyte stellate cells (HSC), particularly
in light of the finding that ATI-type receptors on human-
activated HSC mediate the vasoconstrictive and mitogenic
actions of ANG II (12, 22). Blockade of the ATI receptor
may therefore result in relaxation of the activated HSC and re¬
duced intrahepatic resistance and portal pressure. This selec¬
tive blockade may also result in the unopposed action ofANG
II on AT2 type receptors, leading to endothelium-mediated
vasodilatation, further enhancing the pharmacological effects
of such agents (23).
Initial attempts at ANG II receptor blockade were hindered
by pronounced systemic hypotension (24), although the latter
was not seen at higher doses possibly due to the partial ago¬
nist effect of saralasin at such doses, leading to vasoconstric¬
tion and potentially hypertension (23). Newer agents such as
losartan and irbesartan, which have no intrinsic agonist ac¬
tivity, have resulted in greater success (15,17). Losartan was
used at a dose of 25 mg in 45 patients with cirrhosis, and
either moderate or severe portal hypertension in a study by
Schneider and colleagues (15). Both acutely after 4 h and
following chronic administration there was a significant re¬
duction in the portal pressure approaching 45%, the largest
reported to date for any pharmacological agent. This is par¬
ticularly impressive considering the minimal effect on blood
pressure, with only one patient experiencing symptomatic
hypotension.
A recent paper, however, does not support the observa¬
tion by Schneider (18). This study randomized 25 patients to
losartan following a variceal hemorrhage, and compared the
portal hypotensive effect of 6 wk therapy with that of propra¬
nolol (n = 15). Propranolol produced a significantly greater
reduction in the HVPG (10% vs 2%,), despite the fact that
losartan had a significant effect on MAP (—8%), which was
not seen with propranolol. There was a significant reduction
in the glomerular filtration rate in Childs B patients taking
losartan, with propranolol having no detrimental effect on re¬
nal function. Adverse effects related to therapy were similar
in both groups.
Our results contrast with those ofSchneider and colleagues
(15), but are in keeping with that ofGonzalez-Abraldes et al.
(18). This is despite using the same dose of losartan that
resulted in activation of the renin-angiotensin system, as ev¬
idenced by a significant increase in PRA. Our study design
differs in a number ofways from that of Schneider et al. First,
we studied preascitic cirrhotic patients. This was to mini¬
mize the potential risk of systemic hypotension with ANG II
blockade in patients with more advanced cirrhosis (24). Sec¬
ond, significant proportions of patients in Schneider's study
were on diuretics, both in the treatment and control groups.
Clearly, this will have an effect on circulating volume, and the
degree of activation of the renin-angiotensin system. Third,
the timing of the hemodynamic measurements is different.
Schneider et al. performed the measurements at 4 h post dos¬
ing compared with 12 h for our study. It is known, however,
that the pharmacological actions of losartan last up to 24 h
(25). Losartan is a pro drug that is converted to the active
metabolite E-3174, whose maximum plasma levels are ob¬
tained after 3—4 h. This may explain why we saw no effect on
the HVPG in the three patients in whom we repeated measure¬
ments sixty min after acute dosing. The half-life ofE-3174 is
6-9 h and the levels in plasma in cirrhotics are 1.7 times those
ofhealthy individuals (26). This may partly explain the differ¬
ence in the results, but for a drug to be considered for therapy
itmust have a sustained chronic effect on portal hypertension.
In the study by Gonzalez-Abraldes (18) the timing ofthe mea¬
surements is not clear. Finally, our sample size is smaller, and
a larger sample size may have resulted in a significant differ¬
ence. Our study shows that the drug is biologically active in
cirrhotic patients as evidenced by a significant decrease in the
MAP and increase in the renin activity. Although we cannot
rule out that the inclusion ofmore patients may result in a sta¬
tistically significant effect on FIVPG, we feel it is unlikely to
show greater clinical effect. One could argue that the dosing
may be inadequate, but our dosage was the same as used in
the Schneider study and was enough to cause sufficient block¬
age of ANG II receptors as demonstrated by the significant
increase in ANG II levels following chronic dosing. Higher
doses may not prove to be more effective, and are likely to
significantly increase the risk of adverse systemic side ef¬
fects as demonstrated by Gonzalez-Abraldes and colleagues
(18).
Girgrah et al. have recently studied the renal effects of
losartan in prcascitic cirrhotics (27). This study demonstrated
that the renin-angiotensin system is activated even in early
cirrhosis, a finding that is in keeping with that of our recent
study (13). It was suggested by the authors that losartan, at
a dose of 7.5 mg per day, improved natriuresis by blocking
the sodium-retaining actions ofANG II proximal to the distal
tubule. Our findings are not in keeping with this observation,
but the sample size of the patients in whom the 24-h sodium
excretion was measured was small. Our study also exam¬
ined the chronic rather than acute effect of losartan, and the
dietary intake of sodium was not so strictly regulated. Crea¬
tinine clearance was unaffected, suggesting that at this dose
in preascitic cirrhotic patients losartan appears to have no
adverse renal effects. In other patients with more severe liver
disease, and especially those on potassium-sparing diuretics,
problems with renal function and electrolyte imbalance may
occur as demonstrated by Gonzalez-Abraldes and colleagues
(18).
In conclusion, although low-dose losartan appears to be
well tolerated in this group of patients, and has no adverse
renal effects, we have not shown a significant reduction
in HVPG following chronic dosing with losartan in well-
compensated cirrhotic patients. Losartan therefore is unlikely
to have a place in the management of patients with cirrhosis
and portal hypertension who are at risk of variceal hemor¬
rhage.
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Ten years' follow-up of 472 patients following transjugular
intrahepatic portosystemic stent-shunt insertion at a single
centre
Dhiraj Tripathi3, Ahmed Helmy3, Kim Macbeth3, Sherzad Balata3, Hock F. Luia,
Adrian J. Stanley3, Doris N. Redheadb and Peter C. Hayes3
Background Transjugular intrahepatic portosystemic
stent-shunt (TIPSS) is increasingly used for the
management of portal hypertension. We report on
10 years' experience at a single centre.
Methods Data held in a dedicated database was retrieved
on 497 patients referred for TIPSS. The efficacy of TIPSS
and its complications were assessed.
Results Most patients were male (59.4%) with alcoholic
liver disease (63.6%), and bleeding varices (86.8%).
Technical success was achieved in 474 (95.4%) patients. A
total of 13.4% of patients bled at portal pressure gradients
=S 12 mmHg, principally from gastric and ectopic varices.
Procedure-related mortality was 1.2%. The mean follow-up
period of surviving patients was 33.3 ±1.9 months.
Primary shunt patency rates were 45.4% and 26.0% at 1
and 2 years, respectively, while the overall secondary
assisted patency rate was 72.2%. Variceal rebleeding rate
was 13.7%, with all episodes occurring within 2 years of
TIPSS insertion, and almost all due to shunt dysfunction.
The overall mortality rate was 60.4%, mainly resulting from
end-stage liver failure (42.5%). Patients who bled from
gastric varices had lower mortality than those from
oesophageal varices (53.9% versus 61.5%, P < 0.01). The
overall rate of hepatic encephalopathy was 29.9% (cfe novo
encephalopathy was 11.5%), with pre-TIPSS
encephalopathy being an independent predicting variable.
Refractory ascites responded to TIPSS in 72% of cases,
although the incidence of encephalopathy was high in this
group (36.0%).
Conclusions TIPSS is effective in the management of
variceal bleeding, and has a low complication rate. With
surveillance, good patency can be achieved. Careful
selection of patients is needed to reduce the
encephalopathy rate. Eur J Gastroenterol Hepatol 16:9-18
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Introduction
Transjugular intrahepatic portosystemic stent-shunt
(TIPSS) has improved the management of the compli¬
cations of portal hypertension, and has largely replaced
surgical treatment modalities in patients with advanced
cirrhosis and variceal bleeding [1], Randomized con¬
trolled trials [2—10] and meta-analyses [11.12] confirm
the superiority of TIPSS over endoscopic treatments in
controlling variceal bleeding and preventing rebleeding.
In addition, TIPSS is effective in the management of
gastric variceal bleeding [13] and refractory ascites
[14,15]. Fuithciliiuic, TIPSS can be successfully used
as a 'bridge' to liver transplantation without any detri¬
mental effects [16,17].
The principal disadvantages of TIPSS are the
development of shunt insufficiency and hepatic en¬
cephalopathy. Up to 50% of shunts will become
insufficient within 1 year of insertion [18-20], Current
0954-691X © 2004 Lippincott Williams & Wilkins
surveillance portography, and intervention if required,
ensures excellent secondary assisted patency rates
[21,22], and explains the very low rates of rebleeding.
The use of new covered stents promises superior
patency rates, but current evidence is limited to small
series with a short follow-up [11,23—26], Hepatic
encephalopathy occurs in approximately one-third of
patients with TIPSS, and results in a significant
reduction in the quality of life and increased hospital
admissions [12].
Most studies arc small and do not indicate an improve¬
ment in the mortality rates following TIPSS insertion
112]. However, we have previously shown that TIPSS
can result in a favourable outcome in patients with
Child class C cirrhosis with variceal bleeding, when
compared with endoscopic methods [27], Most rando¬
mized controlled trials do not have the statistical power
to demonstrate difference in survival.
DO!: 10.1097/01 .meg.0000085540.79233.86
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We report our experience of T1PSS in almost 500
patients over a 10-year period, the second largest series




Between July 1991 and July 2001, 497 patients were
referred for T1PSS. The TIPSS was successfully in¬
serted in 474 patients (95.4%). Data was collected on
all these patients prospectively, and entered into a
dedicated database. Two patients required a TIPSS
following orthotopic liver transplantation (OLT) and
were excluded from the analysis, leaving 472 patients
for the final analysis. In another 40 patients in a clinical
trial, angiographic surveillance was continued only for
up to 1 year post-TIPSS insertion, with variceal band
ligation started following TIPSS insertion and contin¬
ued indefinitely [28]. These patients were excluded for
analysis of variceal rcbleeding, mortality, shunt func¬
tion, and hepatic encephalopathy. Patient consent and
ethics committee approval were not necessary for a
retrospective audit such as this.
Procedures
TIPSS insertion was performed as previously reported
[29,30], The index TIPSS was created using Palmaz
stents (Johnson and Johnson, Nordcrstedt, Germany) in
20 patients, the newer covered stents (Wallgraft; Boston
Scientific, Boston, MA, USA or Jostent; Jomed, Zurich,
Switzerland) in 35 patients, and Wallstents (Boston
Scientific) in the remainder, with eight of these cases
requiring re-stenting with a covered stent during
follow-up. All patients had intravenous Cefotaxime 1 h
pre-procedure and for 48 h post-procedure. Doppler
ultrasound was performed at 1 week. Urgent portogra¬
phy was carried out if there was Doppler evidence of
shunt dysfunction, or if there was clinical evidence of
shunt dysfunction, such as variceal rebleeding or in¬
creased ascites.
Follow-up
All subjects were followed up at 4-6 month intervals
with full clinical, haematologic.al and biochemical as¬
sessment, until death, liver transplantation, or loss to
follow-up. Routine portography was performed every
6 months where possible, or at other times if there was
clinical evidence of shunt dysfunction such as rebleed¬
ing or increased ascites.
Definitions
Variceal rebleeding
Any subsequent haemateniesis or melaena confirmed
endoscopically. Non-variceal causes of rebleeding were
also documented.
Early mortality
Death within 6 weeks of the index variceal bleed.
Shunt insufficiency
An increase in the portal pressure gradient (PPG) to
> 12 mmHg or an increase in the PPG > 20% from the
post-TIPSS value where the post-TIPSS value is < 12
mmHg [31]. The Doppler criteria for shunt insuffi¬
ciency is a peak velocity of =£ 90 cm/s [20,32].
Primary patency
The absence of shunt insufficiency, without interven¬
tion during TIPSS surveillance.
Secondary assisted patency
The absence of shunt insufficiency with intervention.
Successful portal pressure reduction
A PPG immediately post-TIPSS of < 12 mmHg (where
PPG pre-TIPSS >12 mml lg) or a >20% reduction
in the PPG pre-TIPSS (where PPG pre-TIPSS
< 12 mmHg).
Statistical analysis
Data were analysed using the SPSS statistics package
(version 9; SPSS Inc., Chicago, Illinois, USA), and
expressed as means ± standard error of the mean. Data
for mortality, encephalopathy and rebleeding were
analysed using the Kaplan-Meier method and log-rank
test. The chi-squared test and the Student /-test were
used to compare unpaired data. Cox regression analysis
was performed to determine independent variables
predicting variceal rebleeding, survival, and shunt in¬
sufficiency. Significance was taken at the 5% level.
Results
Baseline patient characteristics are presented in Table
1. The most common indication for TIPSS insertion was
oesophageal variceal haemorrhage (« = 313, 66.3%), and
most patients had Child C disease (« = 246, 52.1%)
of alcoholic origin (>/ = 300, 63.6%). There were 22
patients (4.7%) who were lost to follow-up.
TIPSS procedure
Technical success
Technical success was achieved in 472 (95%) patients,
and was not possible in the remainder due to: (1) portal
vein thrombosis (//— 4); (2) intraperitoneal bleeding
from the portal vein («= 2); (3) death during the
procedure from cardiovascular instability (// = 1); and
(1) the inability to access the hepatic or portal circula¬
tion due to the patient's anatomy (» = 16).
Successful portal pressure reduction
This was achieved in 354 (83.9%) patients. Patients
with gastric variceal bleeding had lower PPGs pre-
TIPSS compared with oesophageal variceal bleeding
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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Table I Baseline characteristics of subjects
Characteristic r? = 472
Mean age (years) 54.1 ± 0.6
Sex (male/female) 280/192
Child-Pugh score 9.7 ±0.1
Etiology [n (%)]
Alcoholic cirrhosis 300 (63.6)
Cryptogenic cirrhosis 42 (8.9)
Viral hepatitis 39 (8.3)
Primary biliary cirrhosis 38 (8.1)
Autoimmune hepatitis 13 (2.8)




Oesophageal variceal bleeding 313 (66.3)
Gastric variceal bleeding 65 (13.8)
Refractory ascites 50 (10.6)
Oesophageal and gastric variceal bleeding 21 (4.4)
Ectopic variceal bleeding 12 (2.5)
Portal hypertensive gastropathy 7 (1.5)
Other 4 (0.9)
Mean follow-up period (months)
Overall 19.9 ± 1.1
For surviving patients 33.3 ± 1.9
Values expressed as mean ± standard error of the mean.
"Includes nodular regenerative hyperplasia (n = 3), congenital hepatic fibrosis
{n = 3), haemochromatosis (n = 4), Budd-Chiari syndrome (n = 2),
myelofibrosis (n = 2), alpha 1 antitrypsin deficiency {n — 1), hepatic amyloid
{n — 1), secondary biliary cirrhosis from choledocholithiasis and stenting of
common bile duct (n — 1), chronic granulomatous hepatitis (n ~ 1),
cholangiocarcinoma (n — 1), and Poems' syndrome (n — 1).
(Table 2). Fifcv-tive patients (13.4% of all variceal
bleeders) bled at PPG =£ 12 mm! Ig, with gastric varices
accounting for most of these cases (Table 3).
Procedure-related mortality
There were six deaths (1.2%) during or as a direct
result of the TIPSS procedure. These were due to
intraperitoneal haemorrhage (n — 2) and perforation of
the gallbladder leading to overwhelming sepsis (n = 1).
Three patients died during the procedure as a result
of cardiac arrest (pulseless electrical activity in two
Table 3 Subgroup analysis of patients who bled at portal pressure
gradient (PPG) =£ 12 mrnHg
Patients who bled at PPG
Source of variceal bleed s-~. 1 2 mmHg [n (%)l
Oesophageal varices {n = 313) 24 (7.7)
Gastric varices (n = 65) 25 (38.5)
Gastric and oesophageal varices (n — 21) 2 (9.5)
Ectopic varices (n — 12) 4 (33.3)
patients and asystole in one patient). Other non¬
fatal procedure-related complications are presented in
Table 4.
Shunt function
Most cases of shunt insufficiency occurred within the
first year (Fig. 1). particularly the first 6 months follow¬
ing index TIPSS insertion (31.4%). Intimal hyperplasia
was the most common abnormality ( Table 5). Of the
387 episodes of shunt insufficiencies in the first 2 years
post-TIPSS insertion, 46 (11.9%) were associated with
variceal rebleeding. This compares with 96 episodes of
shunt insufficiencies in 53 patients after 2 years, where
there was just one episode associated with variceal
rebleeding (1%, P <0.001). The majority of these
patients (92.5%, n = 49) had successful portal pressure
reduction at the time of index TIPSS insertion. In
patients who had at least one portogram during follow-
up (n = 295), the overall secondary assisted patency
rate is 72.2%. Of the variables assessed (age and sex of
patient, Pugh score, prothrombin time, stent diameter,
requirement for ventilation, PPG pre-TTPPS and post-
TIPSS, PPG reduction post-TIPSS, successful PPG
reduction post-TIPSS, and alcoholic aetiology), none
independently predicted shunt insufficiency on multi¬
variate analysis.
Variceal rebleeding
Of the 371 patients selected for analysis, variceal
rebleeding occurred in 51 (13.7%) patients. In total
Table 2 Haemodynamic data for patients (n = 472) who had



















Values expressed as mean ± standard error of the mean. PPG, Portal pressure
gradient.
A
versus B P < 0.001, c versus D P < 0.05.
"Defined as a PPG post-TIPSS of < 12 mmHg (where PPG pre-TIPSS
> 12 mmHg) or a > 20% reduction in the PPG pre TIPSS (where PPG pre
TIPSS < 1 2 mmHg).
Table 4 Non-fatal procedure-related complications
Complication Number of patients affected
Portal vein thrombosis" 5
Intraperitoneal haemorrhage 5
Portal vein to bile duct fistula 2
Neck haematoma from central line insertion 4
Local collection between gallbladder and liver 2
Central line sepsis 2
Shunt migration 2
Presumed shunt sepsis 2
Tension pneumothorax from central line insertion 1
Right atrial clotb 1
Haematoma around TIPSS 1
TIPSS, transjugular intrahepatic portosystemic stent-shunt.
"Three cases were successfully evacuated and two required thrombolysis with
streptokinase.
bNotcd at follow-up portography, which was aspirated via a 10 Fg sheath, and
seen later at echocardiography pre-orthotopic liver transplantation.
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Kaplan-Meier analysis of cumulative shunt insufficiency (n — 432).
Table 5 Causes of shunt insufficiency during follow-up
Abnormality on portography Number of episodes Number of patients affected
Intimal hyperplasia 289 157
Hepatic vein stenosis 100 72
Thrombosis within shunt 31 28
Occluded shunt 60 46
Portal vein thrombosis 3 3
there were 59 episodes of variceal rebleeding, with
oesophageal variceal rebleeding in 11 episodes (71,6%),
gastric variceal rebleeding in 13 episodes (22.0%), and
both gastric and oesophageal variceal rebleeding in two
episodes (3.4%). Following five episodes of variceal
reblceding, patients died rapidly from hepatic decom¬
pensation before T1PSS portography could take place.
Following the other 51 episodes (91.5% of all episodes
of variceal rebleeding), portography revealed evidence
of shunt insufficiency in 16 (85.2%) episodes. Shunt
intervention at the time of portography resulted in
successful shunt function in 41 (89.1%) episodes of
shunt insufficiency. In the other five cases where it was
not possible to re-establish shunt function, principally
due to unsuccessful attempts at insertion of a parallel
stent, two patients were entered successfully into a
banding programme, one patient was treated success¬
fully with thrombin for bleeding gastric varices, and
two patients underwent surgery. One of these patients
required oesophageal transection and splenectomy, and
the other patient splenectomy and underpinning of
veins following gastric variceal rebleeding.
The 1 year and 2 year cumulative rebleeding rates are
14.5% and 18.37% respectively (Fig. 2a). There was
only one patient who had an episode of variceal
rebleeding 2 years after TIPSS insertion associated with
shunt dysfunction. In this patient it was not possible to
bring the PPG post-TIPSS to below 12 mm Fig after
the index TIPSS insertion, thus resulting in an insuffi¬
cient shunt, The following variables were entered into
multivariate analysis: (1) age and sex of patient; (2)
alcohol aetiology; (3) Pugh score; (4) gastric and oeso¬
phageal variceal bleeding as an indication; (5) require¬
ment for ventilation; (6) successful portal pressure
reduction following TIPSS. Cox regression analysis
revealed that the Pugh score of greater than 7
(P = 0.01), requirement for ventilation (P < 0.05), and
failure to achieve successful portal pressure reduction
following index TIPSS insertion (P < 0.05) indepen¬
dently predicted variceal rebleeding (Table 6 and Fig.
2b,c).'
There were 21 additional episodes of non-variceal
rebleeding with the causes as follows: (1) banding/
sclerotherapy induced ulceration (w =11); (2) peptic
ulceration (;/ = 6); (3) Mallorv—Weiss tear (// = 2); (4)
oesophagitis (« = 1): and (5) arterial bleeding (n = 1).
There were 11 documented rebleeding episodes where
the source of the bleed was not identified at endoscopy,
or the patient did not have an endoscopy.
Mortality
There were 261 deaths (60.4%) in the 432 patients
selected for this analysis (Table 7). The early mortality
rate was 27.2%, and 1 year, 2 year and 5 year cumula¬
tive survival rates are 55.2%, 45.8% and 27.0%. respec¬
tively (Fig. 3a). 'Fhe following variables were entered
into multivariate analysis: (1) age and sex of patient; (2)
alcohol aetiology; (3) gastric or oesophageal variceal
bleeding, and ascites as an indication for TIPSS; (4)
Pugh score; (5) requirement for ventilation; (6) PPG
pre-TIPSS; and (7) successful portal pressure reduction
post-TIPSS. Multivariate regression analysis revealed
the Pugh score, age of patient, requirement for meeh
anical ventilation at index TIPSS insertion, and oeso¬
phageal variceal bleeding or ascites as an indication for
TIPSS, to be independent factors predicting mortality
(Table 6). Patients in Child Pugh class C had signifi¬
cantly higher cumulative mortality (Fig. 3b), with a
5 year survival rate of 18.2% compared with 37.2% for
patients in Child class A and Child class P> (/' < 0.001).
Further analysis of patients with Pugh score > 12
revealed an early mortality rate of 54.2%. with 1 year
and 2 year survival of 33.7% and 31.4%, respectively.
Figure 3c illustrates the difference in mortality in
favour of patients who required a TIPSS for gastric
variceal bleeding compared with oesophageal variceal
bleeding. Figure 3d illustrates the detrimental effect of
ascites on mortality when compared with other indica
tions for TIPSS.
Orthotopic liver transplantation
Of the population in whom a TIPSS was successfully
inserted (« = 472), there were 43 patients (9.1%) who
Copyright ® Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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Kaplan-Meier analyses of cumulative variceal rebleeding: (a) in all subjects (n — 371); (b) in Pugh class A/B (—, n = 168) versus class C (—.
n = 203) patients; and (c) in patients with successful portal pressure gradient (PPG) reduction (—, n = 313) versus unsuccessful PPG reduction
(—, n — 58).
Table 6 Variables independently predicting poor clinical outcome following transjugular
intrahepatic portosystemic stent-shunt (TIPSS)
Clinical outcome Variable P value
Mortality High Pugh score < 0.001
Increasing age < 0.01
Requirement for mechanical ventilation < 0.01
Oesophageal variceal bleeding < 0.05
Ascites < 0.05
Variceal rebleeding High Pugh score < 0.01
Requirement for mechanical ventilation < 0.05
Failure to achieve successful portal pressure < 0.05
gradient reduction following TIPSS insertion
Hepatic encephalopathy Pre-TIPSS encephalopathy < 0.05
underwent OLT at 13.8 ± 2.7 months following TIPSS
insertion. There were no adverse complications or
mortality directly as a result of the presence of a
TIPSS. '
Hepatic encephalopathy
Hepatic encephalopathy was classified into de novo or a
deterioration of pre-existing encephalopathy using the
Parson-Smith criteria [31]. In the 432 patients included
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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Tabic 7 Mortality data (n - 2C1) following transjugular intrahepatic
portosystemic stent-shunt (TIPSS) insertion
Cause of death n (%)
Liver failure 111 (42.5)
Sepsis 60 (23.0)
Variceal rebleed 34 (13.0)
Hepatoma 11 (4.2)
Cerebrovascular accident 9 (3.5)
Non-varlceal rebleed 6 (2.3)
TIPSS procedure related3 6 (2.3)
Other 24 (9.2)
■'Procedure related mortality for the entire study population is 1.2%.
for analysis, there were 137 (31.7%) patients who were
encephalopathic prior to TIPSS insertion (38.0% with
Grade I. 26.3% with Grade II, 21.2% with Grade III,














(29.9%) patients developed encephalopathy during fol
low-up. Of these 48 (11.1%) patients were encephalo¬
pathic prior to TIPSS insertion and had the following
outcomes: (1) deterioration of encephalopathy managed
by therapeutic occlusion of the shunt (n = 6) or reduc¬
tion in stent diameter (n = 1), OLT (n — 3), or termina¬
tion of portographic surveillance, with the shunt allowed
to become insufficient and the patient entered into a
banding program (n = 1); (2) rapid resolution of hepatic
encephalopathy following the initial variceal bleed with¬
out recurrence (n = 12), or with recurrence due to
rebleeding (« = 1), or with spontaneous tde novo recur¬
rence (;/ = 2); (3) death shortly following TIPSS due to
liver/multi-organ failure (»= 8), variceal rebleeding
(// = 4), or sepsis (n = 3); and (4) improvement in en¬
cephalopathy with persistent mild episodes easily amen¬
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Kaplan-Meier analyses of cumulative survival: (a) in all subjects (n = 432); (b) in Pugh class A/B (—, n — 202) versus class C (—, n = 230)
patients; (c) in oesophageal (—, n — 272) versus gastric variceal bleeding (—, n = 65) patients; and (d) in patients with ascites (—,n — 50)
versus other primary indications for transjugular intrahepatic portosystemic stent-shunt (—, n - 382).
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The remaining 81 (18.9%) patients were not encephalo¬
pathy prior to TIPSS insertion and had the following
outcomes: (1) development of Vie novo" hepatic ence¬
phalopathy requiring therapeutic intervention with oc¬
clusion of the shunt (« = 13), reduction in the stent
diameter (« = 1), oi OPT (// — (>), (2) development of
V/c novo' hepatic encephalopathy that resolved with
conservative therapy with no shunt intervention re¬
quired (n — 24), or persisted with the patient subse¬
quently dying from severe end stage liver failure
(n = 4); (3) hepatic encephalopathy due to rebleeding
that improved after satisfactory management of the
bleed (n = 9), or persisted with the patient subse¬
quently dying from end-stage liver failure in = 22); and
(4) hepatic encephalopathy related to sepsis that im¬
proved following antimicrobial therapy (« -—1), or led
to severe hepatic decompensation and death in =1).
Multivariate regression analysis of variables of interest
(indication for TIPSS, sex, age, Pugh score, alcoholic
aetiology, pre-TIPSS encephalopathy, PPG post-
TIPSS, diameter of the index TIPSS, and the require¬
ment for mechanical ventilation) revealed the presence
of pre-TIPSS encephalopathy (P < 0.01) to indepen¬
dently predict post-TIPSS encephalopathy (Table 6).
Ascites
In 50 (10.6%) patients, refractory ascites was the
primary indication for TIPSS, with none of these
patients experiencing variceal bleeding at the time of
TIPSS insertion. All patients had failed to respond to
repeated paracentesis or diuretic therapy, with two
patients having had unsuccessful surgical periteno
venous shunts (Denver and La Veen). Two patients
had Budd-Chiari syndrome. Thirty-six (72.0%) patients
responded to the TIPSS, but in 10 (27.8%) of these
patients there was recurrence of ascites due to shunt
insufficiency in = .5), renal impairment (u = 2), progres¬
sive liver failure despite a patent TIPSS («= 2), or
therapeutic occlusion of the TIPSS to treat intractable
hepatic encephalopathy («=1). Fourteen (28%) pa¬
tients did not respond to the TIPSS due to inability to
maintain adequate shunt function (« = 5), worsening
renal function (ti — 4), spontaneous bacterial peritonitis
in = 2), hepatoma and tumour thrombus in = 1), rapidly
deteriorating liver function (;/ = 1), or other malignancy
(n = 1). In total, six patients underwent OLT. In the
patients with Budd-Chiari syndrome, one required
decompressive surgery following failure to overcome a
blocked TIPSS, and the other patient died as a result
of an intracranial haemorrhage while on anticoagulant
therapy. The average stent diameter of 10.6 ± 0.3 mm
was similar in the groups that did and did not respond.
The mortality was higher iP < 0.05) where ascites was
the primary indication for TIPSS compared with other
indications (Fig. 3d). The incidence of hepatic ence
phalopathy also appeared higher in the ascitic popu¬
lation (36.0%) compared with those that required a
TIPSS for variceal bleeding (25.6%), although this just
failed to reach statistical significance iP = 0.08).
Discussion
TIPSS has established itself to have a major role in the
management of portal hypertension, and with better
expertise and additional indications is likely to be
increasingly used. It is clear that TIPSS is effective in
the prevention of variceal rebleeding, although current
data from most randomized controlled trials do not
suggest an improvement in mortality [12]. Our experi¬
ence reflects 10 years of TIPSS in a single centre, and
mirrors that of most other units with an overall success
rate of 95.4%, and a procedure-related mortality of
1.2%. Both these figures are likely to improve in the
future with increasing expertise.
Our findings confirm the efficacy of TIPSS in the
prevention of variceal rebleeding, with an overall
rebleeding rate of 13.7%, with most episodes occurring
early during follow-up and almost always related to
shunt dysfunction. Intervention to correct shunt insuffi¬
ciency was very effective, with only five cases where
TIPSS intervention failed. An interesting observation
was of just one variceal rebleeding episode after
2 years, despite shunt dysfunction. The fact that 92.5%
of patients who experienced shunt insufficiency after
2 years had successful PPG reduction at the time of
index TIPSS insertion may partly explain this, since we
have identified haemodynamic success to indepen¬
dently predict varices rebleeding. Perhaps most of
these patients had also selected themselves us being in
the better prognostic group as they had survived
beyond 2 years, and thus less likely to bleed. In
keeping with our previous findings, the severity of liver
disease prior to TIPSS insertion has a profound effect
on rebleeding rates (Fig. 2b) [22], but even in those
patients with Child class C disease the efficacy of
TIPSS in preventing variceal rebleeding has previously
been shown to be better than endoscopic modalities
[6]. The Pugh score, requirement for ventilation, and
failure to achieve successful PPG reduction at the
index TIPSS independently predicted variceal rebleed¬
ing.
There is some controversy regarding the therapeutic
haemodynamic goals for TIPSS insertion, with some
advocating a reduction in the PPG of 20-50% rather
than simply a reduction in the PPG to < 12 mmHg
[33]. Using the latter criteria has its limitations, particu¬
larly in those patients that bled at PPG =£ 12 mml-Ig, of
which there are a considerable number in our popu¬
lation (13.4% of all cases of variceal haemorrhage), in
contrast to previous studies (Tables 2 and 3) [34]. Our
criteria for successful portal pressure reduction apply to
all patients. We have shown previously that patients
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with gastric varices frequently bleed at lower portal
pressures [35], and that achieving pressures much lower
than 12 mmllg following TIPSS insertion may be
necessary to prevent rebleeding [36], A possible expla¬
nation for the lower portal pressure in patients with
gastric varices could be the development of sponta¬
neous spleno-renal porto-systemic shunts, or reduced
portocollateral resistance [371. It is unclear why gastric
varices bleed at lower pressures, but fundal varices may
bleed as a result of increased variceal wall tension
owing to their large size, since variceal wall tension
plays an important role in determining the risk of
variceal bleeding [38],
Shunt insufficiency occurred frequently, with most
episodes being easily treated resulting in good second¬
ary assisted patency. The observation noted earlier of
just one episode of shunt dysfunction after 2 years
associated with variceal reblceding, brings into question
the rationale of continuing invasive portographic fol¬
low-up beyond this time. The introduction of covered
stents, and very promising patency rates reported in
uncontrolled series [26,39], may reduce the need for
TIPSS surveillance in the future.
Mortality in the TIPSS population remains high,
despite correction of portal hypertension in the vast
majority, with most deaths due to liver failure and/or
sepsis. The Pugh score, presence of ascites, and
requirement for mechanical ventilation are independent
factors predicting mortality. Around one-half of all
deaths occur within the first year (Fig. 3a). This reflects
the underlying liver disease, and particularly in our
population, the fact that most patients continue to
consume alcohol. A trend towards reduced mortality in
patients with gastric variceal bleeding compared with
oesophageal variceal bleeding has previously been
noted [35], and this is confirmed in the present study.
It is probable that the reduced portal pressure in the
former group (Table 2), both pre-TIPSS insertion and
post TIPSS insertion, makes a significant contribution.
Our unit and others have demonstrated the significance
of portal pressure on mortality, particularly if measured
shortly after a variceal bleed [40,41 j.
Post-TIPSS hepatic encephalopathy remains a contro¬
versial topic. It is important to separate the encephalo¬
pathy related to the variceal bleed or other precipitants
such as sepsis from that occurring dc novo, as seen in
some trials. In our population, the overall encephalo¬
pathy rate of 29.9% is similar to the literature, but only
11.6% of patients developed dc novo encephalopathy.
The only independent variable predicting post TIPSS
encephalopathy was pre-TIPSS encephalopathy, a find¬
ing that we have previously reported |21|. One has to
question the use of TIPSS in severely encephalopathie
patients, but in clinical practice the severity of ence¬
phalopathy is related to the severity of the variceal
bleed and liver disease, and TIPSS is often used as a
salvage procedure in such patients, where clearly it is
preferable to surgical treatment.
Initial enthusiasm for TIPSS in refractory ascites was
dampened by results published by Lebrec et aI., where
patients randomly assigned to TIPSS had worse 1 year
and 2 year survival compared with repeated paracent¬
esis [42], However, this study had very small numbers
in the TIPSS arm (n = 13), and the findings have been
challenged by a recent publication by Rdssle and
colleagues [14]. The latter study included 29 patients
randomly assigned to TIPSS, and showed convincingly
an improved survival and a reduced incidence of
recurrent ascites compared with paracentesis, with im¬
provement in renal function and no difference in the
incidence of hepatic encephalopathy. Two recent ran¬
domized studies comparing TIPSS versus paracentesis
plus albumin [43], and TIPSS plus medical therapy
versus medical therapy [44], reinforce the efficacy of
TIPSS in the prevention of recurrent ascites and
development of hepato renal syndrome. I lowever, sur¬
vival is unaffected, with hepatic encephalopathy and
costs greater in the TIPSS arms. The better survival for
patients in the TIPSS arm in the study by Rossle et aL
may have been due to patients in the paracentesis arm
not routinely receiving albumin, thus resulting in great¬
er circulatory instability [45]. The survival of our pa
tients is worse than that for the other studies mainly
due to our unsclcctcd patients having more advanced
liver disease. Our findings demonstrate a definite
response to TIPSS, although in a significant number
ascites recurred. These finding are consistent with that
of other uncontrolled series [46 50], with two studies
showing renal function to predict the response to
TIPSS [46.47]. In over one-half of these cases the
reason for TIPSS failure was shunt insufficiency, with
one patient having had an occlusion of the shunt due to
encephalopathy. In experienced centres, TIPSS ap¬
pears to be a valuable addition to the management of
refractory ascites in those patients who have failed to
respond to other therapies, but careful selection of
patents and rigorous TIPSS surveillance is needed to
minimize failure.
In our population only 9.1% of patients had an OLT.
This reflects the high proportion of patients who have
alcoholic liver disease, and the fact that most of them
continue to drink, and are therefore not transplant
candidates. There have been several studies investigat¬
ing the use of TIPSS as a bridge to OLT. including
some from our unit [16,17,25]. There is little evidence
that TIPSS has any detrimental effect on the liver
transplant or subsequent patients and graft survival.
Careful selection of patients is required on account of
the potential of a TIPSS to cause deterioration in any
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pre-existing hepatic encephalopathy. Since the TIPSS
used in the present study extend from the portal vein
to the inferior vena cava, there is the potential to
interfere with OLT. However, studies performed in
our unit so do not show any greater operative time or
transfusion requirements [16,17]. The present study
also illustrates the use of TIPSS post-OLT, although
the outcome in the two patients was not favourable.
Studies looking at TIPSS post-OLT have been limited
in size, and it is not possible to make valid conclusions
[24J. Another unusual indication in our population is
Budd-Chiari syndrome, with once again rather poor
results, although we only had two cases. These patients
are inherently difficult to manage, with some having an
underlying coagulation disorder resulting in increased
risk of TIPSS thrombosis despite the use of anti¬
coagulation. Others have reported greater success [SI],
but it is important to bear in mind that these patients
may be more suitable for surgical shunts or in cases of
cirrhosis OLT.
In conclusion, our experience with TIPSS over a
10 year period confirms the efficacy of TIPSS in the
management of portal hypertension, particularly vari-
ccal bleeding. The mortality rate following TIPSS is
related to the severity of liver disease, and mortality is
greater in patients with refractory ascites. Patients with
gastric variceal bleeding are particularly suited to
TIPSS, a finding that has been demonstrated by others
[13,15,35]. Careful selection of patients is needed to
reduce post-TlPSS encephalopathy. The high inci¬
dence of shunt insufficiency post-TIPSS can easily be
overcome by regular surveillance, but contributes to
reduced efficacy in the management of refractory
ascites. In the future polytetrafluoroethylene-covered
stents, if shown to have better patency rates in con¬
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